Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is a clinically and genetically heterogeneous lymphoid malignancy with molecular subtypes and subsets defined by distinct molecular signatures and clinical outcomes. Many subtypes and subsets are at high-risk for treatment failure with standard immuno-chemotherapy [ 1 – 4 ]. DLBCL is by far the most common category and disease entity of B-cell non-Hodgkin lymphoma (NHL) in adults, with one of the highest mortality rates of B-cell NHL in most developed areas of the world [ 1 – 3 ]. In Europe and USA, the current annual incidence of NHL is estimated to be 15–20 cases/100,000 [ 5 ]. DLBCL accounts for approximately 30–40 % of all newly diagnosed B-cell NHL cases in Western countries, and for an even higher percentage in developing countries [ 6 – 9 ]. The median age of DLBCL at diagnosis falls between the sixth and seventh decade [ 1 , 9 ]. DLBCL corresponds to a group of lymphoid malignancies composed of large cells with vesicular nuclei, prominent nucleoli, basophilic cytoplasm and a high proliferation rate [ 9 ]. DLBCL is usually aggressive, characterized by the appearance of rapidly growing tumors in lymph nodes, spleen, liver, bone marrow or other organs [ 10 ]. Nearly 90 % of aggressive mature B-cell NHL tumors in the Western world are identified as DLBCL [ 6 , 7 ]. More than half of DLBLC patients can be cured with current multi-agent chemo-, radio- and/or immunotherapeutic regimes, combined with or without autologous stem cell transplantation, representing one of the successes of modern cancer therapy. However, approximately 30 to 40 % of patients will develop relapsed or refractory disease that remains a major cause of morbidity and mortality in most developed areas of the world [ 2 , 3 , 6 , 7 ].

Gene expression and genome sequencing analyses have not only increased our understanding of DLBCL subtypes and the molecular basis of chemotherapy resistance but also led to the identification of novel molecular DLBCL subsets and rational targets for drug interventions that may allow for subtype/subset-specific molecularly targeted precision medicine and personalized combinations to both prevent and treat relapsed/refractory DLBCL. Recent studies identified several novel potential drug targets such as, the BET bromodomain protein 4, phosphoribosyl-pyrophosphate synthetase 2, macrodomain-containing mono-ADP-ribosyltransferase 9, deltex-3-like E3 ubiquitin ligase, NF-kappaB inducing kinase, programmed cell death 1 and transforming growth factor beta receptor.

In the present review we give a systematic overview of the current drug targets and experimental treatments for newly diagnosed and relapsed/refractory DLBCL. We also provide comprehensive and updated lists of current drug targets and preclinical and clinical experimental studies in DLBCL, including mechanism based combinatorial studies. The use of novel approaches for relapsed/refractory DLBCL, such as antibody drug conjugates and chimeric antigen receptor-modified autologous T cells will also be discussed. A special focus is given on STAT1, ARTD9, DTX3L and ARTD8 as novel potential drug targets in distinct molecular subsets of DLBCL, respectively.

Oncogenic pathways in DLBCL

The majority of DLBCLs are thought to arise from normal antigen-exposed B cells that are at separate stages of differentiation and are undergoing clonal expansion in the germinal center (GCs) of peripheral lymphoid organs [ 1 – 3 ]. DLBCLs are considered clonal malignancies that evolve and progress through a range of multistep transformation processes, i.e., chromosomal translocations through errors in the Ig gene remodeling processes during normal B cell differentiation [ 11 – 13 ].

Progression of DLBCLs to a more aggressive state either evolves slowly over time as a consequence of clonal evolution (selective growth and survival benefits of subclones) or alternatively, through the rapid outgrowth after catastrophic intracellular events that result in subclones characterized by extensive DNA rearrangements that have occurred simultaneously and that confer a significant survival advantage [ 3 , 11 , 12 , 14 ]. Consistent with their clinical and genetic (clonal) heterogeneity, several diverse genetic abnormalities have been identified in DLBCL including aberrant somatic hypermutations, nonrandom chromosomal deletions, balanced reciprocal translocations deregulating the expression of proto-oncogene products such as BCL6, REL, BCL2 or c-MYC, and often associated with dysregulated apoptosis or defective DNA repair [ 2 , 3 , 12 , 13 , 15 – 17 ].

Several recent whole-genome/exome sequencing studies identified over 300 DLBCL cancer genes that are recurrently mutated in primary DLBCLs [ 12 , 13 , 15 – 22 ]. These recurrent mutations are located both in genes that are well known to be functionally relevant in DLBCL and in genes for which a functional role in DLBCL has not been previously suspected [ 12 , 16 , 17 , 22 ]. It is thought that the primary or early oncogenic events are chromosomal translocations involving oncogenes such as BCL6, BCL2, REL or c-MYC whereas the secondary or late oncogenic events consist of clonally represented recurrent mutations/gene alterations including BCL2, PRDM1, CARD11, MyD88, TNFAIP3, CREBBP, TP53, EZH2, MLL2, MYOM2, PIM1, LYN, CD36, B2M, CD79B, MEF2B, ANKLE2, KDM2B, HNF1B, NOTCH1/2, DTX1 and MYCCD58 [ 12 , 13 , 15 – 22 ]. Moreover, alterations in a variety of DNA repair and DNA damage signaling genes, such as ARTEMIS, DNA-PKS, KU80, KU70, CHECK2 or ARTD1/PARP1 that affect the MMR and/or NHEJ DNA repair pathways have been recently identified in DLBCL tumors and most likely also constitute intermediate cancer driver events in lymphomagenesis [ 23 , 24 ]. Overexpression of proto-oncogene products through mutation or translocation of BCL6, BCL2, REL, or c-MYC, constitutive activation of canonical and/or non-canonical nuclear factor kappa B (NF-κB) pathways through genetic lesions and mutations in TNFAIP3, CARD11, CD79A/B, MyD88 or TRAF2 and TRAF3 genes, respectively [ 15 – 18 , 25 – 27 ], and/or epigenetic reprogramming, triggered by mutations in genes such as TET1, MLL2, EZH2, MEF2B, EP300 and CREBBP [ 15 – 17 , 19 , 20 , 28 – 30 ], account for some of the most frequent cancer driver events in DLBCL [ 2 ]. The alterations in gene expression of proto-oncogene products and/or tumor suppressors provide tumor cells with gene expression plasticity, escape from apoptosis and enhanced growth through constitutive survival and proliferative signals. See next sections. For a detailed description of oncogenic pathways in DLBCL, the readers are referred to the recent excellent reviews [ 2 , 3 , 31 – 36 ].

Distinct disease entities and molecular subtypes of DLBCL

Based on the morphological, biological pathological, and/or clinical grounds, DLBCL has been subdivided into four distinct categories and disease entities within the 4th. Edition of the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues (2008) [ 1 , 9 , 37 , 38 ]: 1.) DLBCL with a predominant extranodal location, including primary mediastinal (thymic) large B-cell lymphoma (PMLBCL), 2.) Large cell lymphomas of terminally differentiated B-cells, 3.) B-cell neoplasms with features intermediate between DLBCL and other lymphoid tumors, including B-cell neoplasm with features intermediate between DLBCL and Burkitt lymphoma (DLBCL/BL) and 4.) The biologically and clinically heterogeneous and therefore collectively termed DLBCL, not otherwise specified (DLBCL-NOS) [ 37 , 39 – 41 ].

Gene-expression profiling (GEP) and cell-of-origin (COO) studies (cell-of-origin signatures) have confirmed the physiological heterogeneity of the disease and defined at least three molecular subtypes of DLBCL: Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL), belonging to the WHO category DLBCL with a predominant extranodal location [ 37 ] and two subtypes, belonging to the WHO category DLBCL-NOS [ 9 ]. The DLBCL-NOS category has been subdivided based on the origin and gene expression signature (COO signature) into at least two/(three) molecular, biologically and clinically distinct subtypes: the two fully classified subtypes germinal center B-cell-like (GCB)-DLBCL and activated B-cell-like (ABC)-DLBCL, the not yet fully classified T cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL) and cases, that remain non-classified, termed type-3 or NC-DLBLCL [ 35 , 39 , 40 , 42 – 44 ]. These DLBCL-NOS subtypes originate from B cells at different stages of development and have distinctive mechanisms of oncogenic activation and different clinical outcomes (Fig. 1 ) [ 2 , 3 , 9 , 35 , 39 , 40 , 42 , 43 ]. A summary of clinical, pathological, and molecular characteristics of the molecular subtypes of DLBCL is shown in Table 1 . GCB and ABC subgroups represent up to 45 % and 35 %, respectively, of DLBCL-NOS cases [ 1 , 35 ]. The not yet fully classified T/HRLBCLs account for roughly 1–5 % of all DLBCL cases [ 1 , 45 – 47 ] whereas the residual 15–20 % of DLBCL are unclassifiable DLBCLs, including type-3-DLBCL [ 1 , 35 ]. Fig. 1 Origins of germinal center (GC)-derived and non-GC derived molecular subtypes of DLBCL. Germinal center (GC)-derived molecular subtypes of B-cell lymphoma originate from GC B cells that are blocked at different stages of development and have distinctive mechanisms of oncogenic activation and different clinical outcomes. T cell/histiocyte-rich large B-cell lymphoma. (T/HRLBCL) is thought to originate from a progenitor cell of germinal center origin. T/HRLBCLs are characterized by scattered large B cells immersed in a T-cell rich background with frequent presence of histiocytes. GC B cell (GCB)-like diffuse large B-cell lymphoma (DLBCL) originate from light zone B cells. Activated B cell-like (ABC) DLBCL shows characteristics of the late post–germinal center plasmablasts, a normally transient state that is committed to terminal plasmacytic differentiation. Primary mediastinal (thymic) large B-cell lymphomas (PMLBCL) shows characteristics of late post-germinal center thymic B cells and are thought to originate from thymic asteroid medulla B cells. Adapted from REF [ 3 , 70 , 86 ]. Information for this figure was gleaned from the following references: references: T/HRLBCL [ 37 , 38 , 42 , 43 , 45 – 47 , 111 , 112 , 116 ], GCB-DLBCL [ 2 , 3 , 13 , 35 , 39 , 40 , 42 , 43 , 65 – 74 , 86 ], ABC-DLBCL [ 2 , 3 , 13 , 35 , 39 , 40 , 42 , 43 , 65 , 66 , 70 , 86 , 87 , 96 ] and PMLBCL [ 1 , 3 , 9 , 35 , 48 , 49 , 51 , 52 , 62 , 63 , 70 , 86 ]. Abbreviations: FDC follicular dendritic cell, Ag antigen Table 1 Summary of clinical, pathological, and molecular characteristics of the molecular subtypes of DLBCL Molecular subtype Immuno phenotype Presume d cell of origin Diagnostic molecular features Etiology Frequency a Clinical features T/HRLBCL CD20, CD45,k (CD79A/B), CD15 — , (CD30 — ), Progenitor cell of germinal center B- cell Gene expression profiling Unknown ~1–4 % Median age: 30–50 Gender dominance: male Extranodal (vague nodularity is rare) BOB1, PU.1 +/— , CT2, PAX5, (BCL2), BCL6, IRF4 — Diffuse pattern with predominance of reactive T cells Bone marrow involvement: ~ 30 % Survival ~ 50 % at 5 years Curable ~ 45 % GCB- CD20, CD10, CD22, (CD30), (BCL2), (MYC), BCL6, GCET, HGAL, LMO2, PTEN +/— , IRF4 — , FOX — , Germinal center B-cell Gene expression profiling Unknown ~17 % Median age 61 DLBCL Gender dominance: male ≥ female Nodal and extranodal Bone marrow involvement: ~ 15 % Survival ~ 60 % at 5 years Curable ~ 50 % ABC- CD20, CD22, (CD30), (CD79A/B), IRF4, FOXP1, (BCL2), (MYC), BCL6 +/— , GCET — , LMO2 — , Post-germinal center B- cell Gene expression profiling Unknown ~15 % Median age: 66 DLBCL Gender dominance: male ≥ female Nodal and extranodal Bone marrow involvement: ~ 15 % Survival ~ 40 % at 5 years Curable ~30 % PMLBCL CD19, CD20, CD22, CD30, CD45, CD79A, CD3 — , CD10 — , CD21 — BOB1, PU.1, OCT2, PAX5, BCL6, IRF4, c-REL, TRAF1 Post- thymic B- cell Gene expression profiling Unknown ~6 % Median age: 33 Gender dominance: female Mediastinal, thoracic > nodal Bone marrow involvement: rare Survival: > 60 % at 5 years Curable: > 60 % The PMLBCL, GCB and ABC subtypes are histologically indistinguishable and require gene expression profiling (GEP) to be discerned. T/HRLBCL also shows overlapping histological features of other distinct entities and may appear similar to other lymphoid diseases, such as nodular lymphocyte-predominant Hodgkin lymphoma, classical Hodgkin lymphoma, and peripheral T-cell lymphoma. Diagnosis of this entity is occasionally difficult and requires careful immunohistochemical analysis of the tumor cells. GEP can greatly help to classify T/HRLBCL. a Approximate percentage of the particular DLBCL subtype among all patients with B-cell lymphoma. Adapted from REF: [ 3 , 70 , 86 ]. Information for this table was gleaned from the following references: [ 1 – 3 , 15 , 19 , 20 , 29 , 35 , 37 – 40 , 45 – 48 , 50 , 51 , 56 , 62 , 63 , 65 – 70 , 75 , 86 , 87 , 107 , 108 , 111 , 112 , 116 ]. DLBCL diffuse large B cell lymphoma, T/HRLBCL T cell/histiocyte-rich large B-cell lymphoma, GCB Germinal center B cell-like, ABC Activated B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas

Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL)

PMLBCL constitutes roughly 2–4 % of B-cell NHL and 8 % of DLBCLs, respectively [ 1 , 48 ]. It shares morphologic features with DLBCL and some features of classical Hodgkin’s lymphoma (cHL) [ 1 , 9 , 35 , 48 – 50 ]. PMLBCL is characterized by a diffuse proliferation of medium-to-large B cells associated with sclerosis [ 51 ]. The presence of somatic hypermutations suggests a germinal or post-germinal center origin for PMLBCL [ 1 , 48 , 49 , 52 ]. The similar pattern of mutations of IGVH and BCL6 genes found in thymic B cells and PMLBCLs further supports the theory that PMLBCL originates from thymic B cells [ 52 ]. Thus, PMLBCLs is a distinct entity and thought to stem from thymic asteroid medulla B cells of the thymus [ 51 ]. PMLBCL normally affects young women with the mediastinum being the predominant site of lymphoma manifestation [ 48 ]. PMLBCLs have a gene expression signature that is distinct from other forms of DLBCL but closely resemble that of cHL [ 53 – 55 ]. Over 30 % of all PMLBCL signature genes were also more highly expressed in cHL [ 53 – 55 ]. This is characterized by constitutive activation of the NF-κB signaling pathway [ 53 – 55 ], which in part, acts through c-REL containing NF-κB transcriptional complexes [ 56 ]. The SOCS1 gene, a suppressor of Janus kinase (JAK)-2 signaling is recurrently deleted in PMLBCL [ 57 , 58 ].

The expression of interleukin (IL)-13-receptor and downstream effectors JAK2 and signal transducer and activator of transcription (STAT)-1 as well as their activities are both up-regulated in PMLBCL [ 53 – 55 ]. Proliferation and survival of PMLBCL cells relies on JAK/STAT and NF-κB signaling [ 59 , 60 ]. Like cHL, PMLBCLs show low levels of expression of multiple components of the B cell (antigen) receptor (BCR)-signaling cascade [ 53 – 55 ]. Moreover, constitutive STAT6 activation has been identified as a characteristic feature of PMLBCL compared with other DLBCL subgroups [ 3 , 53 – 55 , 61 ]. A summary of the characteristic molecular features of PMLBCL is shown in Table 2 . For a detailed description of the biology and pathology of PMLBCL as well as diagnosis and treatment options, the readers are referred to the recent excellent reviews [ 1 , 48 , 50 , 51 , 62 – 64 ]. Table 2 Summary of the major characteristic molecular features of PMLBCL Genetic Aberration: Gain of function Genetic Aberration: Loss of function Pathways: Upregulated/Gain Pathways: Inhibited/Loss Study JAK2 (9p24.1 Ampl) SOCS1 (Mut) JAK/STAT ( STAT1 , STAT3 , STAT6) c-MYC PD-1/PD-L1/2 [ 57 , 60 , 603 – 605 ] STAT6 (Mut) PTPN1 (Mut) STAT6 PTPN1 [ 558 , 606 ] JMJD2C (9p24.1 Ampl) c-MYC [ 603 ] CD274 (PD-L1) (Tx/ 9p24.1Ampl) PDCD1LG2 (PD-L2) (Tx/Ampl) PD-1 [ 607 , 608 ] TNFAIP3 (A20) (Mut) NF-κB (c-REL), TRAF1 A20 [ 56 , 609 ] CIITA (Tx) PD-1 HLA II complex [ 64 , 610 ] TP53 (Mut) TP53 [ 611 ] Overlapping molecular features of PMLBCL and ABC-DLBCL are marked as italic. Overlapping molecular features of PMLBCL, GCB-DLBCL and ABC-DLBCL are marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless of subtype. DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas, Del deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, PRDM1/BLIMP1 B lymphocyte-induced maturation protein 1, PD-L1/L2 programmed cell death ligand 1/2, JMJD2C jumonji domain containing 2c, PTPN1 phosphotyrosine phosphatase N1, SOCS1 suppressor of cytokine signaling 1, TNFAIP3 tumor necrosis factor, alpha-induced protein, 3, NF-κB nuclear factor-kappa B, TRAF TNF receptor-associated factor, STAT signal transducer and activator of transcription, HLA human leukocyte antigens

Germinal center B cell-like (GCB)-DLBCL-NOS

GCB-DLBCLs are thought to arise from normal germinal center B cells [ 65 ] and show features that are consistent with germinal center B cell derivation [ 13 , 66 – 70 ]. GCB-DLBCLs largely express gene products, such as BCL6, HGAL and LMO2 [ 13 , 65 – 69 ] that define normal germinal center B cells within the germinal center light zone [ 71 ]. Malignant GCB-DLBCL clones continue to undergo somatic hypermutation of their variable immunoglobulin heavy chain gene and have often switched IgH classes that are mediated by AID, an enzyme that is characteristically expressed at high levels in germinal center B cells [ 72 – 74 ]. The GCB-DLBCL subtype is characterized by low level of NF-κB activation and its survival is not dependent on NF-κB [ 13 , 18 ]. Various oncogenic pathways are deregulated in GCB-DLBCL and contribute to its molecular pathogenesis. Oncogenic (deregulated) intracellular signaling pathways in GCB-DLBCL are summarized in Fig. 2 .

Translocations of BCL2 and/or c- MYC genes are commonly observed in GCB-DLBCLs [ 13 , 66 , 75 ]. These translocations lead to constitutive activation of c-MYC and the anti-apoptotic BCL2 protein [ 76 ] and to a malignant transformation by preventing terminal differentiation or blocking apoptosis [ 2 , 3 ]. 20 % have gain of function mutations of the histone methyltransferase EZH2, which is a master regulator of the GCB phenotype and cooperates, at least partly, with BCL2 and BCL6 to mediate lymphomagenesis in GCB-DLBCL [ 20 , 29 , 77 – 79 ]. GCB-DLBCL is furthermore characterized by downregulation of the phosphatase and tensin homologue (PTEN) and concomitant upregulation of phosphatidylinositol-3-kinase (PI3K) signaling pathway (Fig. 2 ) [ 13 ]. Upon loss of the PTEN gene or repression of the PTEN promoter through the mir-17-92 microRNA cluster, phosphatidylinositol-3 phosphate accumulates and AKT and mTORC1 are activated, further promoting cell survival, proliferation, and growth [ 13 , 80 – 83 ]. GCB-DLBCL is also associated with loss of sphingosine-1-phosphate receptor-2 (S1PR2) - G-protein alpha 13 (Gα13) signaling, which negatively modulates GC B-cell migration and PI3K signaling [ 15 – 17 , 84 ]. Fig. 2 Oncogenic (deregulated) intracellular signaling pathways in germinal center B cell-like (GCB) diffuse large B-cell lymphoma (DLBCL). Germinal center B cell-like diffuse large B-cell lymphoma (GCB-DLBCL) are characterized by the inactivation or loss of the phosphatase and tensin homologue (PTEN) and S1PR2-Gα13-ARHGEF1 signaling pathways, which both negatively modulate GC B cell migration and phosphatidylinositol-3-kinase (PI3K) signaling [ 13 , 82 – 84 , 324 , 593 ]. In addition, activating mutations of the histone methyltransferase EZH2 (enhancer of zeste homologue 2) and master regulator of the GCB phenotype promote epigenetic changes that, at least partly, cooperate with the B-cell lymphoma 2 (BCL2) and BCL6 to mediate lymphomagenesis in GCB-DLBCL [ 77 , 79 ]. A subset of GCB-DLBCL is characterized by translocations affecting the c-MYC and/or the BCL2 loci [ 80 , 81 , 87 ]. These translocations lead to constitutive activation of c-MYC and the anti-apoptotic BCL2 protein and to a malignant transformation by preventing terminal differentiation or blocking apoptosis. The different colors that are used in the figure indicate molecules that belong to a specific pathway and/or lead to a specific outcome. Adapted from REF: [ 3 , 70 , 86 , 109 ]. Information for this figure was gleaned from the following references: [ 2 , 3 , 13 , 15 – 18 , 20 , 29 , 39 , 66 , 75 – 84 , 86 , 87 , 93 , 109 , 123 , 148 , 247 – 251 , 259 , 324 , 325 , 352 , 354 – 356 , 360 – 365 , 367 , 374 , 375 , 377 , 380 – 382 , 384 – 386 , 593 , 612 ]. Abbreviations: S1PR2 sphingosine-1-phosphate receptor-2, Gα13 (GNA13) heterotrimeric G protein alpha 13, ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1, PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2, EZH2 enhancer of zeste homologue 2

The GCB-DLBCL subtype also frequently carries additional mutations affecting epigenetic modification such as mutations in genes encoding the histone acetyltransferases CREB-binding protein (CREBBP) and E1A-binding protein p300 (EP300) as well as the histone-lysine N-methyltransferase and myeloid/lymphoid or mixed-lineage leukemia protein 2 (MLL2) [ 15 , 19 , 20 , 29 ]. Other characteristic features of GCB-DLBCLs are the amplification of MDM2, a negative regulator of the tumor suppressor TP53, as well as deletions of the tumor suppressor gene TP73 [ 13 ]. A summary of the characteristic molecular features of GCB-DLBCL is shown in Table 3 . The GCB subtype has a cure rate of about 70 to 80 % with currently available therapies [ 13 , 85 ]. For a more detailed description of the biology and pathology of GCB-DLBCL, the readers are referred to the recent excellent reviews [ 2 , 35 , 39 , 70 , 86 ]. Table 3 Summary of the major characteristic molecular features of GCB-DLBCL-NOS Genetic Aberration: Gain of function Genetic Aberration: Loss of function Pathways: Upregulated/Gain Pathways: Inhibited/Loss Study BCL2 (Tx/Ampl/Methyl) BCL2 Pro-apoptotic signaling [ 75 , 362 , 365 ] EZH2 (Mut) EZH, BCL2 , BCL6 BLIMP1 , CREBBP ; EP300 [ 16 , 17 , 77 – 79 ] BCL6 (Tx/Ampl/Methyl) BCL6 BLIMP1 , CREBBP ; EP300 [ 87 , 93 , 148 , 386 , 612 ] MEF2B/(MEF2C) (Mut) BCL6 BLIMP1 , CREBBP ; EP300 [ 16 , 17 , 28 ] MDM2 (Ampl) TP53 (Del/Mut), TP73 (Del) TP53 and TP73Pro-apoptotic signaling [ 16 , 17 , 155 , 613 , 614 ] c-MYC (Tx/Ampl/Methyl) c-MYC , miR-17-92, BCR, PI3K/AKT/mTORC1 ISGs/IFITs, PTEN [ 80 , 81 , 87 ] miR-17-92 BCR, PI3K/AKT/mTORC1 ISGs/IFITs, PTEN [ 13 , 80 , 81 ] P2RY8 (Mut) PI3K/AKT/mTORC1 (Mut) [ 15 – 17 , 84 ] S1PR2 (Mut) PI3K/AKT/mTORC1 (Mut) [ 15 – 17 , 84 ] GNA13 (Mut) PI3K/AKT/mTORC1 Gα13 [ 15 – 17 , 84 ] ARHGEF1 (Del/Mut) PI3K/AKT/mTORC1 ARHGEF1 [ 15 – 17 , 84 ] PTEN (Del/Methyl/miR) PI3K/AKT/mTORC1 PTEN [ 13 , 82 , 83 , 593 ] B2M (Del/Mut) B2M , HLA-I complex [ 16 , 17 , 615 , 616 ] CD58 (Del/Mut) CD58 , HLA-I complex [ 16 , 17 , 615 , 616 ] MLL2 , MLL3 (Mut) BCL6 MLL2/3 , CREBBP ; EP300 [ 12 , 16 , 17 , 20 ] CREBBP ; EP300 (Del/Mut) BCL6 , HSP90 , CREBBP ; EP300 , BLIMP1 , TP53 [ 16 , 17 , 19 , 386 , 388 ] TNFRSF14 (Mut) HVEM/FAS [ 16 , 17 , 617 ] FAS (Mut) FAS/ Pro-apoptotic signaling [ 16 , 618 ] TRAF3 (Del/Mut) Non-canonical NF-κB signaling (p52/RELB) , ?? [ 26 , 27 ] ?? ?? STAT1 [ 470 ] Overlapping molecular features of GCB- and ABC-DLBCL are marked as bold italic. Overlapping molecular features of PMLBCL, GCB-DLBCL and ABC-DLBCL are marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless of subtype. DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas, Del deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, CREBBP CREB-binding protein, EP300 E1A-binding protein p300, EZH2 enhancer of zeste homologue 2, NF-κB nuclear factor- kappa B, PRDM1/BLIMP1 B-lymphocyte-induced maturation protein 1, TNFAIP3 tumor necrosis factor, alpha-induced protein 3, TRAF TNF-receptor-associated factor, MLL myeloid/lymphoid or mixed-lineage leukemia, TNFRSF14 tumor necrosis factor receptor superfamily, member 14, MDM2 murine double minute E3 ubiquitin protein ligase 2, STAT signal transducer and activator of transcription , P2RY8 purinergic receptor P2Y, G-protein coupled 8, S1PR2 sphingosine-1-phosphate receptor 2, MEF2B myocyte enhancer factor 2B, PTEN phosphatase and tensin homolog, FAS TNF receptor superfamily, member 6, HLA human leukocyte antigens, ISGs/IFITs interferon stimulated genes/interferon inducible transcription factors

Activated B cell-like (ABC)-DLBCL-NOS

The second subtype, ABC-DLBCL has experienced the germinal center and is thought to arise from post-germinal center B cells that are arrested during plasmacytic differentiation [ 13 , 65 , 70 , 87 ]. ABC-DLBCLs have a COO signature that is reminiscent of the plasmablast stage of B cell development [ 65 ]. ABC-DLBCLs largely express genes normally induced during in vitro activation of peripheral blood B cells, including genes that define the end stage memory B cells or plasma cells, such as the transcription factors IRF4 and XBP1 [ 13 , 65 , 66 , 87 ]. IRF4 is transiently expressed during normal lymphocyte activation and is essential for the proliferation of B cells in response to signals from the activated B cell (antigen) receptor [ 88 , 89 ]. Thus, constitutive expression of interferon response factor (IRF)-4 in ABC-DLBCLs contributes to unchecked proliferation of DLBCL tumors [ 90 , 91 ]. X-box binding protein 1 (XBP1) is the master regulator of immunoglobulin secretion [ 35 , 92 ]. On the other hand, ABC-DLBCLs acquire genetic alterations that repress BLIMP1 expression and function, thereby blocking the differentiation into end stage plasma cells [ 92 – 94 ]. ABC-DLBCL is characterized by genetic abnormalities that play an important role in its pathogenesis. For instance, the p16INK4A/p14ARF tumor suppressor locus is deleted in approximately 30 % of ABC-DLBCLs and is associated with inferior outcome within this subtype [ 13 , 95 ]. A summary of characteristic molecular features of ABC-DLBCL is shown in Table 4 . Table 4 Summary of the major characteristic molecular features of ABC-DLBCL-NOS Genetic Aberration: Gain of function Genetic Aberration: Loss of function Pathways: Upregulated/Gain Pathways: Inhibited/Loss Study MyD88 L265P (Mut) MyD88 (other) TLR/MyD88 NF-κB , IRF4 IRF7/IFNβ (Type 1 interferon) [ 16 – 18 ] CD79A, CD79B (Mut) B-cell receptor NF-κB , IRF4, IRF7/IFNβ (Type 1 interferon) [ 16 , 17 ] CARD11 (Mut) NF-κB , IRF4 IRF7/IFNβ (Type 1 interferon) [ 16 – 18 ] TRAF3 (Del/Mut) Canonical NF-κB (p65/p50) and non-canonical NF-κB (p52/RELB) signaling , IRF4 IRF7/IFNβ (Type 1 interferon) [ 16 – 18 , 26 , 27 , 160 ] TRAF2 (Del/Mut) SPIB (Tx/Mut) CARD11/ NF-κB , IRF4 IRF7/IFNβ (Type 1 interferon) [ 13 , 16 , 17 , 87 , 90 ] REL (Ampl) _ _ [ 619 ] BCL2 (Tx/Ampl/Methyl) BCL2 Pro-apoptotic signaling [ 362 ] MYC (Tx/Ampl/Methyl) c-MYC [ 87 , 107 ] BCL6 (Tx/Ampl/Methyl) BCL6 BLIMP1 , CREBBP ; EP300 [ 87 , 93 , 148 , 386 , 612 , 620 ] MEF2B (Mut) BCL6 BLIMP1 , CREBBP ; EP300 [ 13 , 16 , 17 , 28 ] STAT3 (Mut) IL6/10, JAK/STAT3 [ 307 , 316 ] ?? ?? STAT1 [ 470 ] FOXP1 (Ampl) Wnt/β-catenin TP53/Pro-apoptotic signaling [ 13 , 621 , 622 ] TP53 (Del/Mut) TP53 and TP73Pro-apoptotic signaling [ 16 , 17 , 155 , 614 TP73 (Del) B2M (Del/Mut) B2M , HLA-I complex [ 16 , 17 , 615 , 616 ] CD58 (Del/Mut) CD58 , HLA-I complex [ 16 , 17 , 615 , 616 ] MLL2 , MLL3 (Mut) MLL2 , CREBBP ; EP300 [ 12 , 16 , 17 , 20 ] CREBBP ; EP300 (Del/Mut) BCL6 , STAT3 , HSP90 CREBBP ; EP300 , BLIMP1 , TP53 [ 17 – 19 , 386 , 388 , 392 ] CDKN2A/B (Del/Methyl) P16INK4a/pRB p14ARF/TP53 [ 13 , 120 ] TNFAIP3 (Del/Mut) NF-κB , IRF4 A20 [ 13 , 16 – 18 ] PRDM1 (Del/Mut) BLIMP1 [ 13 , 16 , 17 ] Overlapping molecular features of ABC-DLBCL and PMLBCL are marked as italic and those of GCB- and ABC-DLBCL are marked as bolditalic. Overlapping molecular features of PMLBCL, GCB-DLBCL and ABC-DLBCL are marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless of subtype. DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas, Del deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, NF-κB nuclear factor-kappa B, TLR Toll like receptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11, IRF4 interferon-regulatory factor 4, CREBBP CREB-binding protein, EP300 E1A-binding protein p300, EZH2 enhancer of zeste homologue 2, PRDM1/ BLIMP1 B-lymphocyte-induced maturation protein 1, TNFAIP3 tumor necrosis factor, alpha-induced protein 3, TRAF TNF-receptor-associated factor, MLL myeloid/lymphoid or mixed-lineage leukemia, CDKN1A cyclin-dependent kinase inhibitor 1A, MDM2 murine double minute E3 ubiquitin protein ligase 2, STAT signal transducer and activator of transcription, FOXP1 forkhead box P1, IRF7 interferon-regulatory factor 7, IFNβ interferon beta, MEF2B myocyte enhancer factor 2B, FAS TNF receptor superfamily, member 6, HLA Histocompatibility antigen, domains alpha

ABC-DLBCLs express genes that are upregulated in B cells with activated BCR signaling [ 13 , 96 ] see also next sections. BCR-mediated NF-κB-dependent survival signaling plays important roles in certain B-cell malignancies [ 97 – 99 ]. Similar to PMLBCL, a key feature of the more aggressive ABC-DLBCL subtype is the constitutive activation of NF-κB-dependent gene expression and its dependency on the activity of NF-κB family members for proliferation and survival [ 18 , 54 , 66 , 76 , 100 ]. NF-κB is a family of inducible transcription factors consisting of five members, REL-A (p65), REL-B, c-REL, NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100) [ 101 ]. Inhibition of this pathway using either a dominant active form of NF-κB inhibitory protein inhibitor of kappa B (IκB)-α or a specific IκB kinase inhibitor is toxic to ABC- but not to GCB-DLBCL cell lines [ 59 , 100 ]. The NF-κB family members REL-A, REL-B and c-REL have the capacity to regulate transcription of various subsets of genes involved in cell proliferation and resistance to apoptosis [ 102 ]. ABC-DLBCLs shows a more restricted, potentially developmentally regulated NF-κB target gene signature [ 54 , 76 , 100 ]. Activation of NF-κB has been identified as a key driver in apoptosis resistance in ABC-DLBCL and PMLBCL leading to poor outcomes in patients with ABC-DLBCL [ 18 , 54 , 100 ]. In 39 % of ABC-DLBCL cases, constitutive activation of NF-κB-dependent gene expression is activated by somatic, gain-of-function mutations in the myeloid differentiation primary response gene (88) ( MyD88 ) [ 103 ]. The most common MyD88 mutant, L265P, spontaneously coordinates a signaling complex in which interleukin-1 receptor-associated kinase (IRAK)-4 phosphorylates IRAK1, leading to inhibitor of kappa B (IκB) kinase (IKK) and NF-κB activation [ 103 ]. In addition, 10 % of ABC-DLBCL patients harbor activating mutations in the gene encoding caspase recruitment domain-containing protein 11 (CARD11) leading to constitutively active NF-κB family members [ 104 ]. CARD11 is a key signaling adaptor that coordinates a BCR and CD40-mediated signaling complex that activates NF-κB pathways [ 105 , 106 ]. ABC-DLBCLs with wild-type CARD11 depend on constitutively active BCR signaling [ 104 ]. Both wild-type and mutant CARD11 are essential for chronic active BCR signaling and survival in ABC-DLBCL [ 103 ]. Approximately, 20 % of ABC-DLBCLs have mutations in the BCR signaling molecules CD79B and CD79A [ 66 , 96 , 104 ], which lead to constitutively active BCR signaling [ 66 , 96 ]. Oncogenic (deregulated) intracellular signaling pathways in ABC-DLBCL are summarized in Fig. 3 . Translocations of both BCL2 and c- MYC genes also occur in ABC-DLBCLs and contribute to the inferior survival of the ABC subtype of DLBCL [ 107 ]. Both GCB-DLBCL and ABC-DLBCL share genetic lesions that lead to inactivation of chromatin modifiers, owing to mutations in CREBBP, EP300 and MLL2 [ 15 , 19 , 20 , 29 ], as well as to immune escape, owing to inactivation of β2 microglobulin (B2M), CD58 and genes encoding human leukocyte antigens (HLA-A, HLA-B and HLA-C) [ 15 , 19 , 20 , 29 , 108 ]. The ABC subtype has a cure rate of about 40 to 50 % with currently available therapies [ 13 , 85 ]. For a detailed description of the biology and pathology of ABC-DLBCL, the readers are referred to the recent excellent reviews [ 2 , 3 , 35 , 39 , 70 , 86 , 102 , 109 , 110 ]. Fig. 3 Oncogenic (deregulated) intracellular signaling pathways in activated B cell-like (ABC) diffuse large B-cell lymphoma (DLBCL). The oncogenic constitutive activation of canonical nuclear factor-kappa B (NF-κB) family members in activated B cell-like diffuse large B-cell lymphoma (ABC-DLBCL), together with a blockade in terminal B cell differentiation, which is in part mediated by BCL6, represent the hallmarks of ABC-DLBCL pathogenesis [ 13 , 16 – 18 , 102 ]. The different colors that are used in the figure indicate molecules that belong to a specific pathway and/or lead to a specific outcome. Adapted from REF: [ 3 , 70 , 86 , 109 ]. Information for this figure was gleaned from the following references: [ 2 , 3 , 12 , 13 , 15 – 20 , 27 , 29 , 54 , 60 , 70 , 75 – 81 , 86 , 87 , 90 , 91 , 93 , 96 – 100 , 103 , 104 , 107 , 109 , 123 , 133 , 148 , 160 , 161 , 171 , 232 , 233 , 247 – 251 , 254 – 257 , 259 , 271 , 285 , 286 , 307 – 311 , 313 – 317 , 360 – 365 , 367 , 374 , 375 , 377 , 380 – 382 , 384 – 386 , 572 , 612 , 620 ]. Abbreviations: BCR B cell receptor, BTK Bruton’s tyrosine kinase, SYK spleen tyrosine kinase, PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, CD40L CD40 ligand, JAK Janus kinase, IRF4 interferon-regulatory factor 4, MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein 1, BCL10 B cell lymphoma protein 10, TLR Toll-like receptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11, PKCβ protein kinase Cβ, STAT3 signal transducer and activator of transcription 3, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2

T cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL)

T cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL) is an aggressive DLBCL with a poor clinical outcome, similar to ABC-DLBCL [ 45 , 47 ]. T/HRLBCL accounts for approximately 5 % of DLBCL [ 111 , 112 ]. Many T/HRLBCL tumors, especially cases containing numerous histiocytes behave aggressively and show resistance to current therapies for DLBCL [ 45 ]. T/HRLBCL occurs in younger patients, predominantly affects men, and involves liver, spleen, and bone marrow with greater frequency than classical DLBCL [ 45 , 111 ]. T/HRLBCL is thought to stem from a progenitor cell of germinal center origin [ 111 ]. T/HRLBCL is an uncommon morphologic subtype characterized by a minor population of scattered large neoplastic B cells existing in a background of predominant reactive T-lymphocytes with frequent presence of histiocytes [ 37 , 45 , 111 ]. No recurrent genetic rearrangements and/or mutations directly affecting the biology and pathology of T/HRLBCL have been identified yet [ 111 – 115 ]. According to the WHO classification 2008, T/HRLBCL is considered a separate clinically heterogeneous not yet fully classified entity [ 38 , 45 – 47 ]. However, several recent morphological and GEP studies [ 42 , 43 , 46 , 116 ] indicate that T/HRLBCL and the T/HRLBCL-like variant nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), initially defined as distinct entities, may represent a spectrum of the same disease [ 42 , 43 ]. T/HRLBCL and NLPHL were found to share rare imbalances on chromosomes 4q and 19p suggesting a similar precursor for both disorders [ 113 , 114 ]. The different clinical behavior of these lymphomas may be strongly influenced by differences in the lymphoma microenvironment [ 42 ].

The T/HRLBCL associated diffuse T cell- and histiocyte-rich infiltrates are important for a tolerogenic host immune response and for escaping the T cell-mediated immune surveillance [ 45 , 46 ]. Genes found to be upregulated in T/HRLBCL overlapped significantly with genes found to be related to an unfavorable immune response in a subset of follicular lymphomas and DLBCL [ 85 , 117 ], particularly with genes found to be related to host inflammatory response in the host response subtype DLBCL, HR-DLBCL (see next sections) [ 116 ]. T/HRLBCL and subsets of NLPHL have therefore been suggested to represent together a distinct clinical and molecular subtype of DLBCL-NOS [ 42 , 43 ]. The gene expression signature of T/HRLBCL is dominated by interferon gamma (IFNγ) and STAT1-dependent pathways and suggests a macrophage/histiocyte-activated status that is required for the tolerogenic host immune response [ 45 , 46 , 116 , 118 ]. For a detailed description of the biology and pathology of T/HRLBCL, as well as diagnosis and treatment options, the readers are referred to the recent excellent reviews [ 45 , 47 , 111 ]. In the following sections we will mainly focus on the two molecular subtypes of DLBCL-NOS; GCB- and ABC-DLBCL.

Molecular signatures associated with poor prognosis

More recent GEP studies using multiple clustering methods revealed the existence of at least seven distinct DLBCL-NOS subsets with poor prognosis. The first study identified three discrete DLBCL-NOS subsets defined by their unique transcriptional profiles (consensus cluster (CC) signature): Oxidative phosphorylation (OxPhos)-DLBCL, B-cell receptor (BCR)/proliferation (BCR)-DLBCL, and host-response (HR)-DLBCL [ 116 ]. Several other recent studies provided evidence for at least four additional molecular subsets associated with poor prognosis: c-MYC-driven (MD)-DLBCL [ 119 ], stromal-II signature-subtype DLBCL [ 85 ], CDKN2A/2B (9p21)-deletion signature subtype DLBCL [ 120 ] and RCOR1- ( TRAF3 ) - deletion signature subtype DLBCL [ 121 ]. An overview of molecular signatures in DLBCL-NOS associated with poor prognosis is presented in Table 5 . Table 5 Overview of molecular signatures in DLBCL-NOS associated with poor prognosis Molecular signature Cell of origin (COO) Prognosis Molecular features Potential drug targets Study Oxidative phosphorylation GCB (46 %) ABC (18 %) type-3 (36 %) (n.c.i.) 5y OS: 53 % Oxidative phosphorylation (↑) TCA cycle (↑) Lipogenesis (↑) Glycolytic flux (↓) Proteosomal activity (↑) BCR signaling (↓) Fatty acid metabolism, PPARγ, γ-glutamyl cysteine synthase, [ 97 , 116 , 122 , 123 , 134 ] BCR/proliferation GCB (23.4 %) ABC (53.2 %) type-3 (23.4 %) (n.c.i.) 5y OS: 60 % BCR signaling (↑) NF-κB signaling (↑) BCL6 (↑) Proliferation genes (↑) BTK, PI3K, mTORC1/2, BCL6, BCL2, STAT3, NF-κB [ 98 , 116 , 133 , 134 , 312 , 314 ] Host response GCB (46 %) ABC (18 %) type-3 (36 %) (n.c.i.) 5y OS: 54 % TCR signaling (↑) STAT1 signaling (↑) NF-κB signaling (↑) PD-1, STAT1, DTX3L, ARTD9 NF-κB, BCL2 [ 116 , 134 , 340 , 344 – 346 , 469 , 470 , 472 ] C-MYC-driven GCB (35-50 %) ABC (45-55 %) type-3 (5-10 %) (n.c.i.) 5y OS: ≤40 % (ABC!) (n.c.i.) c-MYC (↑) Proliferation genes (↑) BCL2 (↑) (BCL6) (↑) Anti-apoptotic signaling (↑) BRD2 and 4, PRPS2 BCL2, (BCL6) [ 107 , 119 , 138 – 144 , 150 , 399 , 414 ] Stromal-II Independent of COO(n.c.i.) n.c.i. Endothelial markers (↑) Key regulators of angiogenesis (↑) CXCR4/CXCL12 axis, VEGFR2 [ 85 ] CDKN2A/2B (9p21) deletion GCB (4 %) ABC (30 %) (n.c.i.) n.c.i. Loss of p15INK4B, p16INK4A, p14ARF, Loss of RB1/E2F regulation, Proliferation genes (↑) Cellular metabolism (↑) Immune and inflammatory response (↓) [ 13 , 120 , 623 ] RCOR1- ( TRAF3 ) - deletion GCB (15 %) ABC (15 %) (n.c.i.) 5y OS: 55 % Non-canonical NF-κB signaling (↑) Loss of RCOR1 signaling HDAC class II signaling (↓) NF-κB, NIK [ 27 , 121 , 160 ] DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, n.c.i . not completely investigated, TCA tricarboxylic acid, PPARγ peroxisome proliferators activated receptor-gamma, BCR B cell receptor, NF-κB nuclear factor-kappa B, STAT signal transducer and activator of transcription, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, PI3K phosphoinositide 3-kinase, BTK Bruton’s tyrosine kinase, NIK NF-κB inducing kinase, RB1 Retina blastoma protein 1, mTORC1/2 , mammalian target of rapamycin (mTOR) complex 1 and 2, DTX3L deltex (DTX)-3-like E3 ubiquitin ligase, ARTD9 ADP- ribosyltransferase-9 diphteria toxin like, PRPS2 phosphoribosyl-pyrophosphate synthetase 2, BRD2 and 4 bromodomain and extra terminal (BET) protein-2 and 4, CXCL12 CXC chemokine ligand 12 (also called stromal-cell-derived factor 1, or SDF-1), CXCR4 CXCL12 receptor, VEGFR2 vascular endothelial growth factor receptor 2; RCOR1 REST corepressor 1, HDAC histone deacetylase

OxPhos-signature-subtype DLBCLs

The first signature identified by Monti S. et al., termed oxidative phosphorylation (OxPhos) signature, is characterized by overexpression of genes that regulate oxidative phosphorylation, mitochondrial function and the electron transport chain, such as the nicotinamide adenine dinucleotide dehydrogenase (NADH) complex and cytochrome c/cytochrome c oxidase (COX) complex as well as adenosine triphosphate (ATP) synthase components [ 40 , 116 , 122 ]. OxPhos-DLBCL tumors have also higher levels of the antiapoptotic BCL2 related family member, BFL-1/A1 and exhibit genetic lesions affecting the intrinsic and extrinsic apoptotic pathways [ 40 , 116 , 122 ]. The OxPhos-DLBCL subset does not display any chronic or active/functional BCR signaling [ 97 ] and is insensitive to inhibition of BCR survival signaling [ 122 , 123 ]. OxPhos-DLBCL display enhanced mitochondrial energy transduction, greater incorporation of nutrient-derived carbons into the tricarboxylic acid cycle, and increased glutathione levels [ 122 ]. Although the exact nature of survival pathways in this group of tumors is not known, - based on findings in other cancer models- it has been suggested that the increased fatty acid metabolism observed in OxPhos-DLBCL may serve as an alternative survival pathway that is triggered by glucose deprivation or lack of glucose uptake [ 122 ]. Indeed, disturbing the fatty acid oxidation program and glutathione synthesis is selectively toxic to the OxPhos-DLBCL tumor subset [ 122 ]. 46 % of OxPhos-DLBCL tumors analyzed in theses studies were classified as GCB-, 18 % as ABC- and the remainder 36 % were designated type-3-DLBCL-NOS [ 116 ].

BCR/proliferation-signature-subtype DLBCLs

The second subtype signature identified by Monti S. et al., termed BCR/proliferation has increased expression levels of many components of the BCR signaling cascade (CD19, Ig, CD79A, BLK, SYK, PLCγ2, and MAPK4) and enhanced BCR signaling activity [ 97 , 98 , 116 ]. BCR/proliferation-DLBCL tumors also show increased expression levels of cell-cycle regulatory factors, (including CDK2 and MCM family members), DNA damage response signaling factors (such as PMS2 family members, H2AX, PTIP, and TP53) as well as higher levels of various essential B cell-specific transcription factors (such as BCL6, MYC, STAT6, PAX5, OBF1 and E2A). 53.2 % of BCR-DLBCL tumors analyzed in theses studies were classified as ABC-, 23.4 % as GCB- and 23.4 % as type-3-DLBCL-NOS [ 116 ].

In normal untransformed B cells, BCR signaling is activated in an active antigen-dependent manner that initiates the germinal center response [ 96 , 124 – 128 ]. Antigen-induced aggregation of the BCR activates BCR signaling through receptor oligomerization and phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMS) by SRC family kinases, including FYN and B lymphocyte kinase (BLK) [ 129 , 130 ]. Following ITAM phosphorylation, the spleen tyrosine kinase (SYK) is then recruited to the dually phosphorylated ITAMs through its tandem SRC homology 2 (SH2) domains, resulting in SYK phosphorylation and recruitment of additional adaptor proteins and initiating downstream signaling through phosphatidylinositol-3-kinase (PI3K) [ 124 ], Brutons’s tyrosine kinase (BTK) and finally the activation of protein kinase C (PKC)-β, which in turn phosphorylates many substrates including CARD11 [ 105 , 106 ]. Active antigen-dependent BCR signaling engages multiple downstream pathways, [ 105 , 106 , 129 , 130 ].

Normal untransformed B cells also exhibit tonic, ligand (antigen)-independent, ITAM-transmitted BCR signaling, that promotes subsequent development and survival of mature B cells in the periphery [ 96 , 124 – 128 ]. Tonic active BCR signaling engages the phosphoinositide 3-kinase (PI3K) pathway only and is also relevant to B-cell malignancies [ 96 , 124 – 128 , 131 ]. A role for tonic BCR signaling has been postulated for GCB-DLBCL based on the sensitivity of certain cell lines of this lymphoma subtype to R406, a broad range small molecule inhibitor of SYK [ 97 ]. However, genetic knockdown of proximal BCR subunits (IgM, Ig-kappa, CD79A and CD79B) killed only ABC-DLBCL with wild-type CARD11 but did not kill other lymphomas including various GCB-DLBCL cell lines [ 96 ]. Moreover, GCB-DLBCL tumors do not acquire highly recurrent mutations in the BCR signaling or canonical NF-κB pathways [ 96 ]. Thus it remains to be elucidated whether SYK is indeed essential in GCB-DLBCL or other receptors might be required for activation of the observed BCR-like signaling in GCB-DLBCL [ 31 ].

A third type of BCR signaling, termed chronic active BCR signaling, have been characterized in B-cell malignancies, which can involve mutations of BCR pathway components or be triggered by (auto-) antigens present in the tissue microenvironment [ 96 , 124 – 128 , 131 ]. Similar to the antigen-activated active BCR signaling in normal B cells chronic active BCR signaling, which typifies ABC-DLBCL, engages multiple downstream pathways, including PI3K/AKT/mTORC1 and canonical NF-κB signaling pathways [ 31 , 96 , 105 , 106 , 110 , 124 – 131 ]. Chronic active BCR signaling is distinct from tonic BCR signaling, which stimulates the PI3K pathway but not the NF-κB signaling pathways [ 31 ]. Up to 20 % of ABC-DLBCLs have somatic gain of function mutations in the immunoreceptor tyrosine-based activation motifs (ITAM) of the BCR subunits CD79B and CD79A, which lead to chronic BCR signaling [ 66 , 96 , 104 ]. However, CD79A/B mutants do not initiate BCR signaling de novo when introduced into heterologous cells, but rather increase the amplitude of ongoing BCR signaling through increased BCR surface expression and attenuation of LYN kinase activity, a negative regulator of BCR signaling [ 66 , 96 ]. LYN functions as a feedback inhibitor of BCR-stimulated signaling [ 132 ]. LYN is frequently mutated and inactivated in ABC-DLBCL [ 21 ]. This new pathogenetic mechanism in ABC-DLBCL was therefore termed chronic active BCR signaling [ 96 ]. Certain BCR-dependent ABC-DLBCLs also exhibit constitutive PI3K activation, which modulates downstream NF-κB signaling [ 98 , 133 ].

HR-signature-subtype DLBCLs

Several studies have shown that differences in the tumor microenvironment of DLBCL affect survival after treatment with rituximab-based chemotherapeutic regimens [ 85 , 116 , 134 , 135 ]. HR-DLBCL was identified by a microenvironment gene expression signature and is associated with increased expression of inflammatory mediators, such as multiple components of the T-cell receptor (TCR), molecules associated with T/NK-cell activation and the complement cascade, downstream targets of IFNγ and/or IFNγ/STAT1 signaling and upregulation of NF-κB pathways [ 116 , 134 ]. The robust NF-κB target gene signature of HR-DLBCL partially overlaps with that of PMLBCLs, implicating the NF-κB survival pathway in this subtype [ 40 , 54 , 116 ]. HR-DLBCL lack most of the common cytogenetic abnormalities seen in OxPhos-DLBCL or BCR-DLBCL and occur in younger patients who often have splenomegaly and bone marrow involvement [ 116 ]. The molecular profiles and clinicopathologic features of HR-DLBCL tumors resemble those of T/HRLBCL [ 46 , 116 ]. In contrast to OxPhos-DLBCL and BCR-DLBCLs, HR-DLBCL tumors are associated with a brisk, but ineffective host immune/inflammatory response and with a prominent T-cell/dendritic cell infiltrate as previously described for T/HRLBCL [ 46 , 47 , 116 , 134 ]. 30.6 % of HR-DLBCL tumors analyzed in theses studies were classified as GCB- and 16.8 % as ABC-DLBCL. However the large majority (53 %) was sub-classified as type-3-DLBCL-NOS [ 116 ]. Remarkably, the clinical outcome of HR-DLBCLs upon R-CHOP treatment is not improved despite their increased host immune/inflammatory response [ 116 , 134 ]. Thus, it has been suggested that similar to T/HRLBCL, either their immune responses are inhibited by counter-regulatory mechanisms or HR-DLBCL tumors were resistant towards R-CHOP-based chemotherapy, or a combination of both [ 116 , 134 ].

The clinical outcome of tumor microenvironment/host inflammatory HR-DLBCL is quite similar to those of BCR/proliferation-DLBCL and OxPhos-DLBCL, with a 5-year survival of 54 to 60 % [ 40 , 116 , 134 ].

MD-subtype DLBCLs

The c-MYC overexpressing subsets of DLBCL-NOS have been recently suggested to be sub-classified as c-MYC-driven (MD) subtype of GCB-, ABC and type-3-DLBCL-NOS [ 119 ]. C-MYC is overexpressed in up to 15 % of DLBCL-NOS and in up to 58 % of DLBCL, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma (DLBCL/BL) as a result of the t(8,14) translocation (5–14 %), gain/amplification (8q24) (21–38 %) or other, epigenetic mechanisms (28–41 %) [ 136 , 137 ]. In accordance with the concept of c–MYC translocations arising in the GC microenvironment, most of the DLBCL-NOS cases harboring a c-MYC gene translocation show a GCB-type gene expression profile and/or a GCB phenotype [ 107 , 138 – 147 ]. Large fractions of DLBCL (58–83 %) with the t(8,14) translocation contain concurrent rearrangements of the anti-apoptotic BCL2 oncogene and are referred to as double-hit lymphomas [ 107 , 137 , 144 ]. Double-hit cases harboring a c-MYC gene translocation and BCL6 rearrangements have also been reported, although at a much lower frequency than with BCL2 [ 148 ]. In addition, in some cases with the t(8,14) translocation, there is a concurrent rearrangement of both anti-apoptotic BCL2 and BCL6 oncogene(s), which are referred to as triple-hit lymphomas [ 107 , 144 ]. A recently published comprehensive study of double-hit and triple-hit lymphomas showed that 62 % of double hit lymphomas involve BCL2 and 18 % involved BCL6, the remaining cases were triple-hit lymphomas [ 149 ].

DLBCLs with high co-expression of c-MYC and BCL2 proteins have an aggressive clinical course and an inferior overall survival when treated with R-CHOP [ 143 , 144 , 150 ]. The aggressive nature of double-hit and triple-hit lymphomas is likely due to the concurrent rearrangement of both the pro-proliferative c-MYC oncogene and the anti-apoptotic BCL2 oncogene [ 107 , 144 ]. C-MYC/BCL2 co-overexpression in DLBCL is more common in the ABC subtype and contributes to the overall inferior prognosis of patients with ABC-DLBCL [ 107 , 144 ]. Several studies indicate that the overexpression of the c-MYC protein might be a prognostic marker for poor survival in DLBCL, independent of BCL2 [ 138 – 142 ]. Thus, MD-DLBCLs, composed of the c-MYC-driven subsets of DLBCL-NOS and DLBCL/BL, including subsets of the newly defined categories of double-hit and triple-hit DLBCL have been suggested to represent an independent clinically highly relevant diagnostic molecular subtype [ 119 ]. However, it is still controversial whether the high expression of c-MYC has prognostic significance as a sole marker, independent of BCL2 co-overexpression [ 107 , 144 – 147 ]. Indeed, it has been recently suggested that only high co-expression of both c-MYC and BCL2 proteins may serve as an independent predictor of very poor survival in DLBCL [ 107 , 144 – 147 ]. The significantly worse outcome in patients with double-hit and triple-hit DLBCL may include both synergistic action of c-MYC and BCL2/BCL6 as well as other molecular features originating from the more numerous genetic aberrations in double-hit and triple-hit DLBCL [ 151 , 152 ]. For instance, TP53 inactivating mutations/deletions have been detected in a large number of high-risk subgroup of relapsed/refractory double-hit DLBCLs with c-MYC and BCL2 [ 152 – 154 ] but not c-MYC and BCL6 gene translocations [ 152 ]. TP53 mutations constitute an early recurrent event in lymphomagenesis of c-MYC/BCL2 double-hit DLBCLs, leading to BCL2 driven evasion of apoptosis free from TP53-mediated control and contribute to the highly aggressive morphological and clinical phenotype of this entity [ 152 – 157 ].

Stromal-II signature-subtype DLBCL

A large GEP study performed by Lenz G. et al. identified an additional microenvironment (stromal) gene expression signatures associated with superior or inferior outcomes, respectively after treatment with rituximab-based chemotherapeutic regimens [ 85 ]. Three gene-expression signatures, - termed germinal-center B cell, stromal-I and stromal-II signatures - were identified that predicted survival in patients who received CHOP or R-CHOP, respectively [ 85 ]. The stromal-I-signature, related to extracellular matrix deposition and histiocytic infiltration was associated with a good outcome [ 85 , 158 ]. By contrast the angiogenesis-related stromal-II signature reflected tumor blood-vessel density and was found to be highly associated with a poor outcome [ 85 ]. This stromal-II signature includes genes encoding key regulators of angiogenesis such as vascular endothelial growth factor (VEGF) receptor 2, growth factor receptor-bound protein (GRB)-10, which mediates VGFR2 signaling; integrin alpha 9, which enhances VEGF signaling and the endothelial receptor tyrosine kinase TEK, the receptor kinase for angiopoietin signaling [ 85 ]. DLBCLs with overexpression of the stromal-II gene expression are associated with increased tumor blood-vessel density [ 85 ]. The stromal-II gene expression signature has been therefore suggested to represent an angiogenic switch in which the progression of a hyperplastic lesion to a fully malignant tumor is accompanied by new blood-vessel formation [ 85 ].

CDKN2A/2B (9p21) deletion signature-subtype DLBCL

Jardin F. et al. recently defined an additional signature-subtype of DLBCL characterized by deletions of the cyclin-dependent kinase inhibitor genes CDKN2A and/or CDKN2B [ 120 ]. DLBCL with CDKN2A/2B (9p21) deletions have a specific gene expression profile and a poor prognosis under R-CHOP treatment [ 120 ]. The CDKN2A/2B locus encodes 2 different proteins: p16INK4A and p14ARF. Analysis of the 9p21 genomic region indicated that transcripts encoding p14ARF and p16INK4A were both disrupted in most patients with CDKN2A/2B deletion [ 120 ]. CDKN2A/2B deletion impairs both p14ARF/p53 and p16INK4A/pRB pathways. Loss of CDKN2A/2B is observed in up to 35 % of DLBCL-NOS patients and is significantly associated with a poor prognosis after R-CHOP treatment, independently of the international prognostic index (IPI) and COO [ 120 ].

CDKN2A/2B deletion is predominantly observed in ABC-DLBCL [ 13 , 120 ]. CDKN2A/2B is deleted in up to 30 % of ABC-DLBCL and in up to 4 % of GCB-DLBCL [ 13 , 120 ]. Patients with CDKN2A/2B deletion predominantly show an activated B cell profile and a specific gene expression signature that combines direct and indirect effects of the deletion, characterized by dysregulation of the RB/E2F pathway, activation of cellular metabolism, increase of anti-apoptotic mechanisms and decreased immune and inflammatory responses, including downregulation of FAS (TNFRSF6), IL1R1, AIM1, ARTD12 (PARP12) and TNFRSF1A [ 120 ].

RCOR1- ( TRAF3 ) - deletion signature-subtype DLBCL

A systematic integrative study of high-resolution genotyping arrays and RNA sequencing data of two independent large cohorts of homogenously R-CHOP-treated DLBCL patients identified novel focal and recurrent deletions in the chromatin regulator and transcriptional corepressor gene RCOR1 (encoding CoREST1) that are associated with a novel prognostically significant risk-associated gene expression signature [ 121 ]. RCOR1 deletions define a subgroup of DLBCL patients with unfavorable progression-free survival [ 121 ]. The chromatin regulator and transcriptional corepressor RCoR1/CoREST1 has been linked biochemically to hematopoiesis and is part of the BRAF35-histone deacetylase/LSD1-CoREST histone demethylase and chromatin remodeling complex, where it associates with the C-terminal domain of REST, the histone deacetylases 1 and 2 (HDAC1/2), and the histone demethylase LSD1/KDM1A [ 159 ]. The established Rcor1 loss-associated prognostic gene signature was independent of the cell of origin classification [ 121 ]. This risk-associated gene expression signature comprises 233 genes and is enriched for biological processes that includes upregulation of the proteasome, processing of capped intron-containing pre-mRNA as well as downregulation of signaling events mediated by HDAC class II [ 121 ]. Interestingly, loss of RCOR1 was associated with deletions of the TRAF3 gene, which is located in close vicinity. TRAF3 is a negative regulator of the alternative non-canonical NF-κB signaling pathways in DLBCL, acting as a negative regulator of NF-κB-inducing kinase NIK [ 27 , 160 , 161 ]. Thus, it is very likely that the combination of transcriptional pattern changes mediated by RCOR1 loss and the downstream effects on constitutive NF-κB signaling may cooperate and contribute to the malignant phenotype of this subgroup of DLBCL [ 121 ].

Chemotherapeutical strategies and clinical outcome

Until 1997, the standard treatment for DLBCL was the anthracycline-based chemotherapy regimen of cyclophosphamide, hydroxyldaunorubicin, vincristine, and prednisone (CHOP). The majority of DLBCL patients initially respond favorably when treated with CHOP alone, but around 60 % eventually relapse [ 1 , 109 , 162 ]. Relapsed CHOP-resistant lymphomas disseminate and are highly lethal without autologous stem cell transplantation [ 1 , 109 , 162 ]. DLBCL subtypes differently respond to the standard CHOP chemotherapy. The ABC-DLBCL subtype is associated with a very poor prognosis when treated with CHOP only, the majority of ABC-DLBCL patients treated with CHOP alone will succumb to their disease [ 1 , 109 , 162 ]. In contrast, CHOP only treated patients with GCB-DLBCL and PMLBCL have a significantly better outcome with relatively favorable 5-year overall survival rates [ 1 , 109 , 162 ]. The constitutive activation of the NF-κB and BCR pathways has been suggested to be required for the anti-apoptotic phenotype and chemotherapy-resistance in ABC-DLBCL [ 35 , 109 , 163 ].

Since 1997 the co-administration of the chimeric anti-CD20 monoclonal antibody rituximab and CHOP chemotherapy significantly improved the survival of DLBCL patients, with a cure rate of 60 to 70 % [ 1 , 109 , 162 ]. The humanized chimeric anti-CD20 monoclonal antibody rituximab binds to the CD20 antigen on B-lymphoma cells and leads to the inhibition of five main pathways NF-κB, PI3K/AKT/mTORC1, STAT3, MEK/ERK and p38-MAPK pathways, resulting in downregulation of the expression of BCL2 family members and direct activation of FAS-mediated apoptosis [ 164 – 173 ]. This benefit is observed in both ABC- and GCB-DLBCL patients, though GCB-DLBCL is still associated with a much higher overall survival [ 40 , 85 , 163 ] and a relapse rate of only ∼15 % to 20 % [ 85 , 174 ]. The 3-year progression free survival (PFS) rate and overall survival (OS) rate for R-CHOP treated patients with ABC-DLBCL are approximately 40 % and 45 %, respectively, while the corresponding PFS and OS rate for R-CHOP treated patients with GCB-DLBCL are approximately 74 % and 80 %, respectively [ 85 , 163 ]. Approximately 15 to 30 % of relapsing GCB- and ABC-DLBCL patients have c-MYC/BCL2 or c-MYC/BCL6 double-hit DLBCLs with high co-expression of c-MYC and BCL2 or BCL6 proteins [ 85 , 174 ]. These groups of patients pose a particular urgent clinical need because of a very aggressive clinical course, high chemorefractoriness and inferior overall survival when treated with R-CHOP [ 143 , 144 , 150 ].

The combination of rituximab with R-CHOP [ 175 – 177 ] or dose dense CHOP chemotherapy, every 14 or 21 days [ 178 , 179 ], is now the current standard treatment for most patients with newly diagnosed DLBCL and improves the outcome of DLBCL patients of all ages and risk groups [ 1 ]. The complete remission (CR) rate of newly diagnosed DLBCL is approximately 65–75 % with R-CHOP [ 175 ]. An alternative standard regimen for first-line treatments is DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) [ 180 , 181 ]. Preliminary data from ongoing clinical studies suggest that DA-EPOCH-R therapy might have a superior outcome in some subtypes of DLBCL when compared to R-CHOP therapy [ 180 , 182 , 183 ]. For a detailed description of chemotherapeutic regimens used for the first-line treatment of DLBCL, the readers are referred to the recent excellent reviews [ 1 , 109 , 184 – 186 ]. Unfortunately, specific molecular subsets of DLBCLs at high risk for treatment failure with rituximab and/or anthracycline-based (immuno-)chemotherapy regimes are be coming more frequent [ 187 ]. Even though more than half of DLBLC patients achieve and maintain complete remission after first-line therapy with empiric combination multi-agent chemo-, radio- and/or immunotherapeutic regimes; 30 to 40 % of patients with specific molecular subsets of DLBCLs undergo relapse and approximately 10 to 15 % have refractory disease [ 188 , 189 ]. Relapsed or refractory DLBCL is difficult to treat, with limited therapeutic options. Patients with relapsed/refractory DLBCL have a poor prognosis, with only ~10 % ultimately achieving complete cure [ 188 ].

After finding a significant improvement of survival outcomes in an international randomized phase III trial (PARMA study), high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) has been suggested as the standard therapy for patients with relapsed or refractory DLBCL [ 1 , 190 ]. In addition, a recently performed prospective randomized trial by the Dutch Belgian Hemato-Oncology Cooperative Group established the benefits of rituximab combined with salvage chemotherapy, demonstrating clear survival benefits of combining rituximab with HDC prior to ASCT (HOVON-44 study) [ 191 ]. Rituximab-based HDC/ASCT therapy regimens have become the mainstay of therapy for patients with chemotherapy-sensitive relapsed DLBCL, still sensitive to conventional dose salvage chemotherapy [ 1 , 192 ]. On the other hand, rituximab maintenance appears to have no defined role in relapsed DLBCL after ASCT [ 193 ].

Various salvage regimens are available such as R-DHAP (rituximab, dexamethasone, high-dose cytarabine, and cisplatin) R-DHAP-VIM-DHAP (rituximab-cisplatin, cytarabine, dexamethasone, etoposide - ifosfamide, methotrexate - cisplatin, cytarabine, dexamethasone), R-ESHAP (rituximab, etoposide, steroids, ara-C, and cisplatin), R-DHAX (rituximab, dexamethasone, cytarabine, and oxaliplatin), R-ICE (rituximab, ifosfamide, carboplatin, etoposide), DA-EPOCH-R (etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab), R-GIFOX (rituximab, gemcitabine, ifosfamide, oxaliplatin), R-GEMOX (rituximab emcitabine, oxaliplatin), R-GDP (rituximab plus gemcitabine, cisplatin, and dexamethasone), R-MINE (rituximab mesna, ifosfamide, mitoxantrone, etoposide) or R-BEAM (rituximab plus carmustine, etoposide, cytarabine, and melphala) [ 191 , 193 – 206 ]. However, salvage therapy and transplant conditioning regimens are still suboptimal, as are therapeutic options for patients who relapse following ASCT [ 1 , 192 ]. Thus, the optimal salvage chemotherapy regimen still needs to be determined. A summary of randomized, phase III trial studies of rituximab combined chemotherapy regimens in relapsed/refractory DLBCL is presented in Table 6 . R-ICE or R-DHAP followed by high-dose therapy and autologous stem cell transplantation are the two most widely used regimens worldwide for the treatment of patients with relapsed/refractory DLBCL [ 1 , 192 , 193 ]. Recently, the results of the randomized collaborative trial, which compared R-DHAP to R-ICE followed by HDC/ASCT in relapsed aggressive B-cell lymphoma, including relapsed/refractory DLBCL, have been reported (CORAL study) [ 193 ]. There were no significant differences reported between R-ICE and R-DHAP for ORR, 3-year EFS, or OS [ 193 ]. However, a subsequent subgroup analysis performed on the CORAL database showed that salvage treatment with R-DHAP was superior to R-ICE in the GCB subtype and may improve outcome in patients with GCB-type DLBCL [ 174 , 207 ]. Table 6 Randomized, phase III trial studies of rituximab combined chemotherapy regimens in relapsed/refractory DLBCL Design/regimen Patient characteristics Results Status Study R- DHAP-VIM-DHAP (A) vs. DHAP-VIM-DHAP (B) Prior to BEAM/ASCT Patient No.: 239 Age: 18 to 65 y; Survival benefits of combining rituximab with HDC/ASCT: 2-year FFS: 50 (A) vs 24 % (B) 2-year PFS: 52 (A) vs 31 % (B) Completed phase III [ 191 ] Trial-No: NCT00012051 (HOVON-44 study) R-ICE (A) vs. R-DHAP (B) After HDC/ASCT Patient No.: 477 Age: 18 to 65 y; No survival differences between R-ICE and R-DHAP Rituximab maintenance has no defined role in relapsed DLBCL after ASCT Completed phase III [ 193 , 624 ] Trial-No: NCT00137995 (CORAL study) R-GDP vs. R-DHAP As salvage chemotherapy prior to ASCT Patient No.: 619 Age: 16 to 65 y No survival differences between R-GDP and R-DHAP GDP is associated with less toxicity and hospitalization, and superior quality of life. Completed phase III [ 195 ] Trial-No: NCT00078949 R-BEAM vs. Bexxar/BEAM prior to ASCT Patient No.: 224 Age: 18 to 80 y B-BEAM and R-BEAM regimens produced similar 2-year PFS and OS rates Completed phase III [ 194 ] Trial-No: NCT00329030 Ofatumumab + DHAP vs. R-DHAP As salvage chemoimmunotherapy followed by ASCT Patient No.: 445 Age: 18 to 65 NA Completed phase III Trial-No: NCT01014208 (ORCHARRD study) R-DHAP +/− Bortezomib As induction therapy before HDC/BEAM/ASCT Patient No.: 108 (estimated) Age: 18 to 65 (estimated) NA Ongoing Phase III Trial-No: NCT01805557 (FILVERAL12 study) 90-Yttrium Ibritumomab Tiuxetan (Zevalin) +/− R-BEAM Patient No.: 158 (estimated) Age: 18 to 70 (estimated) NA Ongoing Phase III Trial-No: NCT02366663 (SPINOZA study) DLBCL diffuse large B cell lymphoma, BEAM carmustine, etoposide, cytarabine, and melphala, BEAM/ASCT carmustine, etoposide, cytarabine, and melphala with autologous stem cell transplantation, PFS progression-free survival, FFS failure-free survival, OS overall survival, OS overall survival, HDC high-dose chemotherapy, HDC/ASCT high-dose chemotherapy and autologous stem cell transplantation, R-DHAP rituximab plus dexamethasone, cytarabine, and cisplatinum, R-GDP rituximab plus gemcitabine, cisplatin, and dexamethasone, DHAP-VIM-DHAP cisplatin-cytarabine-dexamethasone -- etoposide-ifosfamide-methotrexate -- cisplatin-cytarabine-dexamethasone, R-ICE ifosfamide, carboplatin and etoposide, Bexxar iodine-131 tositumomab

Unfortunately, not all patients are fit or eligible for the HDC-ASCT. Patients with aggressive non-GCB-DLBCL (ABC-subtype or c-MYC-driven type-3-DLBCL-NOS) respond poorly to treatment with classical R-ICE or R-DHAP based salvage therapy [ 207 – 209 ]. Relapsed DLBCLs resistant to rituximab alone or R-CHOP treatments are refractory to subsequent treatments with the initial chemotherapy regimen and may even exhibit cross-resistance to multiple chemotherapeutic anticancer drugs [ 169 , 210 ]. Many patients ultimately succumb to these aggressive tumors despite second-line chemotherapy and autologous stem cell transplantation, resulting in disappointing 3-year overall survival rates of approximately 30 % [ 4 , 188 , 207 ]. Patients with relapsed/refractory DLBCL who relapse after HDC-ASCT and develop refractory disease have an extremely poor prognosis with only a few, if any, curative therapy options and a median survival of approximately 3 to 4 months [ 188 , 207 ]. The management of patients ineligible for HDC-ASCT or with relapsed/refractory DLBCL relapsing after HDC-ASCT is very difficult and the only remaining treatment option for these patients includes participation in phase 1/2 clinical trials with novel experimental agents or palliative therapy [ 188 , 207 ]. Thus, for the remainder of these patients with relapsed/refractory and high-risk biological subtypes of DLBCL, further improvements in therapy and novel therapeutic strategies are urgently needed. For a detailed description of drug resistance pathways in DLBCL and chemotherapeutic regimens used for the treatment of relapsed/refractory DLBCL, the readers are referred to the recent excellent reviews [ 187 – 189 , 192 , 211 , 212 ].

Selected novel drug targets under study for relapsed/chemo-refractory DLBCLS

Most patients with relapsed or refractory DLBCLs resistant to rituximab and/or R-CHOP chemotherapy are thought to have ABC-DLBCL or type 3-DLBCLs [ 35 ]. Three different types of drug resistance have been defined and are associated with adverse clinical outcomes: Drug resistance of DLBCLs can be inherent from the beginning (innate, due to the genetic heterogeneity of DLBCL tumor cells) [ 213 , 214 ]. This type is called intrinsic genetic resistance, which is associated with recurrent translocations and the presence of specific genetic abnormalities [ 12 , 18 , 213 , 214 ]. Inherited genetic variations can contribute to the risk of therapy-induced side effects [ 12 , 18 , 215 ]. A second type, termed treatment acquired resistance, develops from prior exposure to chemotherapy [ 33 , 213 , 214 ]. Acquisition of chemotherapy resistance in DLBCL is due to the genetic and epigenetic instability of DLBCL tumor cells and emergence of subclonal populations of drug-resistant tumor clones, which eventually leads to the failure of standard rituximab and/or anthracycline-based chemotherapy regimens [ 33 , 213 , 214 ]. A third resistance mechanism, known as tumor microenvironment (TME)/cell adhesion–mediated drug resistance, arises from the interaction of DLBCL tumor cells with the normal stromal tissue [ 216 – 219 ].

Due to the extensive heterogeneous genetic nature of DLBCL, multiple drug-resistant molecular mechanisms are required for the intrinsic genetic resistance and acquisition of chemotherapy resistance in DLBCL. Only a small number of high-risk subsets of DLBCL are associated with increased expression of multidrug pumps (i.e., P-glycoprotein; MDR1/ABCB1) [ 189 , 220 , 221 ] and overexpression does not appear to be consistently associated with chemoresistance in DLBCL [ 221 , 222 ]. Moreover, CD20 mutations involving the rituximab epitope are rare in both de novo and relapsed/refractory DLBCL tumors, and do not represent a significant cause of R-CHOP resistance [ 223 ]. CD20 protein-negative relapses can occur in up to 20 % DLBCL cases after rituximab-containing combination chemotherapies [ 223 – 226 ]. Downregulation of CD20 protein expression strongly correlates with rituximab resistance in vitro [ 227 ]. However its clinical relevance is not yet fully understood [ 223 – 226 ]. Chemotherapy resistance has been mainly associated with down-regulation of intrinsic apoptosis pathways and activation of survival pathways in DLBCL [ 165 , 166 , 169 – 171 , 189 , 228 ]. For instance, repeated exposure to rituximab can generate a therapy-resistant phenotype by the upregulation of the anti-apoptotic BCL2 family proteins [ 169 ] or downregulation of the pro-apoptotic BAK and BAX proteins [ 229 ]. A summary of observed and postulated (immuno)-chemotherapy resistance mechanisms in DLBCL is presented in Table 7 . Table 7 Summary of observed mechanisms underlying drug resistance in DLBCL Resistance mechanisms Resistance type Examples of molecules involved in Examples of drugs affected Study Upregulation or constitutive activation of pro-survival pathways Intrinsic genetic resistance Treatment acquired resistance BCL2 family/c-MYC (↑) Proteasome inhibitors [ 209 , 625 ] BCR signaling (↑), NF-κB (↑) JAK/STAT3 signaling (↑) (Bortezomib), CHOP, Rituximab [ 107 , 138 , 164 , 169 , 171 , 218 , 366 , 398 , 407 , 626 ] PAK1 (MEK/ERK, PI3K/AKT, WNT/β-catenin signaling) (↑) PI3K, mTORC1/2 inhibitors Downregulation or inactivation of pro- apoptotic pathways Intrinsic genetic resistance Treatment acquired resistance TP53 (↓/Mutated) Cisplatin, cytarabine, doxorubicin, etoposide, (−> CHOP, ICE, DHAP etc.) [ 627 – 629 ] Metabolic detoxification of drugs Intrinsic genetic resistance Treatment acquired resistance ALDH1A1, GPX1 Doxorubicin (−> CHOP) [ 630 ] Upregulation or constitutive activation of DNA damage signaling pathways Intrinsic genetic resistance Treatment acquired resistance CHK1/2 (↑) DTX3L, ARTD9 (↑) Doxorubicin (−> CHOP) [ 470 , 547 , 548 , 631 , 632 ] Upregulation of multi-drug export machines Intrinsic genetic resistance Treatment acquired resistance ABCB1, ABCG2 (↑) Doxorubicin (−>CHOP), methotrexate, fludarabine, adriamycin, vinblastine [ 220 , 630 , 633 ] Upregulation or (constitutive) activation of alternative pro-survival pathways Intrinsic genetic resistance Treatment acquired resistance MCL1, BFL1 (↑) BCL2 inhibitors (ABT-737) [ 363 , 364 ] HSP27, HSP70, HSP90 (↑) MCL1, BCL-XL (↑) HDAC3 (↑) Proteasome inhibitors (Bortezomib) Rituximab [ 166 , 268 , 371 , 560 , 561 ] CARD11 mutant or MyD88 mutant mediated signaling -> NF-κB (↑) BTK inhibitors (Ibrutinib) [ 104 , 259 , 634 ] Loss of key negative regulators of pro-survival signaling pathways Intrinsic genetic resistance Treatment acquired resistance 4EBP1 (↓) - > mTORC1 pathway (↑) mTORC1 inhibitors [ 635 ] Mutation(s) in target molecules or target pathways Treatment acquired resistance Ibrutinib binding site mutations in BTK. Gain-of-function mutation in PLCγ2 -> BCR signaling (↑) BTK inhibitors (Ibrutinib) [ 465 ] Downregulation of target molecules CD20 (↓) Rituximab [ 223 – 227 ] TME induced up regulation of pro-survival signaling pathways Treatment acquired resistance TME mediated resistance BCR signaling (↑) ABCG2 (↑) BCL2, BCL-XL, BCL2A1 (↑) CHOP [ 217 , 218 ] [ 633 ] CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, DHAP cisplatin, cytarabine, dexamethasone, etoposide, VIM ifosfamide, methotrexate, ESHAP etoposide, steroids, ara-C, and cisplatin, ICE ifosfamide, carboplatin, etoposide, GDP gemcitabine, cisplatin, and dexamethasone, BEAM carmustine, etoposide, cytarabine, melphala, MDR multi drug resistance, BCR B cell receptor, NF-κB nuclear factor-kappa B, JAK Janus kinase, STAT signal transducer and activator of transcription, PAK1 p21-activated kinase 1, CHK1/2 Chk1 protein kinase 1/2, DTX3L deltex (DTX)-3-like E3 ubiquitin ligase, ARTD9 ADP-ribosyltransferase-9 diphteria toxin like, BCL B-cell lymphoma protein, MCL1 myeloid cell leukemia 1, HSPs heat shock proteins, HDAC histone deacetylase, CARD11 caspase recruitment domain family, member 11, MyD88 myeloid differentiation primary response 88, 4EBP1 eukaryotic translation initiation factor 4E binding protein 1, mTORC1 , mammalian target of rapamycin (mTOR) complex 1, ALDH1A1 aldehyde dehydrogenase 1A1, GPX1 glutathione peroxidase 1, ABCG2 ATP-binding cassette, sub-family G, member 2, ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1 , PLCγ2 phospholipase C gamma 2, BTK Bruton’s tyrosine kinase, TME tumor microenvironment

Multiple driver mutations and aberrant signaling pathways suggested to be required for drug resistance in DLBCL have been recently identified in specific molecular subsets of DLBCLs through gene expression profiling (GEP), transcriptome sequencing, RNA interference screens, and DNA sequencing and have increased our understanding of (chemotherapy-) resistance. A detailed list of novel potential drug targets and agents in DLBCL-NOS, including relapsed/refractory DLBCL is shown in Additional file 1 : Table S1. Numerous small molecule inhibitors acting as GCB- and ABC-DLBCL subtype-specific pathway inhibitors are now in various stages of investigation, including clinical trial phase III studies. Only a few of them have been already approved for the treatment of B-cell malignancies, none of them for the treatment of DLBCL (Table 8 ). At least seven are currently evaluated in clinical phase III studies in patients with newly diagnosed or relapsed/refractory DLBCL (Table 9 ). These drugs are mainly targeting oncogenic factors regulating cell metabolism, proliferation, cell cycle, growth, migration, survival and angiogenesis in a subtype-specific manner. A detailed list of novel single experimental agents in clinical trials in relapsed/refractory DLBCL-NOS is shown in Additional file 1 : Table S2. Completed and ongoing experimental clinical studies combining novel experimental agents with conventional (immuno-)chemotherapy (i.e., R-CHOP, DHAP) in first-line treatment of newly diagnosed DLBCL and/or second-line treatment of relapsed/refractory DLBCL are summarized in Additional file 1 : Tables S3–S5. Table 8 Approved novel drugs for treatment of B-lymphoid malignancies that are currently in clinical evaluation for the treatment of DLBCL Drug name Target/Pathway Manufacturer Approved for the treatment of Ofatumumab (Arzerra) Second-generation anti-CD20 mAb (↓) CD20-pro-survival signaling GSK Genmab B-cell chronic lymphocytic leukemia Obinutuzumab (Gazyva/GA101) Third-generation anti-CD20 mAb (↓) CD20-pro-survival signaling Roche Pharmaceuticals B-cell chronic lymphocytic leukemia Ibrutinib (Imbruvica/PCI-32765) BTK inhibitor (↓) BTK, BCR/NF-κB-pro-survival signaling Pharmacyclics/Janssen Pharmaceutica Mantle cell lymphoma B-cell chronic lymphocytic leukemia Lenalidomide (Revlimid) Immunomodulatory drug (↓) IRF4, BCR/NF-κB-pro-survival signaling (↑) pro-apoptotic STAT2- IFNα/β axis Celgene Multiple myeloma Mantle cell lymphoma Bortezomib (Velcade) Proteasome Inhibitor (↓) NF-κB-pro-survival signaling Millennium Pharmaceuticals Multiple myeloma Carfilzomib (Kyprolis) Proteasome Inhibitor (↓) NF-κB-pro-survival signaling Multiple myeloma Idelalisib (Zydelig/CAL-101, GS 1101) PI3Kδ inhibitor (↓) PI3Kδ PI3K/AKT/mTORC1 pathway Gilead Sciences Inc. B-cell chronic lymphocytic leukemia Small lymphocytic lymphoma Follicular lymphoma Dasatinib SRC kinase inhibitor (↓) SRC family BCR/NF-κB-pro-survival signaling Bristol-Myers Squibb Chronic myeloid leukemia Brentuximab vedotin (Adcetris/SGN-35) (↓) Tubulin (↑) pro-apoptotic signaling Seattle Genetics Inc. Hodgkin’s lymphoma B and T-acute lymphoblastic leukemia Antibody-drug conjugate (ADC) (anti-CD30 mAb conjugated to cytotoxin MMAE) (MMAE is a microtubule disrupting agent) Anaplastic lymphoma kinase-positive large B-cell lymphoma Panobinostat (LBH589) HDAC inhibitor (↓) HDAC, c-MYC pro-survival signaling Novartis Pharmaceuticals Multiple myeloma Alemtuzumab (Campath-1H/LDP-03) Anti-CD52 mAB (↓) CD52-pro-survival signaling Sanofi B-cell chronic lymphocytic leukemia mAB monoclonal antibody, BTK Bruton’s tyrosine kinase, BCR B cell receptor, NF-κB nuclear factor-kappa B, IRF4 interferon-regulatory factor 4, STAT2 signal transducer and activator of transcription 2, IFNα/β interferon alpha/beta, PI3K phosphoinositide 3-kinase, mTORC1 , mammalian target of rapamycin (mTOR) complex 1, HDAC histone deacetylase Table 9 Novel agents in clinical trial phase III studies for first-line and second-line treatment of DLBCL-NOS Drug Agent mechanism or target Pathway Manufacturer Status Studies Enzastaurin ( LY317615 ) PKCβ inhibitor (↓) BCR/ NF-κB pro-survival signaling Denovo Biopharma LLC Completed phase III [ 258 ] Trial-No: NCT00332202 (PRELUDE) Ofatumumab (Arzerra) CD20 Second- generation anti-CD20 mAb (↓) CD20 pro-survival signaling GSK Genmab Completed phase III Trial-No: NCT01014208 (ORCHARRD) Bortezomib (Velcade) Proteasome Inhibitor (↓) NF-κB pro-survival signaling Millennium Pharmaceuticals Ongoing phase III Trial-No: NCT01805557 (FILVERAL12) NCT01324596 (REMoDL-B) Lenalidomide (Revlimid) IRF4 Immuno modulatory drug (↓) BCR/ NF-κB pro-survival signaling (↑) pro-apoptotic STAT2-IFNα/β axis Celgene Ongoing phase III [ 294 ] Trial-No: NCT01122472 (REMARC) NCT02285062 (ROBUST) NCT02128061 NCT01197560 Ibrutinib (PCI-32765) BTK inhibitor (↓) BCR/ NF-κB pro-survival signaling Pharmacyclics Janssen Pharmaceutica Ongoing phase III Trial-No: NCT01804686 NCT01855750 Everolimus (RAD001/Afinitor) mTORC1 inhibitor (↓) PIK/AKT/ mTORC1 pro-survival signaling Novartis Pharmaceuticals Ongoing phase III Trial-No: NCT00790036 Obinutuzumab (Gazyva, Gazyvaro GA101/RO5072759) CD20 Third- generation anti-CD20 mAb (↓) CD20 pro-survival signaling Roche Pharmaceuticals Ongoing phase III Trial-No: NCT01287741 (GOYA) mAB monoclonal antibody, PKCβ protein kinase Cβ, BCR B cell receptor, NF-κB , nuclear factor-kappa B, IRF4 interferon-regulatory factor 4, STAT2 signal transducer and activator, of transcription 2, IFNα/β interferon alpha/beta, BTK Bruton’s tyrosine kinase, mTORC1 , mammalian target of rapamycin (mTOR) complex 1, PI3K phosphoinositide 3-kinase

Most of these drugs are targeting the DLBCL subtypes according to their COO status (GCB- or ABC-specific) and CC status (OxPhos-, BCR- or MD-specific). The most important of these novel drug targets currently under study are discussed below.

Inhibition of BTK and SYK kinases in the BCR-subtype of ABC-DLBCL

As mentioned above chronic active BCR-mediated signaling was recently identified as a critically important pathway in the pathogenesis of ABC-DLBCL [ 96 , 116 , 122 , 230 ]. Chronic active BCR signaling in DLBCL is mainly dependent on the BTK, SYK and PI3K kinases [ 231 ]. The BTK, SYK and PI3K kinases have significant activities in patients with relapsed/refractory ABC-DLBCL [ 96 , 116 , 230 ]. Thus, the BCR-associated kinases SYK and BTK have emerged as promising therapeutic targets for relapsed/refractory ABC-DLBCL. SiRNA-mediated depletion of SYK or BTK as well as inhibition of SYK or BTK by small molecule inhibitors selectively decreased BCR signaling and induced apoptosis of BCR-dependent DLBCL cell lines [ 90 , 98 , 232 – 234 ]. In a phase I/II clinical trial study that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib (PCI-32765), a BTK inhibitor, have shown a promising activity of ibrutinib as a single agent in the BCR- subtype of ABC-DLBCL; a 37 % ORR and a 16 % CR in relapsed/refractory DLBCL was reported for patients with the ABC- subtype compared with only 5 % of those with the germinal GCB subtype [ 235 – 238 ]. Thus, ibrutinib efficacy is limited to ABC-DLBCL patients with a constitutively active BCR signaling pathway [ 235 , 239 , 240 ]. Consistent with the cooperation between the BCR and MyD88 pathways observed in vitro , ABC tumors with concomitant BCR and MyD88 mutations responded to ibrutinib frequently [ 235 ]. However, the highest number of responses occurred in ABC tumors that lacked BCR mutations, as 67 % of ibrutinib responders had wild-type CD79A and CD79B [ 235 ]. Remarkably, ibrutinib does not inhibit the growth and survival of BCR wild-type tumors with MyD88- and/or CARD11 mutations [ 235 , 239 , 240 ] indicating that ibrutinib specifically targets ABC-DLBCL tumors that rely on chronic active BCR signaling [ 235 ].

Ibrutinib is a selective and irreversible BTK inhibitor that binds covalently to a C481 residue in the BTK active site, preventing Y223 phosphorylation required for activation [ 241 ]. Ibrutinib is very well tolerable both as single agent and in combination with R-CHOP [ 235 – 237 , 242 ]. Ongoing clinical phase II studies and several randomized clinical phase III studies are evaluating ibrutinib with or without R-CHOP in patients with newly diagnosed and relapsed/refractory DLBCL 30 ( NCT01325701 , NCT01197560 , NCT01804686 , NCT01855750 ) [ 235 , 236 , 243 – 245 ] (Table 9 and Additional file 1 : Tables S2–S5). Fostamatinib (R406, FosD), a selective oral small molecule inhibitor of SYK, also showed significant activity in relapsed/refractory DLBCL in a phase I/II study [ 246 ] (Additional file 1 : Table S2). More than 20 % of the patients with multiple relapsed/refractory DLBCL responded to therapy with fostamatinib, though the CR was only 5 % [ 246 ]. A multicenter phase II trial of fostamatinib has completed and is pending announcement of the results ( NCT01499303 ) (Additional file 1 : Table S2). Additional phase II trials have been proposed to determine whether fostamatinib may improve the response to rituximab [ 246 ].

Inhibition of PKCβ in the BCR-subtype of ABC-DLBCL

Another potential therapeutic target in relapsed/refractory BCR-subtypes of ABC-DLBCL is the protein kinase C (PKC) isoform PKCβ II. PKCβ II is a serine/threonine kinase isoform amplified through the BCR signaling pathway and is highly expressed in refractory DLBCL [ 247 – 250 ]. PKCβ-II overexpression is an adverse prognostic factor in DLBCL and associated with poor prognosis in BCR-subtypes of ABC-DLBCL and GCB-DLBCL deficient of phosphatase and tensin homolog (PTEN) [ 247 – 251 ]. Preclinical studies demonstrated that sotrastaurin (AEB071) and enzastaurin, two adenosine triphosphate-competitive selective inhibitors of PKCβ, induce apoptosis and inhibit the proliferation of BCR-subtypes of ABC-DLBCL in vitro and in vivo [ 252 , 253 ].

Sotrastaurin selectively inhibited the growth of CD79 mutant BCR-subtypes of ABC-DLBCL in vitro and in vivo whereas the presence of CARD11 mutations resulted in resistance to the inhibitor [ 253 ]. Sotrastaurin is currently being tested in an international multi-institutional phase I/II trial study in patients with DLBCL that harbor either CD79A or CD79B mutations ( NCT01854606 ) [ 109 ]. Treatment with enzastaurin is well tolerated in patients with newly diagnosed DLBCL as well as in patients with relapsed/refractory DLBCL [ 254 – 257 ]. However a recent clinical phase I/II trial study showed that the improved outcome upon treatment using enzastaurin alone was only modest in relapsed/refractory DLBCL ( NCT00042666 , Additional file 1 : Table S2), indicating that enzastaurin is not very effective as single-agent [ 254 – 256 ]. Moreover, a randomized phase III study of enzastaurin as single-agent in patients with newly diagnosed DLBCL did not meet its primary endpoint to improve progression-free survival ( NCT00332202 ) [ 258 ] (Table 9 ). Two clinical phase II studies evaluating the efficacy and safety of enzastaurin in combination with R-CHOP or R-Gemox have been recently completed and are pending announcement of the results ( NCT00436280 , NCT00451178 ) (Additional file 1 : Table S3).

Inhibition of canonical NF-κB signaling pathways in ABC-DLBCL

As already discussed in previous sections recent studies validated the NF-κB signaling pathways as an important therapeutic target in ABC-DLBCL. Receptor-mediated constitutive activation of NF-κB in B-cell malignancies can occur through two distinct signaling pathways: the canonical pathway or classical pathway mediated by the action of RelA/p50 heterodimers and the non-canonical or alternative pathway mediated by the action of p52/p50, RelB/p50 or RelB/p52 heterodimers [ 26 , 27 , 160 , 161 ]. The canonical pathway is the major NF-κB signaling pathway in DLBCLs and activated through BCR, CD40 and/or TLR signaling and by the inhibitor of κB kinase complex (IKKα/β/γ), which in turn, phosphorylates IκB and causes its degradation [ 27 , 160 , 161 ].

The major fraction of oncogenic NF-κB activating mutations in DLBCL is predominantly related to the canonical NF-κB pathway [ 12 , 16 , 18 , 19 , 96 , 104 , 259 ]. The less well-studied non-canonical NF-κB pathway is not yet fully established as a drug target in DLBCL, see next section. ABC-DLBCL and PMLBCL cell lines and primary tumors, including drug-resistant cases, can be sensitized in vitro and in vivo to chemotherapy by treatment with drugs, which can inhibit the canonical NF-κB pathway. For instance, small molecule inhibitors of the IKK complex were found to be selectively toxic for ABC-DLBCL and PMLBCL cell lines, but had no effect on GCB-DLBCL cell lines [ 59 ]. Proteasome inhibitors such as bortezomib or carfilzomib, block the degradation of negative regulators of cell cycle progression as well as of NF-κB inhibitory protein IκBα thereby inducing cell cycle arrest and mitochondrial dependent apoptosis in ABC-DLBCL [ 260 – 262 ]. A preclinical/clinical phase II study demonstrated that targeting the canonical NF-κB pathway through inhibition of the 26S proteasome complex with bortezomib can selectively sensitize patients with relapsed/refractory ABC-DLBCL, but not patients with relapsed/refractory GCB-DLBCL, to chemotherapy (including (R-)CHOP and DA-EPOCH) [ 263 ]. Bortezomib alone as single agent had no significant activity in relapsed/refractory DLBCL [ 263 – 265 ], but when combined with chemotherapy, it showed a significantly higher response (83 % vs. 13 %) and median overall survival (10.8 vs. 3.4 months) in ABC compared with GCB-DLBCL, respectively [ 263 ] (Additional file 1 : Table S5). A subsequent phase I/II study of patients with previously untreated DLBCL investigating bortezomib in combination with R-CHOP demonstrated that the efficacy of bortezomib plus R-CHOP was similar in patients with non-GCB- and GCB-DLBCL, consistent with the concept that the unfavorable non-GCB-DLBCL subgroup with constitutive NF-κB overexpression derives benefit from bortezomib sensitization with chemotherapy [ 266 ] (Additional file 1 : Table S3). A phase II study and a randomized phase III study evaluating the use of R-CHOP with or without bortezomib in unselected patients with newly diagnosed DLBCL (Additional file 1 : Table S4) as well as a randomized phase II/III study of R-DHAP with and without bortezomib in patients with relapsed/refractory DLBCL are currently ongoing ( NCT00931918 , NCT01324596 and NCT01805557 ) (Table 9 ). Unfortunately, not all ABC-DLBCL are bortezomib-sensitive, and patients may eventually develop bortezomib-resistant disease. Preclinical studies showed that proteasome inhibitors not only trigger the accumulation of proapoptotic proteins, but can also up-regulate antiapoptotic proteins, particularly MCL1 [ 267 ] and HSP90 [ 268 ], which are implicated in bortezomib resistance [ 267 – 269 ].

Surprisingly, a recent preclinical study uncovered an unexpected profound regulatory role for the bromodomain and extraterminal domain (BET) proteins BRD2 and BRD4 in cytoplasmic signaling through IKK in ABC-DLBCL [ 239 ]. Inhibition BET proteins by small molecules inhibitors CPI203 and JQ1 as well as siRNA-mediated depletion of BRD2 and BRD4 expression, attenuated oncogenic IKKβ signaling, thereby inhibiting downstream oncogenic NF-κB-driven transcriptional programs and killing ABC-DLBCL cells in vitro and in an ABC-DLBCL xenograft model [ 239 ].

Inhibition of MALT1 in the BCR-subtype of ABC-DLBCL

Recent studies demonstrated that the proteolytic activity of mucosa-associated lymphoid tissue lymphoma translocation (MALT) protein-1 is required for the survival and pathogenesis of ABC- DLBCL with chronic active BCR signaling [ 270 , 271 ] and therefore, represents another new potential therapeutic target in relapsed/refractory cases of the BCR-subtype of ABC-DLBCL [ 270 ]. MALT1 is an enzymatically active signaling component essential for upstream activation of NF-κB upon antigen stimulation of BCR [ 270 ]. MALT1-dependent cleavage of the non-canonical and tumor suppressive NF-κB family member RELB promotes canonical NF-κB activation in DLBCL [ 272 ]. Recent preclinical studies demonstrated that selective inhibition of the proteolytic activity of MALT1 with small-molecule inhibitors blocks the anti-apoptotic NF-κB signaling pathway and elicits toxic effects selectively on MALT1-dependent subsets of ABC-DLBCL cells in vitro and in vivo with very little toxicity towards primary B cells [ 273 , 274 ].

Inhibition of TLR-mediated canonical NF-κB signaling pathways in ABC-DLBCL

As mentioned above, a recent clinical phase II study demonstrated that ibrutinib does not inhibit the growth and survival of BCR wild-type ABC-DLBCL tumors with MyD88 mutations [ 235 , 239 , 240 ]. MyD88 is an initial adapter linker protein in the canonical NF-κB signaling pathway activated by Toll-like receptors (TLRs), including the endosomal TLRs 7, 8, and 9 [ 275 ]. In the presence of the most common MyD88 mutant L265P, ligand activation of those TLRs results in markedly increased signaling with subsequent increased cell activation, cell survival, and cell proliferation in DLBCL [ 103 ]. Thus, direct inhibition of TLR/MyD88 signaling pathways by TLR antagonists might circumvent the resistance of BCR wild-type ABC-DLBCL tumors with MyD88 mutations against ibrutinib. A dose escalation phase I/II study evaluating the efficacy and safety of the TLR antagonist IMO-8400 in patients with relapsed or refractory DLBCL bearing a MyD88-L265P mutation has been recently started ( NCT02252146 ). IMO-8400 is an antagonistic oligonucleotide specifically designed to inhibit ligand activation of TLRs 7, 8 and 9 [ 276 ]. The scientific rationale for assessing the use of IMO-8400 to treat patients with DLBCL and the L265P mutation is based on the observations that IMO-8400 inhibits ligand-based activation of DLBCL cell lines with the L265P mutation and decreases the survival and proliferation of DLBCL cells (unpublished data of preclinical studies performed by Idera Pharmaceuticals, Inc.).

Inhibition of non-canonical NF-κB signaling pathways in TRAF3 -negative ABC-DLBCL

Several recent studies provided strong evidence for an important role of the non-canonical NF-κB signaling pathway in DLBCL, particularly in ABC-DLBCL [ 160 ]. Non-canonical NF-κB signaling appears to be activated by a restricted number of ligands in DLBCL, such as CD30 ligand (CD30L), CD40 ligand (CD40L) and B cell activating factor BAFF, belonging to the TNF superfamily. Binding to the corresponding receptors (CD30, CD40 or BAFF-R/BR3) results in activation and accumulation NF-κB-inducing kinase (NIK), which in turn activates IKKα, the kinase that promotes the processing of p100 into the active p52 isoform, thereby resulting in continuous activation of p52/p50, RelB/p50 or RelB/p52 heterodimers in the nucleus [ 27 , 160 , 161 ]. Pham L.V. et al. recently reported that NIK kinase is overexpressed and accumulates in both GCB-like and ABC-like DLBCL cell lines [ 160 ]. NIK activation is usually tightly controlled through negative feedback mechanisms involving negative regulation by the adaptor/regulator proteins TNF receptor-associated factor 2 and 3 (TRAF2/3) and the cellular inhibitors of apoptosis ubiquitin ligases (c-IAP1/2) [ 27 , 160 , 161 ]. CD30, CD40 and BR3 receptors have been suggested to form a multimeric complex with TRAF3, TRAF2, TRAF5 c-IAP1, and c-IAP2 in DLBCL cells [ 27 , 160 , 161 ]. Both TRAF2 and TRAF3 serve as negative regulators of non-canonical NF-κB signaling pathways and target NIK for constant ubiquitination and degradation [ 161 ]. Loss of this quaternary inhibitory complex can lead to increased NIK protein accumulation and constitutive activation of the non-canonical NF-κB signaling pathway [ 161 ]. Indeed, 10 % of DLBCL cases demonstrate nuclear NF-κB activity exclusively for the non-canonical pathway (indicated by nuclear staining of p52 but not p50) while 20 % of DLBCLs display nuclear staining for both p50 and p52 [ 18 ], strongly indicating that the concurrent activation of both canonical and non-canonical NF-κB pathways occurs in a large fraction of DLBCL [ 18 , 27 , 160 ]. In line with these observation, recurrent loss of function mutations and deletions were recently revealed in genes encoding TRAF2 and/or TRAF3 in DLBCL [ 12 , 15 , 16 , 19 , 26 , 27 , 161 ]. Zhang B. et al. demonstrated that biallelic or monoallelic deletions/mutations of TRAF3 occur recurrently in roughly 15 % of ABC-DLBCL and GCB-DLBCL (in similar fractions) and correlate with non-canonical NF-κB activity in ABC-DLBCL cases [ 27 ]. Modeling these genetic events in mice, Zhang B. et al. demonstrated a key oncogenic role for the non-canonical NF-κB pathways in DLBCL pathogenesis [ 27 ]. Most DLBCL tumors developed in their mice model resembled ABC-DLBCL [ 27 ]. Thus, NIK appears to be an attractive new therapeutic target for ABC-DLBCL treatment, particularly for patients with ABC-DLBCL that are refractory to bortezomib or to the BCR pathway inhibitor ibrutinib. Of interest, proteasome inhibitors such as bortezomib or carfilzomib, can also block the constant ubiquitination and degradation of NIK, thereby upregulating the non-canonical NF-κB signaling pathways. In addition, targeting both arms of NF-κB signaling may also improve the therapeutic outcome in patients with newly diagnosed high-risk DLBCL displaying mutations in both canonical and non-canonical NF-κB pathways [ 12 , 18 , 19 , 27 , 161 ]. Dual targeting of NF-κB pathways has been successfully demonstrated for multiple myeloma in vitro and in a xenograft model [ 277 , 278 ].

Combination therapy simultaneously targeting NIK and IKKβ (as a main kinase of the canonical NF-κB pathway), either using the selective NIK inhibitors (AM-0216 or AM-0561) and a small molecule IKKβ inhibitor (MLX) [ 278 ] or the promising dual inhibitor of NIK and IKKβ, PBS-1086 [ 277 ], showed significant anti-multiple myeloma activity, associated with apoptosis and inhibition of both NF-κB pathways in tumor cells in vitro [ 277 , 278 ] and in a mouse xenograft model of human multiple myeloma [ 277 ]. To our best knowledge, there are no clinical trial studies ongoing, which evaluate the safety and efficacy of NIK inhibitors in patients with newly diagnosed or relapsed/refractory DLBCL.

Inhibition of NF-κB signaling and reactivation of a lethal type I interferon response in the BCR-subtype of GCB and ABC-DLBCL by targeting cereblon

Recent preclinical study demonstrated that the thalidomide-like drug lenalidomide is preferentially suppressing the proliferation and survival of ABC-DLBCL subtypes with minimal effects on non- ABC-DLBCL [ 90 , 91 ]. Thalidomide-like immunomodulatory agents such as lenalidomide or pomalidomide, are clinically important drugs for multiple myeloma and other B-cell malignancies [ 279 – 281 ]. The activity of lenalidomide in ABC-DLBCL has at least two postulated mechanisms: inhibition of BCR-mediated NF-κB-dependent pro-survival signaling pathways in and expression of trancription factor IRF4, which in turn leads to the upregulation of the STAT2/type I interferon death pathway [ 90 , 91 ]. IRF4 overexpression has been shown to enhance NF-κB activation and BCR signaling [ 90 , 91 ]. The lenalidomide-mediated reduction of IRF4 requires the E3 ubiquitin ligase complex coreceptor protein cereblon (CRBN) [ 90 , 91 ]. CRBN a substrate receptor of the Cul4-Rbx1-DDB1-CRBN E3 ubiquitin ligase complex, is a direct target of the immunomodulatory drugs thalidomide, lenalidomide and pomalidomide [ 282 , 283 ]. Thalidomide-like drugs directly bind to CRBN and promote the recruitment of its common substrates such as transcription factors Aiolos and Ikaros to the E3 ubiquitin ligase complex, thus leading to substrate ubiquitinylation and degradation [ 284 ] and subsequent repression of IRF4 and SPIB [ 90 , 91 ]. Repression of IRF4 and SPIB by lenalidomide induces a lethal type I interferon response in ABC-DLBCL by augmenting interferon β (IFNβ) production [ 90 ]. IRF4 and its regulatory partner SPIB prevent IFNβ production by repressing IRF7 in ABC-DLBCLs [ 90 ]. The STAT2/type I interferon (IFNα/β) axis is well known to have a tumor suppressor function in B-cell lymphoma in vitro [ 285 , 286 ] and inhibits tumor growth in vivo [ 287 ]. Loss of the STAT2-IFNα/β axis confers resistance to apoptosis induced by chemotherapeutic drugs in B-cell lymphoma cell lines [ 285 , 286 ]. However, due to their high toxicities, IFNα and -β have not yet been accepted as clinically useful agents in patients with aggressive B-cell lymphoma.

Multiple phase I/II and phase II clinical trial studies revealed that lenalidomide is well tolerated and produces already as single agent durable responses in patients with aggressive relapsed/refractory ABC-DLBCL, leading to an overall response rate (ORR) of up to 53 % and a complete response rate (CR) of up to 23 % in non-GCB-DLBCL (including ABC-DLBCL cases) (Additional file 1 : Table S2) [ 288 – 293 ]. In line with the reported efficacy of bortezomide and ibrutinib for non-GCB-DLBCL, patients with non-GCB-DLBCL showed a higher response to lenalidomide in relapsed/refractory DLBCL (ORR 52.9 %) when compared to patients with GCB-DLBCL (ORR 8.7 %) (Additional file 1 : Table S2) [ 288 ]. In an additional separate ongoing multicenter, randomized clinical phase II/III study, patients with refractory ABC-DLBCL treated with lenalidomide, when compared to GCB patients, showed greater improvements in ORR (45.5 % vs. 21.4 %), PFS (82 weeks vs. 13.2 weeks) and OS (108.4 weeks vs. 30 weeks) [ 294 ] (Additional file 1 : Table S2). Recent phase I/II clinical trial studies have demonstrated that the combination of lenalidomide with R-CHOP is safe and efficacious, particularly in elderly patients [ 291 , 295 – 299 ] (Additional file 1 : Table S5). Several randomized phase III studies evaluating the use of lenalidomide with or without R-CHOP in patients with newly diagnosed DLBCL as well as in patients with relapsed/refractory DLBCL are currently ongoing ( NCT01122472 (REMARC), NCT02285062 (ROBUST), NCT02128061 , NCT01197560 ) [ 281 ] (Table 9 and Additional file 1 : Table S2).

A recent study performed by Hagner P.R. et al. demonstrated that CC-122, a novel immunomodulatory agent-like thalidomide analog, directly binds to CRBN and promotes ubiquitinylation and degradation of Aiolos and Ikaros in DLBCL in vitro , in vivo and in patients with relapsed/refractory DLBCL, resulting in a mimicry of lethal IFN type I signaling through direct de-repression of interferon-stimulated gene (ISGs) transcription and induction of interferon inducible proteins, and ultimately leading to apoptosis in DLBCL [ 300 ]. Surprisingly, CC-122 emerges with features that differentiate it from family member of thalidomide analogs. The anti-lymphoma activity of CC-122 was independent of the cell of origin and observed in both ABC- and GCB-DLBCL cell lines, in contrast to the ABC-subtype selective activity of lenalidomide [ 300 ]. CC-122 has therefore been suggested to belong to a new class of drugs: pleiotropic pathway modifiers [ 300 , 301 ]. These novel properties make CC-122 potentially clinically active in the GCB- subtype of DLBCL in which its predecessor, lenalidomide, has only limited or even no activity [ 300 ].

At least three possibilities have been suggested to explain the differential activity of CC-122 and lenalidomide [ 300 , 301 ]. First, CC-122 may promote the recruitment, ubiquitination and degradation of specific and unique substrates to mediate some of its biological effects distinct from lenalidomide [ 300 ]. Secondly, Aiolos and Ikarus, both known co-repressors of ISG transcription may act independently of IRF4 and interferon secretion in GCB- and type-3 DLBCL [ 300 ]. Thirdly, CC-122 may promote the upregulation of the STAT2/type I interferon death pathway independently of IRF4 in GCB-DLBCL [ 301 ]. Moreover, other potential immunomodulatory mechanisms for its activity in (GCB)-DLBCL likely do exist and may impact the nonimmune environment in vivo , in patients as well [301]. CC-122 has already demonstrated clinical activity as single-agent in DLBCL [ 300 – 302 , 303 ]. CC-122 is currently in phase I trials in patients with newly diagnosed DLBCL or relapsed/refractory DLBCL, either as a single-agent ( NCT01421524 ) [ 300 – 302 , 303 ] (Additional file 1 : Table S2) or in combination with the novel dual mTORC1/mTORC2 inhibitor CC-223 [ 304 ], the novel BTK inhibitor CC-293 [ 305 ] and/or rituximab ( NCT02031419 ) as well as in combination with obinutuzumab, ( NCT02417285 ) [ 303 ] (Additional file 1 : Tables S5 and S14).

Of interest, Shi C.X. et al. recently demonstrated that proteasome inhibitors such as bortezomib and carfilzomib can block Ikaros degradation by lenalidomide in multiple myeloma, when concomitantly added to the lenalidomide treatment [ 306 ]. These data suggest that administration of thalidomide-like agents concurrent with or shortly after proteasome inhibitor administration might be ineffective or at least strongly reduce the efficacy of thalidomide-like agents in DLBCL.

Inhibition of JAK2/STAT3 in ABC-DLBCL

The JAK/STAT3 signaling pathway represents another potential therapeutic drug target for relapsed or refractory ABC-DLBCL. Constitutive STAT3 activation has been recently correlated with poor overall survival in patients with ABC-DLBCL subtype treated with R-CHOP [ 307 – 310 ]. Inhibition of constitutive STAT3 activity sensitizes resistant B-cell NHL cells to chemotherapeutic cytotoxic drugs, including CHOP, cisplatin, fludarabine, adriamycin, and vinblastine [ 164 , 171 ]. STAT3 is persistently phosphorylated (pSTAT3-Y705) in most ABC-DLBCL in an autocrine and paracrine manner (from the tumor microenvironment) [ 311 – 313 ]. Inactivating STAT3 in ABC-DLBCL cells inhibits cell proliferation and triggers apoptosis in vitro [ 312 – 314 ]. Small molecule inhibitors of STAT3 signaling (inhibitors of nuclear translocation or JAKs) are currently under investigation whether they could serve as drugs for relapsed and/or refractory ABC-DLBCL [ 171 , 311 , 315 ] (Additional file 1 : Table S6). A phase I/II is currently being performed in patients with advanced tumors, including refractory DLBCL, evaluating the clinical efficacy and safety of ISIS-STAT3Rx, an antisense oligonucleotide, which inhibits nuclear translocation of STAT3 ( NCT01563302 ). Clinical grade oral inhibitors of JAK1 and JAK2, such as fedratinib (SAR302503/TG101348) or ruxolitinib, which blocks phosphorylation of STAT1 and STAT3 [ 60 ] have been recently proposed for clinical evaluation for the treatment of ABC-DLBCL [ 60 , 316 , 317 ]. A multicentre phase II study of ruxolitinib in patients with relapsed/refractory DLBCL is ongoing ( NCT01431209 ) [ 109 ].

Moreover, a phase I study evaluating the safety and efficacy of the novel JAK1 inhibitor INCB039110 [ 318 ] has been recently started in relapsed/refractory B-cell lymphoma, including DLBCL ( NCT01905813 ) (Additional file 1 : Table S6). In addition, the novel macrocyclic pyrimidine-based selective oral inhibitor of JAK2/JAK2(V617F) and FLT3 kinases, pacritinib (SB1518), which blocks phosphorylation of STAT1, STAT3 and STAT5 has also been suggested for further investigations in clinical studies of patients with relapsed/refractory DLBCL [ 317 , 319 , 320 ] (Additional file 1 : Table S6). A phase I dose-finding and pharmacokinetic/pharmacodynamic study of pacritinib (SB1518) has shown safety and early clinical activity in patients with relapsed B-cell lymphoma, providing the first proof of principle of the potential clinical value of targeting JAK/STAT pathway in B-cell lymphoma [ 317 , 321 ]. Unfortunately, no responses were observed in the five patients with relapsed/refractory DLBCL, which was explained by the small number of patients [ 317 , 321 ] (Additional file 1 : Table S6). To date, pacritinib (SB1518) is the first and only JAK2 inhibitor that has been already evaluated in patients with relapsed/refractory DLBCL [ 317 ].

HDAC inhibitors can also enhance dephosphorylation of STAT3 and are evaluated in ongoing clinical trials in DLBCL, including relapsed/refractory DLBCL (see next sections). Moreover, a recent study provided evidence that STAT3 mediated proliferation and survival of DLBCLs also depends on IL10/IL10-receptor signaling [ 322 , 323 ], suggesting IL10-receptor (IL10R) as a novel JAK2/STAT3 pathway-specific therapeutic target in DLBCLs [ 322 ]. Inhibition of IL10R signaling with an anti-IL10R-blocking antibody induced dose-dependent cell death in all tested ABC-DLBCL cell lines and primary DLBCLs [ 322 , 323 ]. Anti-IL10R treatment resulted in interruption of the IL10/IL10R-STAT3 auto-stimulatory loop [ 322 ].

Inhibition of PI3K/AKT/mTORC1 and PI3K/mTORC2/PKC/AKT pathways in GCB-DLBCL and BCR-subtype of ABC-DLBCL

The constitutive activation of the PI3K/AKT/mTORC1 pathway in GCB-DLBCL plays a central role in promoting survival and chemotherapy-resistance and represents a rational therapeutic target in relapsed or refractory GCB-DLBCL [ 324 ]. Deregulation of the PI3K/AKT/mTORC1 pathway by the inactivation of PTEN, an inhibitor of the PI3K/AKT/mTORC1 pathway, is found in 55 % of GCB-DLBCL cases, but only in 14 % of non-GCB-DLBCL and worsens prognosis [ 324 ]. In preclinical in vitro studies, inhibitors of PI3K, such as LY294002 selectively targeted PTEN- deficient GCB-DLBCL cells [ 324 , 325 ]. In addition, inhibition of target of rapamycin complex 1 (mTORC1) or PI3K blocks proliferation and induces cell death in BCR-subtype of ABC-DLBCL [ 133 , 232 , 233 ]. Idelalisib (formerly GS-1101 and CAL-101), a selective oral reversible inhibitor of the p110δ isoform of PI3K, is currently evaluated in an ongoing early phase I study as a single-agent in patients with relapsed/refractory DLBCL. Moreover, an ongoing early dose escalation and dose expansion phase I study is evaluating the safety and efficacy of idelalisib in combination with the novel BTK inhibitor ONO - 4059 in patients with relapsed/refractory ABC-DLBCL (Additional file 1 : Table S14). In addition, MK-2206, an AKT inhibitor and BKM-120, a pan-class I PI3K inhibitor, are currently being tested in early clinical phase I trials in DLBCL, including relapsed/refractory DLBCLs (Additional file 1 : Table S2).

However, new drugs targeting the PI3K/AKT/mTORC1 pathway appears to have only modest activities as a single-agent in treating patients with relapsed/refractory DLBCL and many patients experience severe side effects [ 326 – 328 ]. For instance, recent phase II trial studies of the oral mTORC1 inhibitors everolimus (RAD001) and temsirolimus, two analogues of the parental compound rapamycin, showed a very modest ORR of 30 to 38 % and CR of only 12 % for DLBCL [ 326 – 328 ] (Additional file 1 : Tables S2 and S5). An ongoing randomized clinical phase III study is further evaluating everolimus in patients with relapsed/refractory DLBCL ( NCT00790036 ) (Table 9 ). The modest activity observed in these clinical studies has been explained in two ways: First, blockade of PI3K/AKT/mTORC1 pathway induces autophagy [ 329 , 330 ], which can serve as a protective mechanism to mitigate the cytotoxicity of drugs targeting the PI3K/AKT/mTORC1 pathway in DLBCL cells [ 329 ]. Autophagy can also serve as a protective mechanism to survive from chemotherapeutic-induced genotoxic stress [ 331 ]. Inhibition of autophagy has been shown to enhance chemotherapy-induced cell death [ 331 ] and enhance the toxic activity of drugs targeting the PI3K/AKT/mTORC1 pathway in DLBCL cells [ 329 ]. Secondly, the weak activity of rapamycin analogues can also be explained by their mTORC1-selective inhibitor activity. Both everolimus and temsirolimus target only the mTORC1 but not mTORC2. mTORC2 is generally considered to be unaffected by rapamycin and produces resistance at least partly via the induction of upstream receptor tyrosine kinase signaling and phosphorylation of AKT on S473, a critical regulatory site that stimulates maximal activity of this important survival kinase [ 332 – 334 ]. Thus, it is hypothesized that dual mTOR kinase inhibitors, blocking both PI3K/AKT/mTORC1 and PI3K/TORC2/PKC/AKT signaling pathways to prevent feedback loops, may have expanded therapeutic potential [ 304 ]. Pre-clinical studies have already demonstrated that dual inhibition of mTORC1/2 can overcome rapamycin and/or temsirolimus resistance in solid cancer types [ 335 ]. An ongoing phase I/II, multi-center study evaluating the safety and efficacy of the novel dual mTORC1/mTORC2 inhibitor CC-223 [ 304 ] in patients with relapsed/refractory tumors, including DLBCLs, is currently testing this hypothesis ( NCT01177397 ) [ 304 ]. A preclinical study performed by Mortensen D.S. et al. provided preliminary evidence that CC-223 can strongly inhibit the growth of GCB-, ABC- and type-3 DLBCL cell lines associated with high mTORC1 and mTORC2 activity in vitro [ 304 ]. Of interest, these data suggest that ABC-DLBCL with high IRF4 tend to be less sensitive towards CC-223 [ 304 ]. In addition, a phase I study evaluating the efficacy and safety of the dual mTORC1/2 inhibitor OSI-027 in patients with solid cancer and B-cell lymphoma, including DLBCL has been recently completed and is pending announcement of the results ( NCT00698243 ) [ 336 ]. OSI-027 is a novel, highly selective, dual mTORC1/2 inhibitor that inhibits the phosphorylation of mTORC1 and mTORC2 [ 336 ]. A previous preclinical study showed that OSI-027 markedly diminished proliferation and induced apoptosis in a variety of lymphoid cell lines and induced tumor regressions in B-cell lymphoma xenograft models [ 336 ]. Moreover, using in vitro screening, Ezell S.A. et al. recently demonstrated that the combination of ibrutinib and AZD2014, a novel dual catalytic inhibitor of mTORC1/mTORC2, is highly synergistic in killing ABC-subtype DLBCL cell lines, weakly expressing IRF4 [ 232 ]. Simultaneous inhibition of BTK and mTORC1/2 caused apoptosis both in vitro and in vivo and resulted in tumor regression in a xenograft model [ 232 ].

Taken together, despite their modest activity as single-agents both everolimus and temsirolimus might be targeted as a clinical strategy for re-sensitization to (R-)CHOP based chemotherapy [ 329 , 337 , 338 ]. Ongoing clinical phase I/II studies are evaluating the safety and activity of salvage therapy consisting of the oral mTORC1 inhibitors everolimus and temsirolimus, added to standard therapy of rituximab or R-CHOP, respectively, in patients with newly diagnosed or relapsed/refractory DLBCL (Additional file 1 : Tables S4 and S5).

Inhibition of programmed death-1 (PD-1) signaling in (HR-like)-subtypes of ABC-DLBCL

Programmed death 1 (PD-1) is an inhibitory receptor expressed on the surface of T cells that functions in conjunction with receptor ligands, PD-L1 and PD-L2 to physiologically limit T-cell activation and proliferation [ 339 ]. Its ligands, PD-L1 and PD-L2, are expressed on antigen-presenting cells [ 339 ]. Binding of PD-L1 or PD-L2 to its receptor inhibits T-cell activation and counterbalances T-cell stimulatory signals, thus primarily limits the T-cell response in peripheral tissues [ 339 ]. The sustained expression of PD-1 and the receptor ligands result in T-cell exhaustion and immune escape [ 339 , 340 ]. This mechanism has been adopted by tumors to prevent antitumor activity in tumor-infiltrating lymphocytes that are present in the tumor microenvironment [ 340 ].

The PD-1/PD-L1 pathway plays an important role in tumor immune evasion [ 340 ]. PD-L1 expression is either driven by direct oncogenic signaling or upregulated on the tumor cell surface via induction by IFNγ or other inflammatory cytokines, as occurs in the course of the normal immune response [ 340 ]. IFNγ/cytokine induced expression of PD-L1 is mainly mediated through JAK2-STAT1 and/or STAT3 respectively [ 341 – 343 ]. PD-L1 is aberrantly overexpressed in subsets of aggressive GCB- and ABC-DLBCL (10–14 % of DLBCL-NOS) with worse prognosis, most likely belonging to the HR-subtype of ABC-DLBCL [ 344 – 348 ]. A recent phase II study of the anti-PD-1 antibody pidilizumab ( NCT00532259 ), administered to patients after ASCT for relapsed/refractory DLBCL demonstrated an overall response rate of 51 % in patients with DLBCL [ 349 ] (Additional file 1 : Table S2). 34 % of patients who had residual disease after ASCT experienced a complete response [ 349 ]. The 16-month progression-free survival was 72 % in the population as a whole and 70 % in high-risk patients [ 349 ]. These data suggest that PD-1 is a very promising target in the treatment and management of relapsed/refractory DLBCL. A phase II clinical trial is currently ongoing to evaluate the role of the anti-PD-1 antibody nivolumab in relapsed/refractory DLBCL [ 344 ] (Additional file 1 : Table S2). There are also efforts to combine anti-PD1 agents with other drugs [ 344 ] (Additional file 1 : Table S2). For instance, a phase I/II clinical trial evaluating the efficacy and safety of the anti-PD-1 antibody MEDI4736 in combination with ibrutinib in patients with relapsed/refractory DLBCL is currently ongoing (Additional file 1 : Table S2).

Inhibition of EZH2 in GCB-DLBCL

The polycomb-group oncogene product enhancer of zeste homologue 2 (EZH2) is a histone methyltransferase and plays a key role in transcriptional repression through chromatin remodeling [ 350 ]. The EZH2Y641F has now been reported as a gain-of-function mutation in > 21 % of GCB-DLBCL and is essentially absent from ABC-DLBCL [ 29 ]. The Y641F mutation in EZH2 results in altered histone-lysine methyltransferase activity [ 351 , 352 ]. The EZH2Y641F mutation can cooperate with c-MYC to accelerate lymphomagenesis in animal models and is implicated in drug resistance [ 353 ]. In addition, EZH2 cooperates with BCL2 and BCL6 to create the GCB phenotype and induce B-cell lymphomas through formation and repression of bivalent chromatin domains [ 77 , 79 ]. Several recent preclinical studies demonstrated that potent and selective S-adenosyl-methionine-competitive small molecule inhibitors of EZH2 such as E7438 (EPZ-6438), GSK-126 or CPI-360 eliminate tumor growth in GCB-DLBCL models with activating EZH2 mutations [ 77 , 354 – 356 ]. GSK-126 is selectively targeting the activating oncogenic mutant form of EHZ2 [ 355 ]. GSK-126 affected the viability of mutant EZH2-containing GCB-DLBCL cells in vitro and in mouse xenograft models with EZH2 mutations in vivo but not of wild-type (WT) EZH2-containing GCB-DLBCL cells or in mouse WT-EZH2 xenograft models [ 355 ]. On the other hand inhibitors such as CPI-360 are broadly efficacious also in GCB-DLBCL models with wild-type EZH2 [ 356 ]. Thus pharmacological inhibition of EZH2 activity may provide a promising treatment for relapsed or refractory GCB-DLBCL overexpressing EZH2 wild-type and/or mutants. Moreover, a recent preclinical study provided evidence for synergistic anti-tumor activity of the EZH2 inhibitor E7438 (EPZ-6438) and glucocorticoid receptor agonists in models of GCB-DLBCL in vitro [ 357 ]. A phase I/II clinical trial study of E7438 (EPZ-6438) in NHL including newly diagnosed DLBCL is currently ongoing ( NCT01897571 ) [ 354 , 357 ].

Inhibition of BCL2, BFL-1 and MCL1 in GCB- and ABC-DLBCL

Deregulation of members of the B-cell lymphoma (BCL)-2 family of pro- and anti-apoptotic proteins are associated with rituximab and/or chemotherapy resistance in DLBCL-NOS [ 358 – 363 ]. BCL2, BCL2-related factor (BFL)-1 and myeloid leukemia cell differentiation protein (MCL)-1 represent novel therapeutic targets for relapsed or refractory GCB- and/or ABC-DLBCL, respectively [ 360 – 364 ]. BCL2 is overexpressed in approximately 40–65 % of DLBCL tumors, owing to t(14;18)(q32;q21) translocations found in 15–30 % of cases, and through additional mechanisms that are not well defined [ 75 , 107 , 144 , 145 , 360 , 362 , 365 , 366 ]. BCL2 is frequently overexpressed in both GCB- and ABC-DLBCL, albeit the mechanisms of BCL2 upregulation are different between GCB- and ABC-DLBCL [ 75 , 362 , 365 ]. ABC-DLBCLs overexpress MCL1 at significantly higher levels compared with GCB-DLBCL, showing IHC positivity in 50 % of ABC and 30 % of GCB tumors [ 363 ]. Recent studies have suggested that overexpression of BCL2 remains a negative predictor of outcome after rituximab-based chemotherapy mainly in GCB-DLBCL [ 360 , 361 ] while MCL1 mainly contributes to chemotherapy resistance in ABC-DLBCL [ 363 ]. On the other hand, in presence of c-MYC overexpression, BCL2 overexpression also contributes to a decreased survival of ABC-DLBCL after rituximab-based chemotherapy [ 107 ].

Structure-based design was used for the development of small-molecule BH3 mimetics that bind to the BH3 hydrophobic-binding groove of the anti-apoptotic proteins BCL2, B-cell lymphoma-extra large (BCL-XL), BCL2-related protein A1 (BCL2A1/A1) and MCL1 and promote apoptosis [ 367 ]. Small-molecule BH3 mimetics include the clinically relevant agents ABT-737, ABT-263 (navitoclax), ABT-199 and GX15-070 (obatoclax) [ 367 – 370 ]. ABT-737 and its oral derivative A263 bind to BCL2, BCL-W and BCL-XL, but not to MCL1, BFL1 or A1 [ 367 , 369 , 370 ], whereas GX15-070, a pan-BCL2 inhibitor also binds to and inactivates MCL1 [ 367 , 368 ]. Preclinical studies indicate that ABT-737, ABT-263 and GX15-070 are effective against GCB- and/or ABC-DLBCL cells in vitro , including bortezomib-resistant DLBCL cells and substantially suppressed tumor growth in vivo [ 363 , 371 – 373 ]. ABT-263 and GX15-070 have been suggested to be effective in patients with relapsed/refractory DLBCL [ 363 , 371 ]. However, on-target BCL-XL inhibition by ABT-263 and GX15-070 led to dose-dependent thrombocytopenia and posed a barrier to maximizing the activity of these agents [ 374 ]. Moreover, a recent preclinical study suggests that patients may eventually develop ABT-737-resistant disease by up-regulating the expression of MCL1 and BFL1 [ 364 ]. ABT-199 (venetoclax), a second-generation orally available derivative of ABT-737 that selectively targets BCL2 is currently under evaluation in clinical trials of B-cell NHL [ 367 , 374 , 375 ]. ABT-199 has greater than 100-fold selectivity for BCL2 over BCL-XL [ 375 , 376 ].

Preclinical and early clinical studies demonstrated that ABT-199 inhibits the growth of aggressive c-MYC-driven mouse B-cell lymphomas and human BCL2-dependent B-cell lymphoma tumors in vivo without causing thrombocytopenia [ 375 , 377 ]. Of interest, a recent study provided preliminary evidence that normal, untransformed mature B cells may also be sensitive to ABT-199, both in vitro and in vivo [ 378 ]. A preclinical study showed that single-agent ABT-199 had only modest antitumor activity against most DLBCL lines and resulted in compensatory upregulation of MCL1 expression [ 379 ]. Moreover, in a phase I clinical trial study, used as a single-agent, ABT-199 has shown a modest overall response rate of up to 33 % in DLBCL, with a complete response rate of only up to 11 % [ 380 – 382 ]. On the other hand, treatment of high-risk DLBCL with ABT-199 combined with the potent new cyclin-dependent kinase inhibitor dinaciclib [ 383 ], which knocks down MCL1 by inhibiting CDK9 [ 379 , 383 ], synergistically induced tumor regression, in xenografts and in a genetically accurate murine model of c-MYC/BCL2 double-hit B-cell lymphoma [ 379 ]. A phase II study is currently ongoing combining ABT-199 with bendamustine and rituximab in relapsed/refractory NHL including relapsed/refractory DLBCL ( NCT01594229 ) (Additional file 1 : Table S5).

Inhibition of BCL6 in the BCR-subtype of GCB- and ABC-DLBCL

B-cell lymphoma protein BCL6 overexpression inhibits apoptosis induced by chemotherapeutic agents in DLBCL [ 32 ]. BCL6 is overexpressed in both GCB- and ABC-DLBCL, albeit through different mechanisms [ 32 ]. Recent studies demonstrated that HSP90 forms a complex with BCL6 and inhibition of HSP90 with the drug PU-H71, a purine scaffold HSP90 inhibitor destabilizes BCL6 and selectively kills BCL6-positive DLBCL cells in vitro and in vivo [ 384 ]. Subsequent studies demonstrated that small molecule inhibitors, including the retro-inverted BCL6 peptide inhibitor (RI-BPI, 79–6) that directly antagonize BLC6 function by disrupting the BCL6-corepressor complexes via binding in the lateral groove of the BCL6 BTB domain and thereby selectively inhibiting the interaction with nuclear receptor co-repressor BCOR, NCOR1 and NCOR2 proteins [ 123 , 385 , 386 ]. The small-molecule inhibitor mediated disruption of the activity of BCL6, can be selectively toxic towards high-risk BCL6-dependent BCR-subtypes of GCB and ABC-DLBCL in vitro and potently suppressed GCB-DLBCL tumors in a DLBCL xenograft mouse model in vivo through reactivating pro-apoptotic genes repressed by BCL6 [ 123 , 385 , 386 ]. RI-BPI mediated inhibition of BCL6 also induces the expression of EP300, resulting in acetylation and activation of TP53 and concomitant acetylation and inactivation of HSP90 [ 386 ]. Moreover the BCL6 activity can also be indirectly blocked in DLBCLs by pharmacologic inhibition of both HDACs and SIRT1/2 [ 387 – 389 ], see next sections. Together, BCL6 represents a novel promising therapeutic target in relapsed/refractory BCR-subtypes of GCB- and ABC-DLBCL. To our best knowledge, there are no clinical trial studies ongoing, which evaluate the safety and efficacy of HSP90 or BCL6 inhibitors in patients with newly diagnosed or relapsed/refractory DLBCL.

Inhibition of HDACs and Sirtuins in GCB- and ABC-DLBCL

Several recent studies identified small inhibitory molecules targeting histone deacetylases (HDACs) and sirtuins as promising potential therapeutic agents in relapsed/refractory GCB- and ABC-DLBCLs [ 387 ]. SIRT1 expression is associated with poor prognosis in DLBCL [ 390 ]. Several HDAC inhibitors (HDACi) are already approved for clinical use or in clinical trials [ 391 ]. HDACi and sirtuin inhibitors can target both GCB- and ABC-DLBCL, albeit through different mechanisms [ 387 , 392 ]. Various HDACi and sirtuin inhibitors can repress GCB-DLBCL as a result of their inhibition of the BCL6 oncogene [ 386 – 389 ]. Inhibition of both HDACs and SIRT1 results in the accumulation of acetylated BCL6 [ 388 ]. Acetylation of BCL6 inhibits the ability of BCL6 to recruit HDAC-containing SMRT co-repressor complexes [ 388 ]. Thus, inhibition of HDACs and Sirtuins in BCL6-positive GCB-DLBCLs (and to a minor extend in ABC-DLBCL) results in the accumulation of inactive acetylated BCL6 and eventually in cell cycle arrest and apoptosis [ 386 , 388 ]. Moreover a recent preclinical and clinical study demonstrated that combined sirtuin and pan-HDAC inhibition synergistically kills DLBCLs with a preference for GCB-DLBCL [ 389 ]. Combined treatment of DLBCL cells with HDACi such as vorinostat in combination with the Sirtuin inhibitor niacinamide produced synergistic cytotoxicity in vitro and in vivo by inhibiting BCL6 and activating TP53 [ 389 ]. Acetylation of p53 strongly stimulates its pro-apoptotic activity [ 393 ]. A subsequent proof-of-principle phase I clinical pilot trial in patients with relapsed or refractory NHL, including DLBCL led to an ORR of 18 % and CR of 18 % [ 389 ]. 46 % of the patients experienced stabilization of their aggressive disease [ 389 ]. In addition, a study performed by Gupta M. et al. demonstrated that HDACi such as LBH589 can effectively suppress STAT3 in ABC-DLBCL [ 392 ]. Inhibition of HDACs leads to increased acetylation of STAT3, dephosphorylation of pSTAT3(Y705), nuclear export of STAT3 to the cytoplasm and blocks survival of ABC-DLBCL cells [ 392 ]. Inhibition of SIRT1 has also been shown to induce dephosphorylation of pSTAT3(Y705), nuclear export of STAT3 to the cytoplasm and thereby inactivation of STAT3 [ 394 ]. Preliminary data from a clinical phase II trial study indicate that HDACi might not work as single-agents in relapsed/refractory GCB and ABC-DLBCL [ 395 ]. Despite an encouraging activity of the HDACi vorinostat in DLBCL was noted in a phase I trial study [ 396 ], subsequent clinical phase II trial studies of oral vorinostat in relapsed DLBCL showed only limited activity against relapsed DLBCL [ 395 ]. Although vorinostat seems not to be very effective as a single-agent, other more potent pan-HDACi such as romidepsin, panobinostat, MGCD-0103, LBH589 have been suggested as rational therapeutic options for clinical trials in relapsed/refractory DLBCL when combined with other agents [ 1 , 397 ].

Inhibition of BRD4 (and BRD2) in the c-MYC-driven subtype of DLBCL-NOS

High c-MYC expression correlates with inferior clinical outcome in R-CHOP-treated DLBCL patients [ 107 , 138 , 366 ]. C-MYC-driven gene (over)expression has been suggested to confer resistance to rituximab immunotherapy [ 107 , 138 , 366 , 398 ]. Recent preclinical studies demonstrated that the transcriptional coactivator and bromodomain and extra terminal (BET) protein BRD4 is required for transcriptional amplification of the c-MYC oncogene [ 398 – 402 ]. BRD4 occupies a small set of exceptionally large super-enhancers associated with genes including the c-MYC oncogene [ 399 , 403 ]. Inhibition of BRD4 (and other BRD family members) by small molecule inhibitors of the BET family, such as the BET-bromodomain inhibitor JQ1, leads to preferential inhibition of c-MYC oncogene expression, growth arrest and extensive apoptosis in a variety of B-cell leukemia and lymphoma cell lines, including c-MYC/BCL2-double-hit DLBCLs and AML cells that overexpress c-MYC in association with BCL2 [ 398 – 401 , 404 ]. I-BET151, another novel highly selective inhibitor of both BRD2 and BRD4 causes transcriptional silencing of the c-MYC gene and c-MYC-dependent programs in myeloma cells by inhibition of BRD2 and BRD4 binding to the promoter of the c-MYC gene and failure to recruit P-TEFb and PAFc1 complexes to the IGH/c-MYC enhancer by BRD2 and BRD4, and lack of subsequent RNA-Pol-II recruitment [ 405 ]. Both JQ1 and PFI-1, another highly selective inhibitor of BRD4 and BRD2, also displayed significant antitumor activities in vivo in xenograft models of DLBCL, Burkitt’s lymphoma or acute myeloid leukemia and thereby improved survival of engrafted mice [ 399 – 402 , 406 ]. Another preclinical study recently demonstrated that the new BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models, including GCB-, ABC-and type-3 DLBCL-NOS [ 407 ]. OTX015 showed strong anti-proliferative activity in a large panel of cell lines derived from mature B-cell lymphoid tumors [ 407 ]. Interestingly, in addition to its broad cytostatic activity, OTX015 selectively induced apoptosis in a genetically defined subgroup of cells, derived from ABC-DLBCL, bearing wild-type TP53 and mutations in MYD88, CD79B and/or CARD11 [ 407 ]. OTX015 targets and inhibits canonical NF-κB, TLR and JAK/STAT3 signaling pathways, as well as c-MYC- and E2F1-regulated genes in DLBCL in vitro and in vivo [ 407 ]. As already mentioned above, inhibition of BRD2 and BRD4 by CPI203 and JQ1 could also inhibit the oncogenic NF-κB activity and kill ABC-DLBCL cells [ 239 ]. Surprisingly, this effect seems to be independent of c-MYC since ectopic provision of c-MYC did not rescue ABC-DLBCL cells from JQ1 toxicity [ 239 ]. Remarkably, Eμ- Brd2 transgenic mice developed predominately ABC-like DLBCLs [ 408 ]. Confirming previous preclinical studies [ 398 , 399 ], Boi M. et al. also showed that BET bromodomain inhibition by OTX015 increases rituximab sensitivity in DLBCL cells [ 407 ]. At least four small-molecule bromodomain inhibitors of BET are in ongoing oncology/hematology early phase I clinical studies (CPI-0610, NCT01949883 ; GSK525762, NCT01587703 ; OTX015, NCT01713582 and TEN-010, NCT01987362 ), which include relapsed/refractory DLBCL (CPI-0610; NCT01949883 ) (Additional file 1 : Table S2). The first results from a phase I study with the orally available BET bromodomain inhibitor OTX015 have been reported with clinical responses in both leukemia and B-cell lymphoma patients in the absence of major toxicities [ 409 , 410 ].

Of interest, a recent study performed by Lu J. et al. showed that JQ1 and OTX015 can lead to BRD4 protein accumulation over time in Burkitt lymphoma (BL) cells and incomplete c-MYC suppression in vitro [ 411 ]. Whether these effects may also occur in DLBCL remain to be investigated. Remarkably, three recent studies provided a novel strategy, which can circumvent these limitations by generating bifunctional phthalimide or VHL-ligand-conjugated versions of JQ1 and OTX015 [ 411 – 413 ]. Lu J. and colleagues designed a hetero-bifunctional proteolysis targeting chimera (PROTAC), ARV-825, by connecting the small-molecule BRD4 binding moiety OTX015 to the E3 ligase cereblon binding moiety of pomalidomide that recruits BRD4 and BRD2 to the E3 ubiquitin ligase cereblon, leading to fast, efficient, and prolonged degradation of BRD4 and BRD2, effective suppression of c-MYC signaling, inhibition of cell proliferation and apoptosis induction in BL in vitro [ 411 ]. In the second study, Winter G.E. et al. generated a bifunctional thalidomide-conjugated version of JQ1, termed dBET [ 412 ]. Treatment of acute myeloid leukemia (AML) cells with dBET1 induced highly selective cereblon-dependent protein degradation of BET family members in vitro and in vivo , resulted in transcriptional downregulation of MYC, induction of antiproliferative responses in leukemia cells in vitro and delayed proliferation and leukemia progression in mice, without toxicity, thus underscoring the potential clinical utility of this approach [ 412 ]. Moreover, treatment with dBET1 or ARV-825 induced a superior apoptotic response compared with JQ1 or OTX015, respectively in primary AML or BL cells [ 412 ]. Pharmacologic destabilization of BRD4 in vivo also resulted in improved anti-tumor efficacy in a human leukemia xenograft compared to JQ1, highlighting the potential superiority of BET degradation over BET bromodomain inhibition [ 412 ]. Moreover a third study using a BET-specific PROTAC, termed MZ1, that tether JQ1 to a ligand for the E3 ubiquitin ligase VHL, demonstrated preferential degradation of BRD4 over BRD2 and BRD3 at low concentrations and did not observe any degradation of JQ1-specific off-targets by MZ1, thus point to a more BRD4-selective pharmacological profile of BET specific PROTACs compared with pan-selective BET inhibitors JQ1 or OTX015 [ 413 ]. Taken together, cereblon-based PROTACs may therefore provide a better and more efficient strategy in targeting BRD4 and BRD2 than traditional small-molecule inhibitors [ 411 , 412 ]. This chemical strategy for controlling target protein stability of BRD proteins may also have broad implications for therapeutically targeting previously intractable proteins in DLBCL [ 412 ].

Inhibition of PRPS2 in the c-MYC-driven subtype of DLBCL-NOS

Using a mouse model of c-MYC-driven B-cell lymphomagenesis, a recent study uncovered the mechanism by which c-MYC coordinates the nexus between nucleotide metabolism and protein biosynthesis. The authors found that the single rate-limiting enzyme, phosphoribosyl-pyrophosphate synthetase 2 (PRPS2), promotes increased nucleotide biosynthesis in c-MYC-transformed cells [ 414 ]. Remarkably the levels of PRPS2 are specifically increased in c-MYC-driven lymphomagenesis and this upregulation tightly correlates with eukaryotic translation initiation factor 4E (eIF4E) expression, which was also directly induced by c-MYC [ 414 ]. Moreover, the authors also demonstrated that loss of PRPS2 in the Prps2 knockout mouse background is synthetically lethal in c-MYC-transformed human and mouse cell lines, but knockout of Prps2 did not affect wild-type cells or mice [ 414 ]. Depletion of PRPS2 levels by siRNA in c-MYC-driven B-cell lymphomas improved survival and induced complete tumor regression in 30 % of mice, strongly indicating that protein and nucleotide biosynthesis controlled by PRPS2 is crucial for c-MYC-driven tumorigenesis [ 414 ]. Together, PRPS2 might be a promising and effective druggable target in c-MYC-driven subtype of DLBCL-NOS.

Reactivation of the pro-apoptotic TGF-β-SMAD pathway through inhibition of DMNTs in relapsed/refractory GCB and ABC-DLBCL-NOS

Several recent studies identified the transforming growth factor-β (TGF-β)-SMAD pathway as a critical target in relapsed/refractory DLBCL [ 415 – 418 ]. By profiling genome-wide DNA methylation at single-base pair resolution in thirteen DLBCL diagnosis-relapse sample pairs and in a GCB-DLBCL cell line, Pan H. et al. identified a relapse-associated DNA methylation signature based on consistently differentially methylated regulatory elements between diagnosis and relapsed pairs [ 418 ]. This signature was linked with specific genes and pathways, including the pro-apoptotic TGF-β-receptor-SMAD pathway suggested to play an important role in relapse of DLBCL [ 418 ].

These data confirm a previous study indicating that methylation aberrations of TGF-β receptor activity pathway-associated genes might be involved in relapse and chemoresistance in DLBCL [ 417 ]. Pan H. et al. demonstrated that prolonged exposure to low-dose DNMT inhibitors (DNMTi) reprogrammed chemoresistant GCB- and ABC-DLBCL cells to become doxorubicin sensitive in vivo [ 417 ]. Recurrent hypermethylation of the promoter region and reactivation of SMAD1 was a critical contributor and required for chemosensitization [ 417 ]. A subsequent phase I clinical pilot study evaluating the priming by DNMT inhibitor azacytidine (AZA) followed by standard R-CHOP in high-risk patients with DLBCL showed a very high rate of complete remission (92 %) and confirmed SMAD1 demethylation and chemosensitization [ 417 ]. AZA and 5-aza-2′-deoxycytidine/decitabine (5-AZA/DAC) mainly inhibit DNA methyltransferases DMNT1 and DMNT3 resulting in the re-expression of tumor-suppressor genes [ 419 , 420 ]. Both studies are in line with a previous report demonstrating that escaping from TGF-β-SMAD5-mediated growth inhibition through microRNA-155-mediated inhibition of SMAD5 is critical to relapse of DLBCL [ 415 , 416 ]. Together these studies delineate a personalized therapeutic strategy for the clinical use of DNMT inhibitors as activator of the pro-apoptotic TGF-β receptor-SMAD pathway in relapsed/refractory GCB- and ABC-DLBCL. Two recent phase I studies evaluating the efficacy and safety of decitabine in combination with the HDACi vorinostat or valproic acid in patients with relapsed/refractory B-cell lymphoma, including DLBCL has been recently completed and are pending announcement of the results ( NCT00109824 , NCT00275080 ) (Additional file 1 : Table S14).

Treatment of relapsed/refractory DLBCL-NOS with antibody drug-conjugates targeting CD19, CD22, CD30 or CD79B positve tumors

Antibody drug-conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the treatment of malignant B-cell lymphomas. ADCs use antibodies to deliver a potent cytotoxic compound selectively to specific antigen expressing malignant cells, thereby maximizing drug delivery while limiting bystander effects of traditional cytotoxic agents, thus improving the specificity and efficacy of chemotherapeutic agents. Over the past several years, the use of ADCs as targeted chemotherapies has successfully entered clinical practice. Most of ADC developed for B-cell malignancies target CD19 or CD22 [ 421 , 422 ]. CD19 is the earliest differentiation antigen of the B-cell lineage and uniformly expressed on all types of B-lymphocytes and the vast majority of B-cell malignancies but not on other normal cells, thereby representing an attractive target in B-cell malignancies, including DLBCL [ 423 , 424 ]. CD19 is a transmembrane protein that forms a signaling complex together with CD21, CD81 and CD225, which decreases the threshold for the activation of B cells mediated by the BCR [ 425 ]. There are already at least seven distinct ADCs in preclinical and clinical studies, evaluating their efficacy in DLBCL, including relapsed/refractory DLBCL: SAR3419 [ 426 , 427 ], MEDI-551 [ 421 ], inotuzumab-ozogamicin (INO/CMC-544) [ 428 – 430 ], moxetumomab-pasudotox (HA22, CAT-8015) [ 421 , 431 ], brentuximab-vedotin (ADCETRIS) [ 432 ], pinatuzumab-vedotin (DCDT2980S) [ 432 ] and polatuzumab-vedotin (DCDS4501A) [ 433 ] (Additional file 1 : Table S7).

SAR3419 is an anti-CD19 antibody conjugated to the cytotoxine Maytansine DM4, a potent inhibitor of tubulin polymerization and microtubule assembly [ 421 , 422 ]. Two recent early phase I multi-dose-escalation safety and pharmacokinetic studies evaluating SAR3419 in patients with relapsed/refractory DLBCL provided preliminary evidence for promising clinical activity in relapsed/refractory DLBCL and demonstrated that SAR3419 can be safely administered to patients with relapsed/refractory DLBCL (Additional file 1 : Table S7) [ 426 , 427 ]. Another CD19-specific ADC currently evaluated in an ongoing phase I study in relapsed/refractory DLBCL is SGN-CD19A ( NCT01786135 , Additional file 1 : Table S7). SGN-CD19A is an affinity-optimized monoclonal anti-CD19 antibody linked to the microtubule disrupting agent monomethyl auristatin E (MMAE) [ 434 ]. An interim analysis of this phase I study showed promising activities in patients with relapsed or refractory DLBCL; with an ORR of 35 % a CR of 20 % and a PR of 16 % [ 434 , 435 ]. Antitumor activity appeared to be higher in relapsed DLBCL with an ORR of 55 %, a CR of 32 % and a PR of 23 % [ 434 , 435 ]. MEDI-551, an affinity-optimized and afucosylated monoclonal anti-CD19 antibody with enhanced antibody-dependent cellular cytotoxicity (Additional file 1 : Table S7). Inotuzumab-ozogamicin is an affinity-optimized monoclonal anti-CD22 antibody linked to the DNA damaging toxin N-acetyl-γ-calicheamicin dimethyl hydrazide (CalichDMH) [ 430 ]. Calicheamicin binds to DNA in the minor groove and introduces double-strand DNA breaks, leading to G2/M arrest and subsequent cell death [ 430 ]. Promising anti-tumor responses were observed in early stage clinical trials, where inotuzumab ozogamicin was administered either as single-agent or in combination with rituximab [ 430 ]. However, subsequent phase II studies evaluating inotuzumab-ozogamicin with rituximab in patients with high-risk relapsed/refractory DLBCL showed mixed results in patients with high-risk relapsed/refractory DLBCL [ 428 , 429 ]. The observed activities were in one study less than that seen with other standard salvage regimens for transplant eligible patients with DLBCL [ 428 , 429 ]. In the first phase II study inotuzumab-ozogamicin has shown an ORR of up to 74 % and a CR of up to 50 % [ 429 ], while in the second phase II study, the observed activity of inotuzumab-ozogamicin was rather modest with an ORR of 40 % and CR of 21 % (Additional file 1 : Table S7) [ 428 ]. Ongoing phase II trials in CD22 expressing DLBCLs are examining inotuzumab-ozogamicin as part of chemotherapy combination regimens (Additional file 1 : Table S7). An additional CD22-specific ADC under investigation is moxetumomab-pasudotox (HA22/BL22), an affinity-optimized monoclonal anti-CD22 antibody linked to a synthetic ADP-ribosylating Pseudomonas exotoxin (PE38) [ 421 , 422 ]. PE38 exerts its cytotoxic effect on cells by mono-ADP-ribosylating elongation factor 2, thereby inhibiting protein synthesis and leading to cell death [ 422 ]. A recent phase II study evaluating the efficacy and safety of moxetumomab pasudotox in patients with relapsed/refractory B-cell lymphoma, including DLBCL has been recently completed and is pending announcement of the results ( NCT01030536 ). Another promising ADC currently being tested in clinical trials in relapsed/refractory B-cell lymphoma, including DLBCL is brentuximab-vedotin (ADCETRIS). Brentuximab-vedotin is a human CD30-specific antibody-drug conjugate, which consists of the chimeric monoclonal anti-CD30 antibody SGN-30 conjugated to the synthetic microtubule disrupting agent monomethyl auristatin E (MMAE) [ 421 ]. After binding to CD30 on the tumor cell surface, brentuximab-vedotin internalizes leading to release of MMAE via proteolytic cleavage and induction of cell-cycle arrest and apoptosis [ 421 ]. CD30, part of the tumor necrosis factor (TNF) receptor family, is an ideal target for ADC-based therapy in DLBCL. CD30 is variably expressed in approximately 20-30 % of DLBCL, with a higher frequency in non-GCB-DLBCL [ 436 – 438 ]. A phase II study, evaluating the efficacy of brentuximab-vedotin in relapsed/refractory CD30- expressing NHL, showed significant activity as single-agent in relapsed/refractory DLBCL with an ORR of 44 %, CR of 17 % and with a median duration of 16.6 months thus far [ 432 ] (Additional file 1 : Table S7). Ongoing phase I and phase II trials in CD30 expressing DLBCLs are examining brentuximab-vedotin after autologous stem cell transplantation, as part of chemotherapy combination regimens (Additional file 1 : Table S7).

In two recent clinical phase I studies, Pfeifer M. et al. demonstrated that pinatuzumab-vedotin and polatuzumab-vedotin are active agents for the treatment of patients with GCB, ABC and/or type-3 subtypes of relapsed/refractory DLBCL, respectively (Additional file 1 : Table S7) [ 433 ]. Pinatuzumab-vedotin is an anti-CD22 ADC and polatuzumab-vedotin an anti-CD79B ADC that are both conjugated to the microtubule-disrupting agent MMAE [ 421 ]. Preclinical experiments unexpectedly showed that both pinatuzumab-vedotin and polatuzumab-vedotin are highly active and induced cell death in the vast majority of ABC- and GCB-DLBCL cell lines [ 433 ], suggesting that both can be used effectively in DLBCL subtypes without the need for sophisticated molecular testing [ 433 , 439 ]. In a subsequent phase Ib study evaluating escalating doses of polatuzumab-vedotin in combination with rituximab in patients with relapsed/refractory DLBCL, Palanca-Wessels M.C. et al. demonstrated that polatuzumab-vedotin has an acceptable safety and tolerability profile in patients with relapsed/refractory DLBCL [ 439 ]. Polatuzumab-vedotin showed significant activity in relapsed/refractory DLBCL with an ORR of 56 % and CR of 14.8 % [ 433 , 439 ] (Additional file 1 : Table S7). Polatuzumab-vedotin is currently being studied in a phase I trial as a replacement for vincristine in combination with immuno-chemotherapy (R-CHOP) in patients with newly diagnosed DLBCL ( NCT01992653 ) [ 439 ] as well as in a phase II study in combination with rituximab or obinutuzumab plus bendamustine in patients with relapsed/refractory DLBCL NCT02257567 (Additional file 1 : Table S7).

Treatment of relapsed/refractory DLBCL-NOS with anti-CD19 or anti-CD20 chimeric antigen receptor T cells

Another potential approach to target chemotherapy refractory DLBCLs are chimeric antigen receptor-modified autologous T cells (CAR T cells) targeted specifically to antigens expressed by B-cell malignancies. T cells that are genetically modified to express chimeric antigen receptors (CARs) recognizing the B cell-associated CD19 or CD20 molecules have emerged as a clinically feasible, potentially potent therapeutic modality and appears to be safe [ 440 – 446 ]. CARs are fusion proteins made up of antigen recognition moieties and T-cell activation domains [ 440 , 447 – 450 ]. T cells expressing anti-CD19 CARs are activated in a CD19-specific manner and recognize and kill CD19 + primary malignant B cells [ 440 , 441 , 443 , 451 – 453 ]. The CAR T cell based immunotherapy approach serves as a form of adoptive T-cell immunotherapy [ 440 , 454 ]. For a detailed description of CAR T-cell based therapies, the readers are referred to the recent excellent reviews [ 440 , 441 , 443 ].

Studies of CAR T cells have mainly been performed in multiple myeloma, chronic lymphocytic leukemia and acute lymphocytic leukemias [ 440 – 446 ]. Initial studies on patients with relapsed DLBCL treated with anti-CD20 or anti-CD19 CAR T cells were not very successful, most likely due to a cellular anti-transgene immune response in some of the patients [ 443 , 455 ]. Moreover previous studies of anti-CD19 CAR T cells showed that multiple patients with indolent B-cell malignancies had specific depletion of normal B cells and lengthy remissions [ 456 – 458 ]. However, interim results of an ongoing study performed by Kochenderfer J.N. et al. on heavily pre-treated patients showed the first patients, which obtained complete remissions (CRs) in chemotherapy-refractory DLBCL after receiving anti-CD19 CAR T cells [ 459 , 460 ]. Using a significantly changed anti-CD19 CAR T cell production process and modified clinical treatment protocol four of the seven evaluable patients with DLBCL obtained CRs, two obtained PRs, and one had stable disease (SD) after infusion of CAR T cells [ 460 ] (Additional file 1 : Table S8). Infusion of anti-CD19 CAR T cells was associated with significant but only transient toxicity [ 460 ]. In addition, preliminary findings from an ongoing phase IIb study ( NCT02030834 ) evaluating the safety and efficacy of the anti-CD19 CAR-T cells in patients with relapsed or refractory DLBCL and follicular lymphoma showed an ORR of 50 %, a CR of 45 % and a PFS of 37 % at median follow up 6 months with acceptable toxicity in the 12 evaluable patients with relapsed or refractory DLBCL (Additional file 1 : Table S8) [ 461 ].

Several additional phase I/II studies with CAR T cells directed against CD19 + B cells are currently being performed in patients with advanced relapsed/refractory DLBCL after autologous stem cell transplant ( NCT01865617 , NCT01475058 , NCT02431988 , NCT02348216 , NCT01840566 and NCT02445248 ) (Additional file 1 : Table S8). Moreover, a preliminary report of an ongoing pilot study ( NCT01735604 ) evaluating the efficacy and safety of anti-CD20 CAR T cells in patients with chemotherapy refractory advanced DLBCL showed that five out of six evaluable patients experienced objective responses in this pilot trial [ 446 ] (Additional file 1 : Table S8). Thus, CAR T cell based immunotherapy approaches represent a promising novel strategy in the treatment of patients with relapsed/refractory DLBCL.

Acquired (secondary) resistance to novel experimental drugs

Unfortunately, several reports already demonstrated that a small proportion of patients with B-cell malignancies had a relapse during therapies with novel experimental agents, such as ibrutinib, lenalidomide or bortezomib [ 280 , 462 – 464 ]. However, the molecular mechanisms of resistance are poorly understood. For instance, recent studies showed that up to 10 to 15 % of patients with chronic lymphocytic leukemia (CLL) [ 462 ] or mantle cell lymphoma (MCL) [ 463 ] treated with ibrutinib have had a partial response (relapse) due to acquired (secondary) drug resistance to ibrutinib during therapy. A subsequent study demonstrated that the observed acquired resistance to ibrutinib in CLL was due at least in part to recurrent mutations in BTK and phospholipase Cγ2 (PLCγ2) genes [ 465 ].

A cysteine-to-serine mutation in BTK at the binding site of ibrutinib was identified in five patients and three distinct mutations in PLCγ2 were identified in two patients [ 465 ]. Functional analysis showed that the C481S mutation of BTK confers resistance to ibrutinib by preventing irreversible drug binding. The R665W, and L845F mutations in PLCγ2 are all potentially gain-of-function mutations that allow autonomous B-cell-receptor activity that is independent of BTK [ 465 ]. PLCγ2 is one of the key regulators of the B-cell receptor signaling pathway [ 110 ]. Thus, the investigation of the molecular mechanisms underlying the observed secondary resistance to novel agents is of great importance. The identification of novel drug targets that may lead to novel alternative therapeutic strategies for patients with drug resistant relapsed/refractory DLBCL is urgently needed to overcome the arising resistance to novel experimental agents. Molecular profiling of advanced cancer patients participating in targeted therapy trials will be important to identify mutational signatures that may predict for drug sensitivity and guide rational patient specific drug combinations.

Tumor microenvironment (TME)/cell adhesion–mediated drug resistance

It is increasingly apparent that differences in the local tumor microenvironment (TME) affect survival of patients with DLBCL after treatment with chemotherapeutic regimens [ 217 , 218 , 466 ]. The local TME seems to be an essential player for the development and disease progression of DLBCL and to dictate lymphoma cell growth, response to therapy, as well as resistance of residual lymphoma cells to chemotherapeutic agents [ 217 , 466 ]. It is thought that specific niches within the DLBCL tumor microenvironment provide sanctuary for subpopulations of DLBCL cells through dynamic stromal cell-tumor cell interactions [ 217 , 466 ]. Adaptive, reciprocal signaling circuits between tumor cells and supportive fibroblast-like stromal cells of TME via positive feedback/feed-forward loops have been suggested to be essential for the observed TME or environmental-mediated drug resistance (EMDR) [ 217 , 218 ]. EMDR in resident DLBCL cells has been suggested to result in small foci of residual disease that subsequently develop complex genetic or epigenetic means of acquired resistance in response to the selective pressure of therapy [ 217 , 466 ]. However, the exact molecular mechanisms involved in EMDR are not yet fully understood in DLBCL and remain to be elucidated.

The dynamic interplay between tumor cells and supportive fibroblast-like stromal cells, mediated through consists of extrinsic signals, which are generated by the lymphoma microenvironment and intrinsic factors encompassing signaling determinants of cell cycle and pro-survival pathways [ 217 , 218 , 466 ]. For instance, it has been recently suggested that chronic and tonic BCR signaling is a central hub for the integration between the extrinsic B cell microenvironment and the intrinsic signaling pathways in B-cell lymphomas [ 218 ]. For a detailed review about TME induced chronic BCR signaling in B-cell lymphomas the readers are referred to the recent excellent review [ 218 ]. In addition, autocrine and/or paracrine IL6 and IL10, two putative DLBCL survival cytokines, have also been proposed to play an important role in EMDR [ 217 , 218 ]. Several studies documented that higher levels of serum IL6 and/or IL10 in patients with more aggressive disease correlated with unfavorable prognostic factors included in the international prognostic index (IPI) [ 323 , 467 ]. As already discussed, IL10 has been recently shown to enhance survival of primary DLBCL cell lines in vitro [ 322 , 323 ]. Signaling downstream of IL6 and IL10 in B-cell lymphoma involves primarily activation of JAK1/JAK2-STAT3 axis and to a lesser extend the JAK1/JAK2-STAT1 or TYK2-MAPK-STAT1 axis [ 313 , 322 , 323 , 468 ]. Activation of the JAK1/JAK2-STAT3 and JAK1/JAK2-STAT1 signaling cascades often results in upregulation of survival factors such as BCL2 family members [ 313 , 322 , 323 , 468 ], IFN/NF-κB signaling-related immune modulatory factors such as PD-1/PD-L1 [ 341 – 343 ], and/or drug resistance related factors such as DTX3L or ARTD9 [ 116 , 469 – 471 ]. Both DTX3L and ARTD9 have been shown to be involved in drug resistance in HR- DLBCL associated with a R-CHOP chemotherapy-induced microenvironment gene expression signature [ 469 , 470 , 472 ], see next sections. For a detailed review about TME or environmental-mediated drug resistance the readers are referred to the recent excellent reviews [ 217 , 218 , 466 ].

Novel potential drug targets in relapsed and/or chemo-refractory HR-subtypes of GCB-, ABC- and type-3-DLBCL-NOS

Except for the antibodies pidilizumab and nivolumab, both targeting PD-1, no small molecule inhibitors, which specifically target relapsed/refractory HR-subtypes of DLBCLs are yet under investigations. However, several recent studies from different labs identified several candidates, including STAT1, the E3 ubiquitin ligase DTX3L (also known as B-lymphoma and BAL-associated protein (BBAP)) and the B-aggressive lymphoma protein and mono-ADP-ribosyltransferase ARTD9 (also known as BAL1 or PARP9), which may be essentially required for the observed chemotherapy resistance in HR-DLBCL and also play a role in editing or inhibiting the host immune response against HR-DLBCL [ 469 , 470 , 473 ]. These studies strongly suggest that STAT1, ARTD9 and DTX3L might serve as novel druggable targets in HR-subtype DLBCL [ 469 , 470 , 473 ]. Moreover, a recent study using an Eμ- c-Myc driven B-cell lymphoma tumor mice model, demonstrated that the ARTD9-related ARTD8 (also known as B-aggressive lymphoma protein BAL2 or PARP14) is overexpressed in mouse B-lymphoma cells and can facilitate c-MYC driven B-lymphoid oncogenesis [ 474 ].

Both ARTD9 and the closely related ARTD8 belong to the intracellular Diphteria toxin-like glutamate/aspartate-specific mono- and polymerizing-ADP-ribosyltransferase (ARTD) superfamily (also known as PARPs) [ 475 – 477 ] that also includes the ARTD9-related B-aggressive lymphoma protein and active mono-ADP-ribosyltransferase ARTD7 (also known as BAL3 or PARP15) [ 475 , 476 , 478 – 480 ], ARTD7, ARTD8 and ARTD9 contain several evolutionary conserved macrodomains [ 475 , 476 , 478 – 480 ], which have been recently shown to act as binding modules for free and protein-linked mono- or poly-ADP-ribose [ 475 , 481 – 483 ]. A schematic comparison of the domain architecture of the macrodomain containing ARTD (PARP) family members ARTD7-9 is presented in Fig. 4 . Both, ARTD8 and ARTD9 have been shown to interact with ARTD1 [ 471 ]. Fig. 4 Schematic comparison of the domain architecture of the macrodomain-containing ARTD family members ARTD7, ARTD8 and ARTD9 Domain architecture of the human diptheria toxin-like macro-domain containing mono-ADP-ribosyltransferases and ARTD family members ARTD7, ARTD8 and ARTD9. The following domains are indicated: The diptheria toxin-like ART(D) domain is the catalytic core required for basal (mono-)ADP-ribosyltransferae (ART) activity. The WWE domain is named after three conserved residues (W-W-E) and is predicted to mediate specific protein-protein interactions in ubiquitin- and ADP-ribose conjugation systems [ 555 , 636 , 637 ]. The macro or A1pp domains are structurally related to the catalytic domain of enzymes that process ADP-ribose-1-phosphate, a reaction product derived from ADP-ribose 1-2′cyclic phosphate generated by TpT [ 638 ]. The macrodomain can serve as ADP-ribose or O-acetyl-ADP-ribose binding module [ 638 ]. RRM is an RNA and poly-ADP-ribose-binding/recognition motif [ 639 ]

ARTD1, also known as PARP1, is the founding member of the ARTD/PARP family and has been suggested to act as a crucial oncogenic factor in various solid cancer types [ 484 – 488 ]. Numerous preclinical and clinical studies provided preliminary evidence that potent ARTD/PARP inhibitors with a high specificity towards ARTD1 and ARTD2, such as olaparib and veliparib (ABT-888) are promising drugs in the treatment of various solid cancer types [ 484 , 485 ]. ARTD1/2-specific inhibitors are not only effective as single-agents to selectively kill DNA repair deficient solid cancer tumors (i.e., BRCAness tumors) but also as radio- and chemosensitizers of DNA repair proficient solid cancer tumors [ 484 , 485 ]. Recent preclinical studies provided preliminary evidence that the ARTD1/2 inhibitors may also target DNA DSB repair deficient B- and T-lymphoid cells [ 489 ]. Several clinical trial phase I/II studies investigating the roles of ARDT1 and ARTD1/2 inhibitors in DLBCL are currently ongoing (Additional file 1 : Table S9). For a detailed description of the oncogenic functions of ARTD1 and ARTD2, the readers are referred to the recent excellent reviews [ 488 , 490 , 491 ].

Inhibition of STAT1 in the HR-subtype of GCB-, ABC- and type-3-DLBCL

STAT1 signaling is mainly activated by IFNγ and mediated through activation of IFNγ receptor and receptor-associated kinases JAK1 and JAK2 [ 492 ]. However, STAT1 can also be activated by other stimuli such as IL6 and IL10, which play crucial roles in tumor survival and progression [ 493 – 496 ].

Ligand-mediated activation of JAK1, JAK2 or tyrosine kinase 2 (Tyk2) lead to tyrosine phosphorylation of STAT1 on Y701, homodimerization and translocation of STAT1 to the nucleus [ 497 – 501 ]. JAK1/2-mediated phosphorylation of STAT1 phosphorylation on Y701 enhances the nuclear shuttling by triggering the nuclear retention of the shuttling STAT1α and STAT1β, which are kept in the nucleus until tyrosine dephosphorylation occurs [ 498 , 501 , 502 ]. STAT1 exists in two mayor isoforms, the full-length isoform STAT1α, which mainly acts as a sequence specific transcriptional activator of gene expression and STAT1β, lacking a complete transactivation domain [ 503 ]. STAT1β can act both as a transcriptional activator and repressor or antagonist of STAT1α, depending on the stimuli and cell type [ 504 – 508 ]. Subsequent nuclear phosphorylation on S727 in the transactivation domain of STAT1α can also occur independent of STAT1 tyrosine phosphorylation [ 509 ]. For instance, BCR signaling enhances S727 phosphorylation through calcium mobilization and activation of multiple serine kinase pathways, resulting in increased transcriptional activation of STAT1 target genes [ 510 ].

STAT1 has been initially considered to act exclusively as tumor suppressor and key regulator of the surveillance of developing tumors, primarily by activating growth-inhibitory and pro-apoptotic signaling in tumor cells, mainly mediated by IRF1 [ 511 – 514 ]. However, recent studies identified STAT1 as a proto-oncogene product in a variety of cancers [ 468 , 470 , 471 , 515 – 518 ]. The oncogenic activity strongly correlated with abnormal expression of STAT1 and pSTAT1(pY701 and/or pS727) in these tumors [ 468 , 470 , 471 , 515 – 518 ]. Constitutively active STAT1 promotes cell survival, invasion, metastasis, chemotherapy and/or radiation resistance in multiple types of solid cancers [ 468 , 470 , 471 , 515 – 523 ]. Several studies have demonstrated that chemotherapeutic agents, such as doxorubicin or other anthracyclines enhance the expression of STAT1, its activation and the nuclear localization of phosphorylated STAT1 in chemotherapy-resistant solid cancer cells [ 516 – 518 , 520 , 524 ]. STAT1 has therefore been suggested as a potential target for radio- and chemosensitization of aggressive solid tumors that constitutively overexpress IFNγ/STAT1-dependent pathways [ 518 ]. Previous reports provided first evidence that a subset of STAT1- dependent antiviral gene products can simultaneously have radio- and chemo-protective pro-survival functions and are associated with oncogenesis in solid cancers [ 518 ].

Recent studies indicate that STAT1 can also act as a proto-oncogene product in hematopoietic cells and accelerate the development of T- and B-lymphoid malignancies [ 468 , 470 , 525 ]. Constitutive activation of STAT1 has been demonstrated in both acute and chronic leukemia [ 468 , 470 , 525 ]. For instance STAT1 promotes B-lymphoid leukemia development, at least in part by maintaining high MHC class I expression independently of IFN signaling [ 525 ]. Upregulation of MHC class I molecules has been suggested to represent a general mechanism to escape tumor surveillance [ 525 ]. A subsequent study identified an oncogenic TYK2-STAT1 pathway in T-cell acute lymphoblastic leukemia (T-ALL) cell lines, mediated through gain-of-function TYK2 mutations or activation of IL10 receptor signaling, that leads to the upregulation of BCL2 and T-ALL cell survival [ 468 ]. IFNγ/STAT1 signaling has therefore been suggested to exhibit both pro- and antitumor properties, depending on the context and cancer type [ 497 ]. Initially, IFNγ/STAT1 signaling helps protecting the host from tumor formation and development (immune surveillance), but subsequently IFNγ can also promote the tumors to resist attack (immunoediting) and escape by Darwinian evolution [ 473 , 497 , 526 ].

Our own recent study implies that STAT1 might also acts as an oncogene in DLBCLs and be required for proliferation, survival and chemoresistance of HR-subtypes of GCB- and ABC-DLBCL [ 470 ]. We observed increased constitutive phosphorylation of STAT1 on Y701 and S727 in the HR-like GCB-DLBCL cell line SUDHL7 and to a minor extend in the pSTAT3(Y705) positive BCR-subtype ABC-DLBCL cell lines OCI-Ly3 and OCI-Ly10 [ 470 ]. SUDHL7 has been suggested to represent a bona fide model cell line for HR-subtype GCB-DLBCL [ 470 ]. Analysis of primary DLBCL samples revealed positive nuclear co-staining for the oncogene product IRF2, STAT1-pY701 and STAT1-pS727 in 18 % of the primary DLBCL tumor samples analyzed, while benign tissue did not show this pattern in any case [ 470 ]. Our siRNA- STAT1 -knockdown studies revealed that STAT1 is required for growth, survival and chemoresistance of HR-subtype GCB-DLBCL cells in vitro . STAT1β together with ARTD9 synergistically down regulated the transcriptional expression of tumor suppressor IRF1, while STAT1α together with ARTD9 up-regulated the expression of the proto-oncogene IRF2 [ 470 ]. IRF2, an antagonist of IRF1 is known to act as an oncogene in various types of cancer [ 527 ]. Recent studies showed that overexpression of STAT1β, the antagonistic isoform of STAT1α increases the growth rate of cells and their resistance to drug-induced apoptosis and cell cycle arrest by repressing STAT1α target genes such as p21 and IRF1 in human B cells [ 505 ]. Our study provides first evidence that STAT1β, together with ARTD9 may negatively regulate a tumor suppressor network (see also next section). Moreover, in line with the observed activity in B-cell leukemia STAT1 might also promote the outgrowth of DLBCL tumors with reduced immunogenicity (immunoediting). Future knockdown or ectopic (co)-overexpression xenograft studies need to be carried out in order to determine whether absence or overexpression of STAT1α and/or STAT1β negatively or positively affects chemoresistance and tumor growth of HR-DLBCL in vivo .

Together, STAT1 may serve as a novel potential drug target for treatment of high-risk relapsed and/or refractory DLBCLs with a brisk, but ineffective, host immune/inflammatory response and IFNγ signature. It remains to be investigated whether constitutive overexpression and/or phosphorylation of STAT1 alone, independent of ARTD9 or DTX3L, may also serve as novel useful prognostic biomarker for poor survival of fatal high-risk relapsed/refractory DLBCL. A model for the postulated functions of STAT1 in DLBCLs is shown in Fig. 5 . Several clinical phase I/II studies, evaluating the safety and efficacy of JAK1 and JAK2 inhibitors in patients with relapsed/refractory B-cell lymphoma, including DLBCL are ongoing ( NCT01905813 , NCT01431209 ) (Additional file 1 : Table S6) or in planning [ 109 , 317 , 318 ]. Fig. 5 Proposed model for the postulated functions of STAT1 in HR-DLBCL-NOS. Chronic exposure to IFNs and chemotherapeutic agents such as alkylating agents, topoisomerase inhibitors, HDAC inhibitors, or proteasome inhibitors, can lead to constitutive oncogenic upregulation of STAT1 and interferon signaling genes (ISGs) during tumor development [ 515 – 518 , 524 , 640 – 643 ] and select tumor clones resistant to a cytotoxic microenvironment and concurrently to genotoxic therapy [ 518 ]. The overall population of tumor cells is sensitive to cytotoxic factors of microenvironment and committed to death because of the secretion of cytotoxic ligands by host cells (T lymphocytes, B lymphocytes, tumor-associated macrophages, dendritic cells etc.) [ 518 ]. The majority of tumor cells are relatively sensitive to radio- and/or chemotherapy. However, a small fraction of tumor cells (HR-DLBCL cells) constitutively express STAT1/ISGs and are resistant to the cytotoxic microenvironment and genotoxic therapy. Oncogenic constitutive expression of STAT1 can activate the prosurvival secretome, including the interleukines IL6 and IL10 [ 322 , 468 , 644 ] and in turn, can enhance selective advantages of surrounding tumor cells [ 518 ]. Moreover, STAT1 pathway can be also activated in the context of IL6 and IL10 [ 322 , 645 ], thereby generating auto-stimulatory feedback loops (IL6-IL16R-STAT1 and IL10-IL10R-STAT1). Thus, IFN/JAK pathway and chemotherapeutic agents may act in concert with other HR-DLBCL specific intrinsic signaling pathways such as IL10/IL10R-JAK1-TYK2 and or IL6/IL6R-gp130-JAK1/2-TYK2 to induce chemotherapy resistance. In addition, oncogenic JAK/STAT1α-autocrine signaling in HR-DLBCL causes enhanced expression of STAT1α dependent proto-oncogenes (i.e., DTX3L ARTD9, IRF2, MCL1, BCL2, BCL6), thereby stimulating proliferation and survival pathways [ 470 ]. In addition, oncogenic STAT1α signaling helps the tumors to escape the attack by the immune system (immunoediting) [ 473 , 497 , 526 ]. Conversely, STAT1β repress the transcriptional activation of anti-proliferative and pro-apoptotic genes (including tumor the suppressors IRF1 and TP53) [ 470 , 471 ] as well as genes involved in immune surveillance [ 473 , 497 , 526 ]. Adapted from REF: [ 470 , 471 , 518 ]. Abbreviations: HR-DLBCL host response DLBCL, ARTD ADP-ribosyltransferase Diphteria toxin-like, STAT signal transducer and activator of transcription, ISG interferon stimulated gene, IL interleukin, JAK Janus kinase, TYK2 tyrosine kinase 2, IRF interferon response factor, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2

Inhibition of ARTD9 in HR- and BCR-subtype of GCB-, ABC- and type-3-DLBCL-NOS

The inactive mono-ADP-ribosyltransferase ARTD9 is a nucleocytoplasmic shuttling protein that has been identified as a potential risk-related gene product in fatal high-risk DLBCLs [ 469 , 472 ]. ARTD9 is constitutively overexpressed in high-risk chemoresistant subsets of DLBCL tumors associated with a brisk, but ineffective IFNγ-mediated host inflammatory response [ 469 , 472 , 473 ]. The large majority of ARTD9-positive HR-subtypes were classified as ABC-DLBCL [ 469 , 472 ]. Recent studies demonstrated that overexpression of ARTD9 is mainly mediated by (IFNγ)-JAK1/STAT1 and/or autocrine (IL6)-JAK1/STAT3 signaling [ 469 – 471 , 528 ]. In line with these observations and with the expression pattern in DLBCL tumors in vivo , ARTD9 is mainly overexpressed in pSTAT1(Y701/S727)-positive HR-subtype GCB-DLBCL cells and pSTAT3(Y705/S727)-positive BCR-subtype ABC-DLBCL cells weekly expressing pSTAT1(Y701/S727) [ 470 ]. Thus, overexpression of ARTD9 in high-risk tumors might also be modulated by differences in tumor microenvironment or relevant signaling pathways. Interestingly, overexpression of ARTD9 could not be observed so far in other pSTAT1(Y701/S727)-positive or pSTAT3(Y705/S727)-positive subgroups of DLBCLs such as T/HRLBCL or PMLBCL, which molecular profiles resemble (at least in part) those of HR-subtype DLBCL tumors [ 46 , 53 – 55 , 116 ].

ARTD9 has been proposed to be associated with lymphocyte migration and may promote the dissemination of malignant B cells in high-risk DLBCL in vivo [ 469 ]. Moreover, doxocyclin-induced overexpression of ARTD9 in an ARTD9-negative low-risk GCB-DLBCL cell line led to the induction of a small subset of IFN(γ)-related genes [ 469 ], thus provided preliminary evidence that ARTD9 might play a direct role in IFN signaling pathways [ 469 ]. Indeed, our own subsequent study identified ARTD9 as a novel oncogenic survival factor, which acts as a crucial negative and positive co-regulator of IFNγ/STAT1 signaling and mediates proliferation, survival and chemoresistance in HR-subtype DLBCL cells [ 470 ]. Inactivation of ARTD9 through siRNA- mediated depletion of ARTD9 not only inhibited cell proliferation and survival but also reversed chemoresistance in high-risk HR-subtype DLBCL cells [ 470 ]. Our study showed that ARTD9 can inhibit the IFNγ/STAT1-dependent anti-proliferative and pro-apoptotic activities of tumor suppressor IRF1 while simultaneously activating the STAT1/IRF2-mediated anti-apoptotic-pro-survival pathways in HR-subtype DLBCL cells [ 470 ]. ARTD9 acts as a repressor of the transcriptional activation of IRF1 and TP53 expression and thereby counteracts the IFNγ-dependent anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-TP53 axis and induces an oncogenic switch in STAT1 from a tumor suppressor to an oncogene [ 470 ]. This may explain why constitutive IFNγ-STAT1 signaling does not lead to apoptosis but rather to survival and chemoresistance in HR-subtype DLBCL cells. The observed ARTD9-mediated down-regulation of tumor-suppressors IRF1 and TP53 may also represent a novel molecular mechanism inactivating the TP53/IRF1 pro- apoptotic pathway in high-risk DLBCL expressing wild-type TP53 [ 470 ]. In addition, ARTD9 simultaneously up-regulates the expression of BCL2 and BCL6 and thereby activates additional anti-apoptotic-pro-survival pathways [ 470 ]. The observed concomitant overexpression of BCL2 and BCL6 in the ARTD9 positive HR-subtype DLBCL cells also indicates that ARTD9 blocks the BCL6-mediated repression of BCL2 [ 470 ], which is frequently disrupted in DLBCL [ 365 ]. Thus, our study provided first evidence that ARTD9 together with STAT1β may negatively regulate a tumor suppressor network, while ARTD9 may concomitantly positively regulate a STAT1- dependent and independent proto-oncogene network in HR-subtype DLBCL [ 470 ]. It will be important to confirm these in vitro observations in vivo through ectopic overexpression of ARTD9 in xenograft DLBCL tumors, alone or in combination with STAT1α and/or STAT1β, respectively.

ARTD9 physically interacts with both isoforms of STAT1, STAT1α and STAT1β through its macrodomains in an ADP-ribosylation dependent manner [ 470 , 471 ]. Co-immunoprecipitation of endogenous BAL1 and STAT1 in presence of increasing concentration of ADP-ribose and subsequent immunoblot analysis for BAL1 and STAT1 revealed that free ADP-ribose could disrupt the interaction between ARTD9 and STAT1 in a dose dependent manner [ 470 , 471 ]. Thus, the observed interaction of ARTD9 with STAT1α or STAT1β, respectively, might be modulated in vivo through the levels of mono-ADP-ribosylation on the corresponding STAT1 isoforms. Our ADP-ribosylation analyses revealed that both STAT1α and STAT1β isoforms could be mono-ADP-ribosylated in vitro by ARTD8 and ARTD10 (unpublished observations). However, we cannot exclude the possibility that the observed interaction might be indirect and mediated through a mono-ADP-ribosylated bridging factor. Thus, the exact molecular mechanisms underlying the observed interaction between STAT1 and ARTD9 as well as the exact functional roles of the proposed mono-ADP-ribosylation activity remain to be investigated. The recent development of distinct ARDT7-, ARTD8- and ARTD10-specific ARTD inhibitors may help us in future to elucidate the ARDT enzyme(s) required for the exact functional roles of the proposed mono-ADP-ribosylation activity in DLBCL [ 529 , 530 ]. In this regard, it will also be important to investigate whether ectopic overexpression of ARTD9 wild-type or ADP-ribose-binding mutant forms of ARTD9 in xenograft DLBCL tumors may positively or negatively affect tumor growth and metastasis in vivo . ARTD9 also interacted with the IFNGR-receptor complex and thereby stimulated directly or indirectly the kinase activity of JAK1/2 and phosphorylation of STAT1 on Y701 [ 470 , 471 ]. However, the exact molecular mechanisms underlying these observations remain to be investigated.

ARTD9 may also be directly involved in editing or inhibiting the IFNγ-dependent host immune response against HR-subtype DLBCL either through its transcriptional co-repressor activity and termination of IFNγ-mediated gene expression and inhibition of the extrinsic IFNγ-induced anti-proliferative and pro-apoptotic STAT1-IRF1-TP53 axes or through its transcriptional co-activator activity and induction of expression of the NK/T-cell inhibitory molecules i.e., PD-1L and increasing the resistance of IFNγ-treated tumor cells towards NK cell- or lymphokine activated killer-mediated lysis [ 470 ]. IFNγ is typically secreted by activated, tumor-infiltrating cytotoxic T lymphocytes and NK and NK/T cells [ 531 , 532 ]. A proposed model for the postulated functions of ARTD9 in DLBCL is presented in Fig. 6 . Remarkably, our study strongly suggests that ARTD9 (may be together with DTX3L) acts both as a negative and positive co-factor in transcription in HR-DLBCL. The observed antagonistic transcriptional activities might be explained by the formation of different ARTD9-containing promoter-specific co-repressor and co-activator complexes. In analogy to other chromatin remodeling and transcriptional cofactors such as the ARTD members ARTD1 or ARTD8, respectively [ 533 – 536 ], and depending on the methylation status of the corresponding promoters and/or enhancers, ARTD9 might differentially interact either with STAT1α/β- or other unknown factor-X-containing transcriptional coactivator complexes (i.e., containing the co-activators CBP/EP300, NCOA and/or BRG1 [ 537 – 539 ]) or with STAT1β-homodimer- or other unknown factor-Y-containing corepressor complexes (i.e., containing the co-repressors MeCP, and NCORs [ 540 , 541 ]). Promoters and/or enhancers of genes involved in survival, proliferation, chemoresistance, autocrine signaling as well as immunoediting are considered as being hypomethylated in HR-DLBCL under these conditions while the corresponding promoters and/or enhancers of pro-apoptotic and anti-proliferative genes are considered as being hypermethylated. Fig. 6 Proposed model for the postulated functions of ARTD9 and DTX3L in DLBCLs. ARTD9 and DTX3L act as novel oncogenic survival factors in relapsed or refractory DLBCL. Constitutively active IL6/IL6R-JAK1-STAT3, oncogenic IFN/IFNGR-JAK1/2-STAT1 and/or IL10/IL10R-JAK1-TYK2-autocrine signaling in HR-DLBCL causes overexpression of ARTD9 and DTX3L, which in turn, further stimulates the phosphorylation of STAT1 on Y701 and subsequently the enhanced expression of STAT1α dependent proto-oncogenes (i.e., ARTD8, ARTD9, DTX3L, IRF2, BCL6, BCL2). Both ARTD9 and DTX3L might also enhance the transcription of DNA damage repair/response genes upon treatment of tumors with genotoxic chemotherapeutic agents [ 548 ]. Conversely, ARTD9 and DTX3L repress together with STAT1β the transcriptional activation of tumor suppressor IRF1 and TP53 [ 470 , 471 ]. Overexpression of ARTD9 inhibits intrinsic and extrinsic IFNγ-STAT1-IRF1/p53-mediated cell death pathways while simultaneously enhancing the STAT1-dependent IRF2-mediated proliferation and BCL6-BCL2 mediated survival pathways. As a consequence ARTD9 induces an oncogenic switch in STAT1 from a tumor suppressor to an oncogene and mediates proliferation, survival and chemo-resistance in HR-DLBCL. Pharmaceutical inhibition of ARTD9 in HR-DLBCL associated with constitutively active STAT1 signaling might therefore reactivate the anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1/p53 axes and reverses chemo-resistance in HR-DLBCL. In addition, endogenous overexpression of DTX3L and/or ARTD9 might also be associated with lymphocytes migration and may promote the dissemination of malignant B cells in high-risk DLBCL in vivo , potentially dependent on STAT3 or PI3K/AKT/mTORC1 signaling [ 471 ]. DTX3L and/or ARTD9 might form specific complexes with non-canonical STAT1:STAT3 heterodimers and activate a migration-specific signaling and gene expression program in HR-DLBCL. Finally, oncogenic. ARTD9/DTX3L-STAT1α signaling might upregulate immunomodulatory genes and may help the tumors to escape the attack by the immune system (immunoediting) [ 470 , 471 , 473 ]. Conversely, ARTD9 and DTX3L together with STAT1β might repress the transcriptional activation of genes involved in immune surveillance [ 470 , 471 , 473 ]. Adapted from REF: [ 470 , 471 ]. Abbreviations: ARTD ADP-ribosyltransferase Diphteria toxin-like, DTX3L deltex (DTX)-3-like E3 ubiquitin ligase, STAT signal transducer and activator of transcription, ISG interferon stimulated gene, IL interleukin, JAK Janus kinase, TYK2 tyrosine kinase 2, IRF interferon-regulatory factor, BCL6 B cell lymphoma protein 6, BCL2 B cell lymphoma protein 2 Future studies are required to decipher the composition of these distinct ARTD9-STAT1 or ARTD9-X-factor co-repressor and co-activator complexes.

Taken together, aberrant constitutive overexpression of ARTD9 may not only serve as a novel useful prognostic biomarker for poor survival of fatal high-risk relapsed/refractory DLBCL but also as a novel rational future drug target for treatment of high-risk relapsed/refractory HR- (and BCR-) subtypes of DLBCL-NOS. The observed macrodomain and mono-ADP-ribosylation-mediated interaction between ARTD9 and STAT1 not only indicates a regulatory cross-talk between ARTD9 and other active members of the ARTD family but also provide the rational base for the development of macrodomain-specific small molecules that can selectively disrupt ARTD9 complex formations in ARTD9-positive relapsed/refractory HR-subtype DLBCLs.

Inhibition of DTX3L in HR- and BCR-subtype of GCB-, ABC- and type-3-DLBCL-NOS

The Deltex (DTX)-3-like E3 ubiquitin ligase DTX3L is an active E3 ubiquitin ligase with C-terminal identity to the Deltex (DTX) family member DTX3 [ 542 , 543 ]. The human DTX family of E3 ubiquitin ligases encompasses six E3 ubiquitin ligases [ 542 – 546 ]. A schematic comparison of the domain architecture of the DTX family is shown in Fig. 7 . DTX3L was originally identified as a binding partner of ARTD9 and as a novel risk-related gene product in high-risk chemotherapy-resistant aggressive forms of DLBCL [ 469 , 542 ]. DTX3L is also overexpressed in HR- and BCR- subtype DLBCLs and at least in part associated with intrinsic IFNγ signaling and constitutive activity of STAT1 [ 469 , 470 ]. Similar to ARTD9, no overexpression of DTX3L could be observed so far in T/HRLBCL or PMLBCL [ 46 , 53 – 55 , 116 ]. In line with the observation that the DTX3L and ARTD9 genes are located in a head-to-head orientation on chromosome 3q21, sharing the same bidirectional STAT1/IRF1 and STAT3-responsive promoter [ 469 – 471 ], DTX3L is mainly overexpressed in pSTAT1(Y701/S727)-positive HR-subtype GCB-DLBCL cells and pSTAT3(Y705/S727)-positive BCR-subtype ABC-DLBCL cells weekly expressing pSTAT1(Y701/S727) [ 470 ]. Fig. 7 Schematic comparison of the domain architecture of the DTX family. Domain architecture of the human Deltex-like E3 ubiquitin ligases and DTX family members DTX1, DTX2A, DTX2B, DTX3, DTX3L and DTX4. The domain organization is based on analogous functional motifs in murine DTX family members DTX1, DTX2, DTX2deltaE and DTX3 [ 589 ], human DTX1 [ 544 , 646 ], and human DTX3L [ 542 , 543 ]. DTX1, DTX2 and DTX4 have well-conserved domains I, II and III. DTX1, DTX2A, DTX2B and DTX4 contain two conserved tandem WWE modules in their domain I [ 646 ]. The N-terminal domains I of DTX1, DTX2A and DTX2B bind through their tandem WWE modules to the ankyrin repeat region of intracellular NOTCH1 [ 646 ]. The WWE domain is named after three conserved residues (W-W-E)and is predicted to mediate specific protein-protein interactions in ubiquitin- and ADP-ribose conjugation systems [ 555 , 636 , 637 ]. DTX3 lacks most of the site corresponding to the binding site for the ankyrin repeats of human NOTCH1. Of interest, the WWE domain of DTX1 serves also as a bona fide poly-ADP-ribose binding module [ 555 ]. Domains II of DTX1, DTX2A, DTX3 and DTX4 contain a proline-rich region (black boxes) that is not found in DTX3L. DTX2B is an alternatively spliced form of DTX2A, DTX2B lack a proline-rich motif (PRM), the fourth of nine predicted DTX2 exons. The most conserved region of all human DTX family members (DTX1, DTX2A, DTX2B, DTX3, DTX3L and DTX4) is their C-terminal part, domain III. The C-terminal domain III of DTX1, DTX2A, DTX2B and DTX4 contain a classic RING finger E3 ubiquitin ligase domain (RING-H2 finger motif; red box); while domain III of DTX3 and DTX3L contain a RING-C3HC4 finger motif found in many E3 ubiquitin ligases (indicated by an orange box). Human DTX3 has a short unique N-terminal domain (yellow box), and DTX3L contains a longer unique N-terminal region (grey box). Abbreviations: RING really interesting new gene, DTX deltex, DTC Deltex C-terminal domain

Several recent studies provided evidence that DTX3L acts tightly together with ARTD9 in proliferation, chemoresistance and survival of solid tumor cells, albeit through different mechanisms [ 471 , 547 , 548 ]. For instance, we could recently demonstrate that DTX3L together with ARTD9 forms a complex with STAT1 and mediates together with ARTD8 and ARTD9 proliferation, chemoresistance and survival of CRPC-like metastatic prostate cancer (mPCa) cells [ 471 ]. DTX3L and ARTD9 act together as repressors of the tumor suppressor IRF1 in mPCa cells [ 471 ]. Remarkably, DTX3L together with STAT1 and STAT3 enhanced cell migration of mPCa cells in an ARTD9-independent manner [ 471 ] and has been suggested to function in a non-canonical STAT1:STAT3 heterodimer-mediated signaling pathway in migration of mPCa cells in vitro [ 471 ]. Thus, it is very likely that DTX3L act also together with ARTD9 in the same proliferation, cell survival and chemotherapy resistance pathways in DLBCL. In analogy to the suggested roles of ARTD9, DTX3L may also be directly involved in editing or inhibiting the IFNγ-dependent host immune response against HR-subtype DLBCL. It will therefore be important to investigate whether ectopic overexpression of DTX3L xenograft tumors (alone or simultaneously in combination with ARTD9 and/or STAT1) may positively or negatively affect chemoresistance, enhanced growth and/or metastasis of HR-DLBCL tumors in vivo .

Several DTX3L studies in solid cancer cell lines strongly indicate that DTX3L might also act in a STAT1/IFNγ independent manner [ 547 , 548 ]. The first studies performed by Yan Q. et al. suggested that DTX3L is implicated in the DNA damage response pathway via monoubiquitinylation of histone H4K91 [ 547 , 548 ]. Ectopically overexpressed GFP-tagged DTX3L and ARTD9 were recruited to sites of DNA damage in solid cancer cells [ 547 , 548 ]. This activity was dependent on ARTD1/PARP1-mediated (n)ADP-ribosylation [ 548 ], see also next sections.

DTX3L together with ARTD9 protected solid cancer cells exposed to DNA-damaging agents and have been therefore suggested to limit the efficacy of chemotherapy-induced DNA damage responses [ 547 , 548 ]. More importantly, a recent in vivo study performed by Thang N.D. et al. provided first evidence that DTX3L mediates invasion and metastasis in melanoma through stimulation of the FAK/PI3K/AKT signaling pathway [ 549 ]. Depletion of DTX3L in murine and human melanoma cells resulted in decreased activity of FAK/PI3K/AKT signaling and reduced invasion and metastasis of murine and human melanoma cells [ 549 ]. It is therefore important to investigate whether DTX3L may cooperate with the PI3K/AKT/mTORC1 or PI3K/AKT/NF-κB signaling pathways in DLBCL.

Besides forming homodimers, DTX3L can also form heterodimers with DTX1 via their respective N- termini in a manner that enhance the E3 ubiquitin ligase activity of DTX3L [ 542 ]. DTX1 is thought to act as a signal repressor or as a mediator of negative feedback for canonical NOTCH1 signaling pathways [ 550 ]. On the other hand, DTX1 can also positively regulate cell context-dependent non-canonical NOTCH1/2 signaling pathways and NOTCH1/2-independent signaling pathways in cancer [ 551 , 552 ]. DTX1 has been shown to enhance the aggressiveness and survival of cancer cells through the activation of the RTK/PI3K/AKT and the MAPK/ERK mitotic pathways and induction of anti-apoptotic MCL1 [ 551 ]. DTX1 is frequently mutated in GCB- and ABC-DLBCL [ 21 , 22 ]. A recent exome sequencing study found DTX1 mutated at high frequency (9–12 %) in a DLBCL cohort derived from Chinese patients [ 21 ]. The Non-silent (gain or loss of function) mutations in DTX1 have been postulated to impair its function as a negative regulator of Notch pathway [ 21 ]. Functionally relevant gain-of-function mutations of NOTCH1 and NOTCH2 were identified in up to 8 % of DLBCL patients and postulated to act as likely drivers of DLBCL pathogenesis [ 16 , 553 , 554 ]. NOTCH2 mutations mainly occur in ABC- and type-3-DLBCL-NOS [ 16 ]. HR-subtype-DLBCL has been shown to overexpress NOTCH2 [ 116 ]. Future studies are required to investigate whether DTX3L might also act independently of ARTD9 together with DTX1 in non-canonical NOTCH1/2-Deltex1-dependent PI3K/AKT signaling pathways in HR subtype DLBCL. Of interest, the WWE domain of DTX1 (Fig. 7 ) serves also as a bona fide poly-ADP-ribose-binding module [ 555 ] and might therefore be also involved in the observed ARTD1 dependent recruitment of DTX3L to sites of DNA damage in solid cancer cells.

Taken together, DTX3L might serve as a novel useful prognostic biomarker for poor survival and as a rational drug target for treatment of high-risk relapsed/refractory HR- (and BCR-) subtypes of DLBCL-NOS.

ARTD8, a novel drug target in HR-, BCR- and MYC-driven DLBCL subtypes?

We have recently shown that both DTX3L and ARTD9 can form nuclear complexes with the closely related macrodomain-containing and enzymatically active ARTD8 [ 471 ]. Although no functional or clinical studies providing evidence for a direct role of ARTD8 in DLBCL have yet been published, we recently showed that ARTD8 is overexpressed in HR-subtype GCB-DLBCL and BCR-subtype ABC-DLBCL cell lines [ 470 ]. We recently demonstrated that ARTD8 mediates in cooperation with DTX3L and ARTD9 survival and proliferation of high-risk metastatic castration resistant prostate cancer (CRPC) cells [ 471 ]. Our study also provided first evidence that the enzymatic activity of ARTD8 is required for survival of metastatic CRPC cells [ 471 ]. These observations imply that ARDT8 might also cooperate with DTX3L and ARTD9 in DLBCL.

Several recent studies by the Boothby lab demonstrated that ARTD8 interacts with STAT6 and amplifies STAT6-mediated gene expression pathways in B and T cells [ 479 , 480 ]. ARTD8 has been suggested to functions as STAT6-specific coregulator of IL4-mediated gene expression and to enhance IL4-induced proliferation and protection of B cells against apoptosis following irradiation or growth factor withdrawal [ 479 , 480 , 556 ]. However, STAT6 may only play a significant role in a small subset of DLBCL-NOS. For instance, STAT6 has been suggested to be inactive in ABC-DLBCL cells due to the overexpression of protein tyrosine phosphatase 1B (PTP1B) in this subtype [ 557 , 558 ]. Thus other DLBCL related factors might be a target of ARTD8. Indeed, it has been suggested that ARTD8 could influence c-MYC-induced B-lymphoid oncogenesis by increasing the cellular metabolic rates [ 474 ]. A recent study using an Eμ- c-Myc driven B-cell lymphoma mice model, demonstrated that ARTD8 is overexpressed in mouse B-cell lymphoma and can facilitate B-lymphoid oncogenesis and alterations in developmental progression driven by c-MYC [ 474 ]. Conversely, ARTD8-deficient mice showed a reduced susceptibility to c-MYC-induced B-cell lymphoma [ 474 ]. Interestingly, ARTD8 also enhance the expression of MCL1 or PIM1, which are both implicated in chemotherapy resistance in DLBCL [ 556 ].

A recent study showed that ARTD8 was overexpressed in over 80 % of primary multiple myeloma (MM) samples tested in this study [ 559 ]. More importantly, this study demonstrated that ARTD8 promotes c-Jun N-terminal kinase (JNK)-2-dependent survival in MM in vitro by binding and inhibiting the kinase activity of JNK1 [ 559 ]. Depletion of ARTD8, or inhibition of the catalytic activities of ARTD8 enhanced the sensitization of MM cells to anti-myeloma agents [ 559 ]. Preclinical studies in DLBCL and MM indicate that obatoclax/bortezomib- or obatoclax/carfilzomib- as well as ricolinostat/carfilzomib mediated lethality in DLBCL cells in vitro and in vivo includes activation of the stress-related JNK1 signaling pathway [ 371 , 560 – 562 ]. It is therefore important to test whether ARTD8 might also function as a druggable oncogenic factor in relapsed or refractory c-MYC-driven double-hit or triple-hit DLBCL, HR- and/or BCR-subtype DLBCLs.

Are the proposed ARTD9-DTX3L-dependent pathways involved in chemotherapy-resistance in DLBCL connected to ARTD1?

Recent studies provided first evidence that ARTD9 and DTX3L might act in a (poly or) mono-ADP-ribosylation-dependent DNA damage response pathway and together with ARTD1 enhance tumor cell survival [ 547 , 548 ]. As already mentioned above, both DTX3L and ARTD9 were recruited to sites of DNA damage in solid cancer cells [ 547 , 548 ]. Moreover, both ARTD9-related macrodomain-containing ARTD family members and ARTD7 and ARTD8 were also localized to sites of DNA damage in a (poly-)ADP-ribosylation and macrodomain-dependent manner [ 548 , 563 ]. Both ARTD8 and ARTD9 have been suggested to act as novel modulators of homologous recombination (HR) required for mitigating replication stress and promoting and genomic stability [ 548 , 563 ], albeit their exact functions in this process remain to be defined [ 548 , 563 ]. These studies indicate that combined inhibition of the enzymatic activities of ARTD1 and ARTD8 inhibitors might potentiate genotoxic chemotherapy by blocking HR-DNA repair and rendering solid cancer cells hypersensitive to DNA damage. We have recently demonstrated that DTX3L forms complexes with ARTD8 and ARTD9 independent of mono-ADP-ribosylation, where as ARTD9 interacts with ARTD8 and other ARTD family members, such as ARTD1 in a (mono-)ADP-ribosylation dependent manner [ 471 ]. Thus ARTD1 might indeed function together with DTX3L and macro-domain-containing macroARTD7-9 in chemotherapy resistance in solid cancer.

However, it remains to be further investigated whether this proposed ARTD1 connected macroARTD(7–9)-DTX3L pathways and mechanisms do also exists in DNA-DSB repair proficient DLBCL, or may be restricted to DNA-DSB repair deficient solid cancer types and certain DNA-DSB repair deficient B and T lymphoid tumor types. Indeed, a recent study provided preliminary evidence that the ARTD1/2 inhibitor olaparib selectively targets ATM mutant (DNA-DSB repair deficient) but not wild-type (DNA-DSB repair proficient) B-lymphoid cells, including proliferating primary CLL cells in vitro and in vivo [ 489 ]. Moreover, one has to be also very cautious because several recent studies provided preliminary evidence that ARTD1 might not act as an oncogenic factor but rather as a tumor suppressor in DNA DSB repair proficient DLBCL and other B-cell lymphoma [ 23 , 564 , 565 ]. For instance, a recent study demonstrated that endogenously overexpressed BCL2 localizes in the nucleus in B-lymphoid tumors and suppresses ARTD1 function and non-apoptotic ARTD1 dependent necrotic cell death in ATM wild-type DLBCL cells [ 564 ]. BCL2 directly interacts with ARTD1 and blocks the enzymatic activity of ARDT1 in CLL and DLBCL cells [ 564 ]. Remarkably, ABT-737 can disrupt the BCL2-ARTD1 interaction and promotes ARTD1 and poly-ADP-ribosylation dependent necrotic cell death in primary ATM wild-type CLL cells [ 564 ]. Thus, ARTD1 might therefore act as a tumor suppressor in absence of BCL2 in ATM wild-type DLBCL. Along this line, ARTD1 activation has been recently shown to be associated with NOTCH1 ligand-mediated apoptosis in B-cell acute lymphoblastic leukemia (B-ALL) where NOTCH1 activation leads to growth arrest and cell death [ 566 ]. The NOTCH1 target Hairy/Enhancer of Split1 (HES1) interacts with ARTD1, activates the enzymatic activity of ARTD1, which then in turn results in ARTD1 overactivation, NAD depletion and necrotic cell death [ 566 ]. Another cautionary study provided preliminary evidence that ARTD1 acts as a transcriptional co-repressor of the BCL6 gene in DLBCL [ 565 ]. ARTD1 binds to the enhancer/promoter region of the BCL6 gene and inhibits the transcriptional activation of BCL6 in a poly-ADP-ribosylation-dependent manner [ 565 ]. In line with these observations, it has been recently shown that a subset of primary DLBCL samples presents loss-of-function mutations in ARDT1 and/or lower expression levels of ARDT1 [ 23 ]. Targeting and inactivation of ARTRD1 by some DLBCL tumors has been suggested to represent a survival adaptation strategy to high degrees of genomic instability in B-cell lymphoma [ 23 ]. These observations strongly indicate that the proposed cancer promoting ARTD1-DTX3L/ARTD9 connection might only exist in solid cancers and support the idea that ARTD1 acts as an ARTD9 and DTX3L independent tumor suppressor in DLBCL. Interestingly, it has been recently shown that macrodomain-containing macroH2A1.1 can inhibit the enzymatic activity of ARTD1 [ 567 , 568 ]. Thus one cannot exclude the possibility that the macrodomain-containing ARTD9, ARTD8 or ARTD7 may indeed functionally interact with ARTD1 in DLBCL and even block the enzymatic and potential tumor suppressor activity of ARTD1 through their macrodomains.

Several preclinical and clinical trial phase I/II studies, which include B-cell lymphoma patients, are currently ongoing to test the efficacy of ARTD/PARP inhibitors as therapeutic agents 7 (NCT00810966, NCT01326702 , NCT00740805 ) [ 488 , 569 , 570 ] (Additional file 1 : Table S9). Thus the ongoing preclinical and clinical trial phase I/II studies and future phase II studies investigating the role of ARDT1/2 specific inhibitors in ARTD9 or BCL2-positive and -negative DLBCL-NOS subtypes will certainly clarify whether the proposed functional crosstalk of ARTD1 and ARTD7-9 may also exist in DLBCL.

Status quo of drugs targeting the STAT1, ARTD8, ARTD9 and DTX3L-mediated pathways

Although the combination of classical therapeutic drugs with highly ARTD8 or DTX3L-specific inhibitors and drugs specifically targeting STAT1 or the macrodomains of ARTD9 might provide a novel therapeutic strategy to increase the sensitivity of relapsed/refractory DLBCL tumors towards classical therapy, the specificity and toxicity of novel agents selectively targeting STAT1, DTX3l, ARTD9 or ARTD8 have to be carefully analyzed to avoid toxic off target effects in the surrounding benign cells/tissues and counter activity of drug-target related proteins (i.e., antagonistic activities of ARTD or DTX family members). Highly selective and potent inhibitors specifically targeting STAT1, DTX3L or ARTD9, respectively are not yet available.

Selective STAT1 inhibitors

Selective STAT1 inhibitors are not yet available due to the observed STAT cross-binding specificity of SH2-domain-based competitive small inhibitors of STAT1 and STAT3 [ 571 ]. STAT1/3 selective SH2-domain-based competitive small inhibitors act through the prevention of the recruitment of STAT1 or STAT3 to the receptor complex and inhibition of their homo- (or hetero-) dimerization, which is critical for nuclear translocation and DNA binding [ 572 , 573 ]. Thus, the SH2-domain-based competitive small inhibitors of STAT3 might therefore not only target the pSTAT3 positive HR-subtype ABC-DLBCL but also pSTAT3 negative HR-subtype GCB-DLBCL. In addition, inhibition of JAK2 does not only block the activation of STAT3 but also the activity of STAT1 in B-cell lymphoma [ 60 ]. Despite clear anti-cancer efficacy in vitro and in vivo [ 574 – 577 ], SH2-domain-based competitive small inhibitors of STAT3 have not yet reached the clinic.

JAK1/JAK2 inhibitors, such as fedratinib (TG101348) [ 60 , 317 ], which strongly reduce the phosphorylation of both STAT1 and STAT3 [ 60 ], have been shown to inhibit ABC-DLBCL growth in vitro and in vivo [ 313 , 316 ]. JAK1/JAK2 inhibitors, such as INCB039110 [ 318 ] or ruxolitinib (INCB18424), are currently in clinical phase I and II trials in B-cell lymphoma, including relapsed/refractory DLBCL ( NCT01905813 , NCT01431209 ), or have been suggested for further clinical evaluation in DLBCL (pacritinib, SB1518), including relapsed or refractory DLBCL [ 109 , 317 , 318 ] (Additional file 1 : Table S6).

Drugs targeting the activity of JAK1/2 mainly block the phosphorylation of STAT1 on Y701 but do only affect the phosphorylation of STAT1 on S727 to a minor extend. Moreover, the activity of uSTAT1, an unphosphorylated form of STAT1 also involved in oncogenesis [ 578 , 579 ], is not inhibited by JAK1/2 inhibitors. In contrast, SH2-domain-based competitive small inhibitors selectively targeting STAT1 will inhibit all isoforms and phosphorylated forms of STAT1.

However partial inhibition of STAT1 or selective inhibition of STAT1:STAT3 signaling pathways could be more beneficial than complete inhibition of STAT1. A recent mice study provided evidence that complete inhibition of STAT1 might affect B-lymphoid development before differentiation to pre-B cells, and particularly blocks the recovery phase from doxorubicin-(chemotherapy) induced hematopoietic toxicity [ 580 ]. STAT1 is required for the efficient B lymphocyte repopulation in the recovery phase in mice and thus particularly the B cell immune function might be disturbed or delayed after hematopoietic reconstitution in a situation of chemotherapy, combined with complete STAT1 inhibition [ 580 ]. On the other hand it is not yet clear whether all STAT1 isoforms (STAT1α and STAT1β) or phosphorylated forms (uSTAT1, pSTAT1(Y701), pSTAT1(S727) or pSTAT1(Y701/S727)) are involved in these process. Thus, small molecule inhibitors that only partially inhibit STAT1, such as of JAK1/JAK2 inhibitors, or indirectly inhibit STAT1 by targeting a subset of STAT1-dependent oncogenic signaling pathways, such as small molecule inhibitors of ARTD9 and DTX3L, might be the more suitable drugs for targeting the oncogenic functions of STAT1 in DLBCL.

Remarkably, recent studies provided evidence that pan-HDACi may not only inhibit the phosphorylation of STAT3 (on Y705) but also the phosphorylation of STAT1 (on Y701). For instance, HDAC4 positively regulates STAT1 activation and mediates STAT1-dependent platinum resistance in ovarian cancer [ 522 ]. HDAC4 deacetylates STAT1, thereby enhancing phosphorylation and nuclear translocation of STAT1 upon cisplatin-treatment in platinum resistant ovarian cancer cells (exposure to chemotherapy) [ 522 ]. Conversely silencing of HDAC4 increased acetyl-STAT1 levels and dephosphorylation of STAT1, thereby prevented platinum induced STAT1 activation and restored cisplatin sensitivity [ 522 ].

Inhibitors targeting the macro-domains of ARTD8 and ARTD9

Since ARTD9 is an inactive enzyme ARTD inhibitors targeting the enzymatic activity of ARTD family members cannot be applied for blocking the function of ARTD9. On the other hand the selective mono-ADP-ribose-specific ADP-ribose-binding activity of the macro-domains of ARTD7, ARTD8 and ARTD9 [ 482 ] presents rational drug targets for the selective inhibition of the oncogenic functions of macro-domain-containing ARTDs. A recent study provided first evidence that the ARTD macrodomains have highly selective binding activities [ 482 ], which makes them even more attractive as druggable targets. The high-resolution crystal structure of the macro-domains of ARTD7 and 8 have already been recently published [ 481 , 482 , 581 ] or deposited in the protein data bank PDBe, allowing now the design of small molecule inhibitors selectively targeting each single macro-domain of ARTD7: http://www.ebi.ac.uk/pdbe/entry/pdb/3v2b , ARTD8: http://www.ebi.ac.uk/pdbe/entry/pdb/3q6z , http://www.ebi.ac.uk/pdbe/entry/pdb/3q71 , http://www.ebi.ac.uk/pdbe/entry/pdb/4d86 , http://www.ebi.ac.uk/pdbe/entry/pdb/3vfq , http://www.ebi.ac.uk/pdbe/entry/pdb/4abl , http://www.ebi.ac.uk/pdbe/entry/pdb/4abk , ARTD9: http://www.ebi.ac.uk/pdbe/entry/pdb/5ail .

ARTD inhibitors selectively targeting the enzymatic activities of ARTD8

Although developed as selective ARTD1/PARP1 inhibitors, family-wide chemical profiling and structural analysis of ARTD/PARP inhibitors demonstrated that many of the best-known inhibitor compounds, which are widely used as so called ARTD1/2-specific research tools as well as in experimental clinical studies, including olaparib, veliparib (ABT-888) and rucaparib, lack clear selectivity towards ARTD1 and ARTD2 and have additional low promiscuous inhibitory activity across the ARTD family, thus exhibiting polypharmacology [ 582 ]. Moreover, recent studies found diverse ARTD-independent mechanisms of action associated with the ARTD1/2-specific clinically relevant inhibitors such as rucaparib, veliparib, and olaparib [ 583 – 585 ]. They have both “beneficial” and detrimental off target effects: For instance rucaparib and to a lesser extend veliparib inhibit PIM1/2 and CDK9 [ 584 ], which are important kinases and signaling factors regulating cell survival and can mediate chemotherapy resistance to available agents, such as rapamycin or BCL2 inhibitors [ 379 , 586 , 587 ]. In addition rucaparib has the capacity to inhibit the phosphorylation of STAT3 most-likely through its inhibition of the STAT3 phosphorylating kinases DYRK1A and/or CDK1 [ 584 ]. Moreover, treatment of BRCA1-deficient cancer cells with olaparib leads to the induction of an IFN-related gene expression signature and activation of IFN-dependent pro-apoptotic signaling pathways in solid cancer cells [ 588 ].

Thus, the development of 4 th and 5 th generation of ARTD inhibitors selectively targeting single ARTD family members without having off target activity is of extraordinary importance for the therapeutic use of ARTD inhibitors. The high-resolution crystal structure of the catalytic domains of ARTD7 and 8 have been recently published [ 529 , 582 ] or deposited in the protein data bank PDBe, allowing now the design of small molecule inhibitors selectively targeting the enzymatic activity of ARTD8: http://www.ebi.ac.uk/pdbe/entry/pdb/4f1q , http://www.ebi.ac.uk/pdbe/entry/pdb/4f1l , http://www.ebi.ac.uk/pdbe/entry/pdb/4py4 . Indeed, using a virtual screening approach, including structural modeling, a set of more than 16 small molecule inhibitors has been recently discovered that bind to ARTD7, ARTD8 and/or ARTD10 [ 529 , 530 ]. The molecules belonged to eight different structural classes, and two of the molecules with good water solubility displayed a promising selectivity for ARTD8 in the low micromolar range [ 529 ].

Inhibitors targeting the DTX-like E3 ubiquitin ligase activity of DTX3L

Drugs selectively inhibiting the E3 ubiquitin ligase activity of the Deltex family members are not yet available. Unfortunately, there are no high-resolution crystal structures of the C-terminal catalytic RING E3 ligase domain of DTX family members published so far. The only reported high-resolution structure of the conserved C-terminal region of DTX proteins is the so called Deltex C-terminal (DTC) domain of human DTX3L [ 543 ]. DTC is of unknown function but has been suggested to be involved in the catalytic process or required for the substrate specificity of DTX family members [ 542 , 543 , 589 ]. The design of small molecule inhibitors selectively targeting the E3 ubiquitin ligase of DTX3L remains therefore dependent on the published RING E3 structures of other E3 ligases. RING E3 ligases do not possess intrinsic catalytic activity and act by simultaneously binding to the charged E2, ubiquitin and the protein substrate [ 279 , 590 ]. Thus the most advanced ligase-based drug discovery strategy to date for targeting RING E3 ligases has been the development of allosteric antagonists or protein-protein inhibitors of E3-substrate binding, that is considered more difficult to target than a catalytic site [ 279 , 590 ]. In contrast to the ARTD inhibitors, the selectivity might not be a crucial prerequisite for drugs blocking DTX3 functions.

Non-selective drugs simultaneously targeting DTX3 and DTX1 might be even more efficient and beneficial for DLBCL patients since DTX1 may also have oncogenic functions in DLBCL and forms distinct heterodimers with DTX3L.

Multi-targeted mechanism-based combinatorial experimental therapies for relapsed/refractory DLBCLs

Since most patients with relapsed/refractory DLBCL show activation of multiple pathways including activation of feedback signaling pathways that can circumvent the drug target, most targeted therapies may not succeed as molecularly targeted single-agent monotherapy. Given the genetic diversity of relapsed/refractory DLBCL subtypes, and given that cells in different functional or anatomical compartments will have differing phenotypes, overcoming drug resistance to conventional and novel experimental immuno-chemotherapeutic regimens is highly reliant on multi-targeted mechanism-based subtype- and signature-specific combinatorial therapies concomitantly targeting multiple signaling pathways to restore apoptotic pathways in tumor cells and to inhibit pro-survival signaling from the stroma environment. Next-generation of multi-targeted combinatorial experimental therapies composed of new targets and conventional (immuno-)chemotherapeutic regimens may thus provide more immediate hope for relapsed/refractory patients who have failed current (immuno-)chemotherapeutic regimens. Ideally, one hopes to exploit synthetic lethality with multi-targeted mechanism-based combinatorial therapies that target the oncogenic rewiring of malignant cells [ 591 , 592 ]. For instance, there is strong evidence for an oncogenic cooperation of the c-MYC and BCL2 signaling pathways in c-MYC-driven c-MYC/BCL2-double hit DLBCL subtypes in vivo [ 107 , 366 , 375 , 377 ]. In mouse models, inhibiting BCL2 using ABT-199 prolongs the survival of mice with c-MYC-driven c-MYC/BCL2-double hit DLBCL tumors [ 375 , 377 ]. In addition, several recent genetic and pharmacological studies in vitro and/or in vivo provided evidence for a functional cooperation between EZH2, BCL2 and BCL6 [ 77 , 79 ], c-MYC and the PI3K/AKT/mTORC1 pathway [ 324 , 593 , 594 ], between NF-κB, STAT3, PI3K and c-MYC [ 233 , 594 , 595 ] as well as between non-canonical NF-κB signaling and BCL6 [ 27 ]. A scheme of mechanism-based combinatorial experimental regimens aimed at disrupting known oncogenic cooperation pathways in GCB-DLBCL and ABC-DLBCL are presented in Figs. 8 and 9 . Fig. 8 Mechanism-based combinatorial experimental regimens aimed at disrupting known oncogenic cooperation pathways in GCB-DLBCLs. Targets for rational mechanism-based combinatorial experimental regimens are shown for GCB-DLBCL ( a and b ). The black thick lines connecting the different drug targets pathways depict established biological interactions and/or dependencies. The single drugs listed in ( a ) have either proven clinical activity in patients with DLBCL or are currently in clinical trials for patients with B-cell lymphoma, including DLBCL. Pathways in GCB-DLBCL targeted by rational drug combinations using drugs tested as single agent in preclinical studies or clinical trials are shown in ( b ). Silvestrol inhibits RNA helicase and translation initiationfactor eIF4A thereby blocking translation (i.e., of oncogenic factors) [ 647 ]. Azacytidine (AZA) and decitabine/5-aza-2′-deoxycytidine (DAC/5-AZA) inhibit DNA methyltransferases (mainly DMNT1 and DMNT3) resulting in the re-expression of tumor-suppressor genes [ 419 , 420 ]. Adapted from REF: [ 601 , 602 ]. Information for this figure was gleaned from the following references: [ 2 , 3 , 13 , 15 – 17 , 20 , 29 , 31 , 66 , 75 – 84 , 87 , 93 , 107 , 123 , 148 , 233 , 255 , 257 , 324 , 325 , 352 , 354 – 356 , 360 – 367 , 374 , 375 , 377 , 380 – 382 , 384 – 386 , 388 , 393 , 407 , 415 – 417 , 594 , 595 , 601 , 602 , 612 , 648 – 650 ]. See also additional tables 2 and 5–9. Abbreviations: Gα13 (GNA13) heterotrimeric G protein alpha 13, ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1, PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, EZH2 enhancer of zeste homologue 2, PD-1 programmed cell death, PD-L1 programmed cell death ligand, TGFβR transforming growth factor beta (TGFβ) receptor, HDACi inhibitors of histone deacetylases, BCL6i inhibitors of BCL6, AZA azacytidine, DAC decitabin Fig. 9 Mechanism-based combinatorial experimental regimens aimed at disrupting known oncogenic cooperation pathways in ABC-DLBCLs. Targets for rational mechanism-based combinatorial experimental regimens are shown for ABC-DLBCL ( a and b ). The black thick lines connecting the different drug targets pathways depict established biological interactions and/or dependencies. The single drugs listed in ( a ) have either proven clinical activity in patients with DLBCL or are currently in clinical trials for patients with B-cell lymphoma, including DLBCL. Pathways in ABC-DLBCL targeted by rational drug combinations using drugs tested as single agent in preclinical studies or clinical trials are shown in ( b ). Bortezomib and carfilzomib inhibit the 26S proteasome complex thereby blocking the degradation of negative regulators of cell cycle progression as well as of NF-κB inhibitory protein IκBα. Lenalidomide is an immunomodulatory agent directly binding to the E3 ubiquitin ligase substrate receptor CRBN and promoting the recruitment of its common substrates to the E3 ubiquitin ligase complex, thus leading to substrate ubiquitinylation and degradation [ 284 ] and subsequent repression of IRF4, a hallmark of ABC-DLBCL cells, thereby inhibiting the BCR-mediated canonical NF-κB-dependent pro-survival signaling pathways [ 90 , 91 ]. Silvestrol inhibits RNA helicase and translation initiationfactor eIF4A thereby blocking translation (i.e., of oncogenic factors) [ 647 ]. Azacytidine (AZA) and decitabine/5-aza-2′-deoxycytidine (DAC/5-AZA) inhibit DNA methyltransferases (mainly DMNT1 and DMNT3) resulting in the re-expression of tumor-suppressor genes [ 419 , 420 ]. Mechanism-based drug combinations targeting the biological interaction between MYC and BCL2 as well as MYC and the PI3K/AKT/mTORC1 pathway are aimed for both GCB- and ABC-DLBCL. Adapted from REF: [ 590 , 591 ]. Information for this figure was gleaned from the following references: [ 2 , 3 , 13 , 16 – 18 , 20 , 29 , 31 , 54 , 57 , 60 , 65 , 66 , 75 – 81 , 87 , 90 , 91 , 93 , 96 – 100 , 103 , 104 , 107 , 123 , 133 , 148 , 171 , 232 , 233 , 242 , 247 – 250 , 255 , 257 , 266 , 270 , 271 , 285 , 286 , 289 , 296 , 297 , 307 – 311 , 313 – 317 , 319 , 323 , 324 , 326 , 327 , 360 – 365 , 367 , 374 , 375 , 377 , 380 – 382 , 384 – 386 , 388 , 393 , 394 , 398 – 402 , 407 , 415 – 417 , 601 , 602 , 612 , 620 , 648 – 652 ]. See also Additional file 1 : Table S2 and S5–S9. Abbreviations: BCR B cell receptor, BTK Bruton’s tyrosine kinase, CD40L CD40 ligand, JAK Janus kinase, CRBN cereblon, IRF4 interferon-regulatory factor 4, MALT1 mucosa-associated lymphoid tissue lymphoma translocation protein 1, BCL10 B cell lymphoma protein 10, TLR Toll-like receptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11, PKCβ protein kinase Cβ, IKK inhibitor kappa B (IκB) kinase, NF-κB nuclear factor-kappa B, NIK NF-κB inducing kinase, STAT signal transducer and activator of transcription, PI3K phosphoinositide 3-kinase, mTORC1 mammalian target of rapamycin (mTOR) complex 1, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, TGFβR transforming growth factor beta (TGFβ) receptor, HDACi inhibitors of histone deacetylases, BCL6i inhibitors of BCL6, PD-1 programmed cell death, PD-L1 programmed cell death ligand, AZA azacytidine, DAC decitabine

Various mechanism-based experimental drug combinations are currently investigated in preclinical models and are already demonstrating promising activities in vitro and in vivo . For instance, combination studies in vitro suggest that the biological crosstalks between the c-MYC, PI3K/AKT/mTORC1, STAT3, IRF4 and/or BCR/NF-κB-dependent signaling pathways represent promising targets in a subset of ABC-DLBCL that may be exploited for a combination therapy of relapsed/refractory DLBCL together with cytotoxic (immuno-)chemotherapeutic agents, that are currently used to treat ABC-DLBCL [ 313 , 595 , 596 ]. Preclinical studies demonstrated that co-administration of the BCR inhibitor ibrutinib with the proteasome inhibitor bortezomib synergistically increased mitochondrial injury and apoptosis in highly bortezomib-resistant GCB and ABC-DLBCL in vitro [ 561 ]. Another recent preclinical study showed that the combination of ibrutinib and lenalidomide is synthetic lethal in blocking IRF4 expression, increasing IFNβ production, and killing ABC-DLBCL cells in vitro and in vivo [ 90 ]. Preclinical studies have also documented synergistic interactions between pan-HDACi (i.e., vorinostat, SNDX-275, or SBHA) and the novel proteasome inhibitor carfilzomib (CFZ) in GCB- and ABC-DLBCL cells sensitive or resistant to bortezomib [ 560 ]. A recent preclinical study showed that combinatorial multilevel inhibition of PI3K/AKT/mTORC1 and CDK1 cell-cycle pathways is very effective in inhibiting DLBCL proliferation and overcoming drug resistance and has been suggested as an effective strategy in treating drug resistant DLBCLs with overactive AKT and CDK1 [ 338 ]. Moreover, a large matrix-based high-throughput screening platform for the rapid and systematic identification of synergistic, additive, and antagonistic drug combinations has been recently established for DLBCL [ 233 ]. This matrix-based strategy was used to screen ABC-DLBCL cell lines for sensitivity to the BCR inhibitor ibrutinib in combination with nearly 500 established or investigational anti-cancer compounds [ 233 ]. This study identified a wide range of compounds, including inhibitors of the PI3K/AKT/mTORC1 signaling pathway (i.e., idelalisib, everolimus, BKM-120), BCL2 family inhibitors (i.e., ABT-199) and other BCR pathway inhibitors that cooperate with ibrutinib to kill ABC-DLBCL cell lines [ 233 ]. In addition, using a similar high-throughput screening platform, a more recent report demonstrated that ibrutinib strongly synergized with BET inhibitors CPI203 and JQ1 in killing ABC-DLBCL cells in vitro and in a xenograft mouse model in vivo [ 239 ]. Moreover, another in vitro screen using a panel of different drugs and DLBCL cell lines showed synergistic or additive effects of the BET inhibitor OTX015 when combined with several anti-lymphoma agents [ 407 ]. In line with previous studies, the combination of OTX015 and ibrutinib was strongly synergistic in ABC-DLBCL cells [ 407 ]. Besides ibrutinib, OTX015 acted also synergistically when combined with clinically achievable doses of other anti-lymphoma drugs such as rituximab, lenalidomide, the PI3Kδ inhibitor idelalisib, the mTORC1 inhibitor everolimus, the demethylating agent decitabine and the HDACi vorinostat [ 407 ]. The strongest synergism was obtained with the mTORC1 inhibitor everolimus [ 407 ]. The combination OTX015/rituximab appeared more active in ABC-DLBCL cell lines [ 407 ], which was explained by the common targeting of the IL10 and STAT3 pathway by both OTX015 and rituximab [ 165 , 407 ]. A detailed list of preclinical multi-targeted combinatorial experimental treatments for DLBCL-NOS is shown in Additional file 1 : Table S10.

Another elegant and efficient way to further circumvent chemotherapy resistance might be the application of rationally designed highly selective dual inhibitors simultaneously blocking two or more molecular targets in DLBCL. The combination of highly selective dual inhibitors may strongly increase the number of concomitantly targeted signaling pathways without leading to severe side effects. As already mentioned before, the dual mTORC1/2 catalytic inhibitor AZD2014 acts highly synergistically in combination with the BTK inhibitor ibrutinib and causes apoptosis both in vitro and in vivo and resulted in tumor regression in an ABC-type DLBCL xenograft model [ 232 ]. A recent high-throughput screening study performed by Griner M. et al. confirmed these results demonstrating that the combination of NVP-BEZ235 and the BTK inhibitor ibrutinib is highly synergistic in killing ABC-subtype DLBCL cell lines in vitro [ 233 ]. NVP-BEZ235 is an ATP-competitive dual panPI3K/mTORC1/2 with retained activity against cells harboring PI3K-activating mutations [ 597 – 599 ]. Moreover, Rahmani and colleagues, recently demonstrated that NVP-BEZ235 in combination with the HDACi panobinostat markedly potentiates HDAC inhibitor activity in DLBCL cells, including in poor-prognosis ABC- and double-hit subtype in vitro and induced tumor regressions in DLBCL xenograft models [ 597 ]. When combined, BEZ235 and panobinostat appeared well tolerated by mice in in vivo studies [ 597 ]. A list of dual inhibitors currently evaluated in preclinical and/or clinical studies in DLBCL is shown in Additional file 1 : Table S11.

Remarkably, several recent clinical studies of multi-targeted combinatorial experimental therapies composed of new targets and conventional (immuno-)chemotherapeutic regimens showed already promising effects and at least in part, could confirm the preclinical observations. For instance, novel agents such as lenalidomide in combination with rituximab were very effective in relapsed/refractory DLBCL, showing ORR of up to 70 % and CR of up to 60 % [ 289 , 429 ] whereas combinations with other novel agents such as mTORC inhibitors were less effective [ 328 ]. Clinical trials with ibrutinib combinations are still ongoing. Moreover, combinations of R-CHOP with lenalidomide or epratuzumab in experimental clinical studies showed promising effects in first-line treatment of DLBCL [ 296 , 297 , 600 ]. A detailed list of ongoing experimental clinical multi-targeted studies combining novel experimental agents with or without conventional (immuno-)chemotherapy in newly diagnosed or relapsed/refractory DLBCL is shown in Additional file 1 : Tables S12-14.

Mechanism based multi-targeted combinatorial therapies combining multiple novel agents with rituximab and/or conventional chemotherapy might represent much more effective treatment regimens with less toxicity for individualized molecular precision therapy in relapsed/refractory DLBCL. These novel multi-targeted drug combinations may be eventually already incorporated as part of a personalized first-line precision therapy, where the impact on preventing relapse will hopefully lead to a significantly improved overall survival for patients with aggressive subtypes of DLBCL. However it is important to note that one has to be cautious regarding the side effects of multi-targeted mechanism-based combinatorial therapies. As more targeted agents are developed, the timing of administration with other agents and dose of each single drug in clinical trials will become increasingly important to define mechanism-based synergistic combinations associated with minimal toxicities rather than simply adding new precision medicines to existing chemotherapeutic regimens, thus ensure maximal efficacy while minimizing side effects.

Unexpected and/or synergistic toxicities can represent a practical limitation to clinical development. Given the synergy between drugs such as ibrutinib or lenalidomide and multiple agents uncovered thus far, it may eventually be possible to combine in a personalized manner conventional immuno-chemotherapeutic regimes with three, four or more novel single-agent drugs simultaneously inhibiting the most important oncogenic signaling pathways to overcome the aggressive nature of HR-and BCR-subtype ABC-DLBCL or other subtypes of relapsed/refractory DLBCLs and thereby ensure maximal efficacy while minimizing side effects. Thus, subtype and subset-specific personalized multi-targeted combinations of novel highly selective therapeutic drugs (i.e., BCL2-, BCL6-, NF-κB- or STAT3-specific small molecule inhibitors) together with or without ADC and/or standard (immuno-)chemotherapy (i.e., R-CHOP or DA-EPOCH-R) might provide a novel therapeutic strategy to increase the sensitivity of relapsed/refractory DLBCLs towards conventional immuno-chemotherapeutic regimens and thus pave the way to develop novel personalized therapeutic strategies for patients suffering from highly aggressive relapsed/refractory DLBCLs.

Concluding remarks

Although the clinical outcome in DLBCL has tremendously improved over the last decades and will likely improve further with the introduction of novel specific anti-cancer agents and therapeutic approaches, relapsed/refractory DLBCL remains a major cause of morbidity and mortality.

Unfortunately, the ongoing efforts exploring novel conditioning regimens and maintenance approaches for relapsed/refractory DLBCL will have limited impact for most of the current patients with relapsed/refractory DLBCL, because only a minority of patients proceed to this second line treatment. On the other hand the improved understanding of DLBCL subtypes and etiology of relapsed/refractory DLBCL is leading to the identification of targeted drugs that not only may allow for subtype-specific and molecularly targeted combinational therapy in the management of patients with relapsed/refractory DLBCL who are not cured in the rituximab era but also to development of very efficient personalized first-line therapeutic regimens. Due to the extensive intra-patient and intra-tumor genetic heterogeneity in DLBCL and the efficiency of single-agent therapies it is evident that rational personalized therapeutic regimens using novel agents directed at distinct cellular pathways and properly tested in well-designed (personalized) clinical trials are needed for optimal therapy for relapsed or refractory DLBCL. Such rational personalized therapeutic regimens will also require both, positive selection strategies to identify patients most likely to respond to therapy as well as a negative selection approach to determine which patients may be resistant to a given therapy [ 601 , 602 ], thus, taking the molecular subtypes and molecular signatures of DLBCL into account. The most suitable strategy to achieve this is to identify the patient specific mutational and gene expression profiles either via a combinatorial analysis using mass-spectrometry (protein expression analysis), next generation sequencing (RNA expression analysis) and candidate gene sequencing (mutation analysis) or alternatively, using combinations of thoroughly validated clinical biomarkers highly specific for each molecular subtype and gene expression signature.

There is preliminary evidence that novel agents such as lenalidomide or epratuzumab could be very effective in relapsed/refractory DLBCL when used as novel agent in combination with rituximab or R-CHOP. Conversely, many other novel agents such as enzastaurin alisertib, or everolimus were less effective when used as novel agent in combinations with rituximab or R-CHOP. Thus, large multicenter non-randomized and personalized long term clinical phase III trials combining 2, 3 or more novel agents with or without standard immunochemotherapy (i.e., R-CHOP21 or DA-ECHOP-R) are required to investigate whether (personalized) multi-targeted combinations of novel experimental agents together with rituximab or CHOP21 regimens have a superior efficacy when compared with optimized R-CHOP21 or DA-ECHOP-R regimens in relapsed/refractory DLBCL or as first line treatments for newly diagnosed high-risk DLBCL.

A better understanding of the functions of novel potential drug targets such as PLCγ2, PRPS2, NOTCH1/2, STAT1, DTX3L, or ARTD9 and the generation of novel highly selective small molecule inhibitors with negligible off target activity are also required to give us the opportunity to develop novel personalized therapeutic strategies targeting novel subtype-specific pathways, thereby also minimizing toxicities by limiting exposure of patients to agents to which their disease would be unlikely to respond. Moreover, acquired drug resistance is very likely mediated by a finite set of pathways whose relative contributions will vary in individual patients which would allow genomic and proteomic analyses to be performed on primary samples from patients with relapsed/refractory DLBCL to determine which targets need to be suppressed or activated to restore sensitivity to drugs that were used successfully in a prior line of therapy, or to optimize the efficiency of the available therapeutic personalized regimens. In addition the interactions between relapsed/refractory DLBCL tumors and their microenvironment are biologically and clinically crucial. Thus, an understanding of how novel potential drug targets such as STAT1, ARTD9 and/or DTX3L may modulate the interaction between (relapsed or refractory) DLBCL tumors and their microenvironment should also provide new therapeutic options.

Together, multi-targeted combinatorial personalized precision therapies composed of multiple novel agents highly selectively targeting at distinct cellular pathways and DLBCL subtypes (i.e., ABC, GCB) or subsets (i.e., BCR, OxPhos, MD or HR) combined with ADC or conventional rituximab based chemotherapy will most likely represent the future mainstay of treatment for patients with newly diagnosed high-risk DLBCL or relapsed/refractory DLBCL and thus may provide hope for relapsed patients who have failed current chemotherapies in the rituximab era.

Additional file

Additional file 1: Table S1–S14. (PDF 747 kb)

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

Both authors designed the outline of the article and wrote the paper. RC and POH wrote the initial draft, and RC, HCW and POH revised and expanded the manuscript. All authors have seen and approved the final manuscript.

Acknowledgements

We are grateful to Dr. D. Markeson, (MRC-UCL, Division of Surgical and interventional Sciences, University College London) for editing and proofreading the manuscript. We also thank all the members of the Institute of Veterinary Biochemistry and Molecular Biology (University of Zurich, Switzerland) and of the Competence Center for Applied Biotechnology and Molecular Medicine (CABMM)), University of Zurich, Switzerland) for helpful discussions. This work was supported by the Swiss National Science Foundation (SNF-31003A_125190) (to P.O.H, H.C.W. and R.C.) and Novartis Foundation for medical-biological research (Nr. 10C63) (to P.O.H.).

References

1. Martelli M Ferreri AJ Agostinelli C Di Rocco A Pfreundschuh M Pileri SA Diffuse large B- cell lymphoma Crit Rev Oncol Hematol 2013 87 2 146 171 10.1016/j.critrevonc.2012.12.009 23375551

2. Schneider C Pasqualucci L Dalla-Favera R Molecular pathogenesis of diffuse large B-cell lymphoma Semin Diagn Pathol 2011 28 2 167 177 10.1053/j.semdp.2011.04.001 21842702 PMC3562715

3. Shaffer AL 3rd Young RM Staudt LM Pathogenesis of human B cell lymphomas Annual review of immunology 2012 30 565 610 10.1146/annurev-immunol-020711-075027 22224767 PMC7478144

4. De Paepe P De Wolf-Peeters C Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities Leukemia 2007 21 1 37 43 10.1038/sj.leu.2404449 17039226

5. Fisher SG Fisher RI The epidemiology of non-Hodgkin's lymphoma Oncogene 2004 23 38 6524 6534 10.1038/sj.onc.1207843 15322522

6. Roman E Smith AG Epidemiology of lymphomas Histopathology 2011 58 1 4 14 10.1111/j.1365-2559.2010.03696.x 21261679

7. Smith A Howell D Patmore R Jack A Roman E Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network Br J Cancer 2011 105 11 1684 1692 10.1038/bjc.2011.450 22045184 PMC3242607

8. Levi F Lucchini F Negri E La Vecchia C Cancer mortality in the European Union, 19881997: the fall may approach 80,000 deaths a year IntJ Cancer 2002 98 4 636 637 10.1002/ijc.10235 11920627

9. Swerdlow SH Campo E Harris NL Jaffe ES Pileri SA Stein H WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2008) 2008 4 Lyon, France IARC Press

10. Coiffier B Diffuse large cell lymphoma Curr Opin Oncol 2001 13 5 325 334 10.1097/00001622-200109000-00003 11555708

11. Martinez-Climent JA Fontan L Gascoyne RD Siebert R Prosper F Lymphoma stem cells: enough evidence to support their existence? Haematologica 2010 95 2 293 302 10.3324/haematol.2009.013318 20139392 PMC2817033

12. Pasqualucci L Trifonov V Fabbri G Ma J Rossi D Chiarenza A Analysis of the coding genome of diffuse large B-cell lymphoma Nat Genet 2011 43 9 830 837 10.1038/ng.892 21804550 PMC3297422

13. Lenz G Wright GW Emre NC Kohlhammer H Dave SS Davis RE Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Proc Natl Acad Sci U S A 2008 105 36 13520 13525 10.1073/pnas.0804295105 18765795 PMC2533222

14. Nowell PC The clonal evolution of tumor cell populations Science 1976 194 4260 23 28 10.1126/science.959840 959840

15. Morin RD Mungall K Pleasance E Mungall AJ Goya R Huff RD Mutational and structural analysis of diffuse large B-cell lymphoma using whole- genome sequencing Blood 2013 122 7 1256 1265 10.1182/blood-2013-02-483727 23699601 PMC3744992

16. Lohr JG Stojanov P Lawrence MS Auclair D Chapuy B Sougnez C Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing Proc Natl Acad Sci U S A 2012 109 10 3879 3884 10.1073/pnas.1121343109 22343534 PMC3309757

17. Zhang J Grubor V Love CL Banerjee A Richards KL Mieczkowski PA Genetic heterogeneity of diffuse large B-cell lymphoma Proc Natl Acad Sci U S A 2013 110 4 1398 1403 10.1073/pnas.1205299110 23292937 PMC3557051

18. Compagno M Lim WK Grunn A Nandula SV Brahmachary M Shen Q Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma Nature 2009 459 7247 717 721 10.1038/nature07968 19412164 PMC2973325

19. Pasqualucci L Dominguez-Sola D Chiarenza A Fabbri G Grunn A Trifonov V Inactivating mutations of acetyltransferase genes in B-cell lymphoma Nature 2011 471 7337 189 195 10.1038/nature09730 21390126 PMC3271441

20. Morin RD Mendez-Lago M Mungall AJ Goya R Mungall KL Corbett RD Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 2011 476 7360 298 303 10.1038/nature10351 21796119 PMC3210554

21. de Miranda NF Georgiou K Chen L Wu C Gao Z Zaravinos A Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients Blood 2014 124 16 2544 2553 10.1182/blood-2013-12-546309 25171927 PMC4199956

22. Khodabakhshi AH Morin RD Fejes AP Mungall AJ Mungall KL Bolger-Munro M Recurrent targets of aberrant somatic hypermutation in lymphoma Oncotarget 2012 3 11 1308 1319 10.18632/oncotarget.653 23131835 PMC3717795

23. de Miranda NF Peng R Georgiou K Wu C Falk Sorqvist E Berglund M DNA repair genes are selectively mutated in diffuse large B cell lymphomas J Exp Med 2013 210 9 1729 1742 10.1084/jem.20122842 23960188 PMC3754869

24. Couronne L Ruminy P Waultier-Rascalou A Rainville V Cornic M Picquenot JM Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma Leuk Lymphoma 2013 54 5 1079 1086 10.3109/10428194.2012.739687 23066952

25. Nogai H Wenzel SS Hailfinger S Grau M Kaergel E Seitz V IkappaB-zeta controls the constitutive NF-kappaB target gene network and survival of ABC DLBCL Blood 2013 122 13 2242 2250 10.1182/blood-2013-06-508028 23869088

26. Bushell KR Kim Y Chan FC Ben-Neriah S Jenks A Alcaide M Genetic inactivation of TRAF3 in canine and human B-cell lymphoma Blood 2015 125 6 999 1005 10.1182/blood-2014-10-602714 25468570

27. Zhang B Calado DP Wang Z Frohler S Kochert K Qian Y An oncogenic role for alternative NF-kappaB signaling in DLBCL revealed upon deregulated BCL6 expression Cell Rep 2015 11 5 715 726 10.1016/j.celrep.2015.03.059 25921526 PMC4426003

28. Ying CY Dominguez-Sola D Fabi M Lorenz IC Hussein S Bansal M MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma Nat Immunol 2013 14 10 1084 1092 10.1038/ni.2688 23974956 PMC3954820

29. Morin RD Johnson NA Severson TM Mungall AJ An J Goya R Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin Nat Genet 2010 42 2 181 185 10.1038/ng.518 20081860 PMC2850970

30. Cimmino L Dawlaty MM Ndiaye-Lobry D Yap YS Bakogianni S Yu Y TET1 is a tumor suppressor of hematopoietic malignancy Nat Immunol 2015 16 6 653 662 10.1038/ni.3148 25867473 PMC4545281

31. Young RM Staudt LM Targeting pathological B cell receptor signalling in lymphoid malignancies Nat Rev Drug Discov 2013 12 3 229 243 10.1038/nrd3937 23449308 PMC7595252

32. Cerchietti L Melnick A Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? Expert Rev Hematol 2013 6 4 343 345 10.1586/17474086.2013.826928 23991920 PMC4083750

33. Morin RD Gascoyne RD Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing Semin Hematol 2013 50 4 303 313 10.1053/j.seminhematol.2013.09.004 24246698

34. Roschewski M Dunleavy K Wilson WH Diffuse large B cell lymphoma: molecular targeted therapy Int J Hematol 2012 96 5 552 561 10.1007/s12185-012-1198-3 23086603

35. Staudt LM Dave S The biology of human lymphoid malignancies revealed by gene expression profiling Adv Immunol 2005 87 163 208 10.1016/S0065-2776(05)87005-1 16102574 PMC1351148

36. Roschewski M Wilson WH Cracking the diverse biologic code of diffuse large B-cell lymphoma Semin Hematol 2015 52 2 55 56 10.1053/j.seminhematol.2015.01.010 25805584

37. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523–531. doi: 10.1182/asheducation-2009.1.523. 10.1182/asheducation-2009.1.523 PMC6324557 20008237

38. Campo E Swerdlow SH Harris NL Pileri S Stein H Jaffe ES The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood 2011 117 19 5019 5032 10.1182/blood-2011-01-293050 21300984 PMC3109529

39. Rosenwald A Staudt LM Gene expression profiling of diffuse large B-cell lymphoma Leuk Lymphoma 2003 44 Suppl 3 S41 47 10.1080/10428190310001623775 15202524

40. Shipp MA Molecular signatures define new rational treatment targets in large B-cell lymphomas Hematology Am Soc Hematol Educ Program 2007, ASH Education Book 2007 2007 1 265 269 10.1182/asheducation-2007.1.265 18024639

41. Gurbuxani S Anastasi J Hyjek E Diffuse large B-cell lymphoma-more than a diffuse collection of large B cells: an entity in search of a meaningful classification Arch Pathol Lab Med 2009 133 7 1121 1134 19642739 10.5858/133.7.1121

42. Hartmann S Doring C Jakobus C Rengstl B Newrzela S Tousseyn T Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma-endpoints of a spectrum of one disease? PLoS One 2013 8 11 e78812 10.1371/journal.pone.0078812 24244368 PMC3823948

43. Boudova L Torlakovic E Delabie J Reimer P Pfistner B Wiedenmann S Muller- Hermelink HK, Rudiger T: Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma Blood 2003 102 10 3753 3758 10.1182/blood-2003-02-0626 12881319

44. Wright G Tan B Rosenwald A Hurt EH Wiestner A Staudt LM A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma Proc Natl Acad Sci USA 2003 100 17 9991 9996 10.1073/pnas.1732008100 12900505 PMC187912

45. Tousseyn T De Wolf-Peeters C T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification Virchows Arch 2011 459 6 557 563 10.1007/s00428-011-1165-z 22081105

46. Van Loo P Tousseyn T Vanhentenrijk V Dierickx D Malecka A Vanden Bempt I T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response Haematologica 2010 95 3 440 448 10.3324/haematol.2009.009647 19797726 PMC2833074

47. Abramson JS T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management Oncologist 2006 11 4 384 392 10.1634/theoncologist.11-4-384 16614234

48. Steidl C Gascoyne RD The molecular pathogenesis of primary mediastinal large B-cell lymphoma Blood 2011 118 10 2659 2669 10.1182/blood-2011-05-326538 21700770

49. Johnsen HE Bergkvist KS Schmitz A Kjeldsen MK Hansen SM Gaihede M Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy Leuk Lymphoma 2014 55 6 1251 1260 10.3109/10428194.2013.839785 23998255

50. Pileri SA Zinzani PL Gaidano G Falini B Gaulard P Zucca E Pathobiology of primary mediastinal B-cell lymphoma Leuk Lymphoma 2003 44 Suppl 3 S21 26 10.1080/10428190310001623810 15202521

51. Martelli M Ferreri AJ Johnson P Primary mediastinal large B-cell lymphoma Crit Rev Oncol Hematol 2008 68 3 256 263 10.1016/j.critrevonc.2008.07.020 18774728

52. Csernus B Timar B Fulop Z Bognar A Szepesi A Laszlo T Mutational analysis of IgVH and BCL-6 genes suggests thymic B-cells origin of mediastinal (thymic) B-cell lymphoma Leuk Lymphoma 2004 45 10 2105 2110 10.1080/1042819042000219467 15370257

53. Savage KJ Monti S Kutok JL Cattoretti G Neuberg D De Leval L The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma Blood 2003 102 12 3871 3879 10.1182/blood-2003-06-1841 12933571

54. Feuerhake F Kutok JL Monti S Chen W LaCasce AS Cattoretti G NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes Blood 2005 106 4 1392 1399 10.1182/blood-2004-12-4901 15870177

55. Rosenwald A Wright G Leroy K Yu X Gaulard P Gascoyne RD Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma J Exp Med 2003 198 6 851 862 10.1084/jem.20031074 12975453 PMC2194208

56. Rodig SJ Savage KJ LaCasce AS Weng AP Harris NL Shipp MA Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma Am J Surg Pathol 2007 31 1 106 112 10.1097/01.pas.0000213334.40358.0e 17197926

57. Melzner I Bucur AJ Bruderlein S Dorsch K Hasel C Barth TF Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line Blood 2005 105 6 2535 2542 10.1182/blood-2004-09-3701 15572583

58. Mottok A Renne C Seifert M Oppermann E Bechstein W Hansmann ML Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities Blood 2009 114 20 4503 4506 10.1182/blood-2009-06-225839 19734449

59. Lam LT Davis RE Pierce J Hepperle M Xu Y Hottelet M Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling Clin Cancer Res 2005 11 1 28 40 15671525

60. Hao Y Chapuy B Monti S Sun HH Rodig SJ Shipp MA Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo Clin Cancer Res 2014 20 10 2674 2683 10.1158/1078-0432.CCR-13-3007 24610827 PMC4084704

61. Guiter C Dusanter-Fourt I Copie-Bergman C Boulland ML Le Gouvello S Gaulard P Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma Blood 2004 104 2 543 549 10.1182/blood-2003-10-3545 15044251

62. Dunleavy K Wilson WH Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? Blood 2015 125 1 33 39 10.1182/blood-2014-05-575092 25499450 PMC4281829

63. Dunleavy K Steidl C Emerging Biological Insights and Novel Treatment Strategies in Primary Mediastinal Large B-Cell Lymphoma Semin Hematol 2015 52 2 119 125 10.1053/j.seminhematol.2015.01.002 25805591

64. Twa DD, Steidl C. Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leuk Lymphoma 2015 Jan 21:1–12. [Epub ahead of print]. 10.3109/10428194.2014.985673 25393674

65. Alizadeh AA Eisen MB Davis RE Ma C Lossos IS Rosenwald A Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 2000 403 6769 503 511 10.1038/35000501 10676951

66. Bea S Zettl A Wright G Salaverria I Jehn P Moreno V Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction Blood 2005 106 9 3183 3190 10.1182/blood-2005-04-1399 16046532 PMC1895326

67. Natkunam Y Zhao S Mason DY Chen J Taidi B Jones M The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas Blood 2007 109 4 1636 1642 10.1182/blood-2006-08-039024 17038524 PMC1794056

68. Lossos IS Alizadeh AA Rajapaksa R Tibshirani R Levy R HGAL is a novel interleukin-4- inducible gene that strongly predicts survival in diffuse large B-cell lymphoma Blood 2003 101 2 433 440 10.1182/blood-2002-06-1931 12509382

69. Natkunam Y Lossos IS Taidi B Zhao S Lu X Ding F Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation Blood 2005 105 10 3979 3986 10.1182/blood-2004-08-3112 15677569 PMC1895083

70. Pasqualucci L Dalla-Favera R The Genetic Landscape of Diffuse Large B-Cell Lymphoma Semin Hematol 2015 52 2 67 76 10.1053/j.seminhematol.2015.01.005 25805586 PMC4646421

71. Victora GD Dominguez-Sola D Holmes AB Deroubaix S Dalla-Favera R Nussenzweig MC Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas Blood 2012 120 11 2240 2248 10.1182/blood-2012-03-415380 22740445 PMC3447782

72. Lossos IS Alizadeh AA Eisen MB Chan WC Brown PO Botstein D Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas Proc Natl Acad Sci USA 2000 97 18 10209 10213 10.1073/pnas.180316097 10954754 PMC27813

73. Lossos IS Okada CY Tibshirani R Warnke R Vose JM Greiner TC Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas Blood 2000 95 5 1797 1803 10688840

74. Smit LA Bende RJ Aten J Guikema JE Aarts WM van Noesel CJ Expression of activation- induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal- center phenotype Cancer Res 2003 63 14 3894 3898 12873980

75. Iqbal J Sanger WG Horsman DE Rosenwald A Pickering DL Dave B BCL2 translocation defines a unique tumor subset within the germinal center B- cell-like diffuse large B-cell lymphoma Am J Pathol 2004 165 1 159 166 10.1016/S0002-9440(10)63284-1 15215171 PMC1618550

76. Rosenwald A Wright G Chan WC Connors JM Campo E Fisher RI The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma N Engl J Med 2002 346 2a 1937 1947 10.1056/NEJMoa012914 12075054

77. Beguelin W Popovic R Teater M Jiang Y Bunting KL Rosen M EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation Cancer Cell 2013 23 5 677 692 10.1016/j.ccr.2013.04.011 23680150 PMC3681809

78. Caganova M Carrisi C Varano G Mainoldi F Zanardi F Germain PL Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis J Clin Invest 2013 123 12 5009 5022 10.1172/JCI70626 24200695 PMC3859423

79. Beguelin W Teater MR Hatzi K Popovich R Jiang Y Bunting KL EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains Blood 2013 122 21 Abstract 1

80. Fassina A Marino F Siri M Zambello R Ventura L Fassan M The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies Lab Invest 2012 92 11 1574 1582 10.1038/labinvest.2012.129 22964854

81. Psathas JN Doonan PJ Raman P Freedman BD Minn AJ Thomas-Tikhonenko A The Myc- miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop Blood 2013 122 26 4220 4229 10.1182/blood-2012-12-473090 24169826 PMC3868926

82. Salmena L Carracedo A Pandolfi PP Tenets of PTEN tumor suppression Cell 2008 133 3 403 414 10.1016/j.cell.2008.04.013 18455982

83. Musilova K Mraz M MicroRNAs in B-cell lymphomas: how a complex biology gets more complex Leukemia 2015 29 5 1004 1017 10.1038/leu.2014.351 25541152

84. Muppidi JR Schmitz R Green JA Xiao W Larsen AB Braun SE Loss of signalling via Galpha13 in germinal centre B-cell-derived lymphoma Nature 2014 516 7530 254 258 10.1038/nature13765 25274307 PMC4267955

85. Lenz G Wright G Dave SS Xiao W Powell J Zhao H Stromal gene signatures in large-B-cell lymphomas N Engl J Med 2008 359 22 2313 2323 10.1056/NEJMoa0802885 19038878 PMC9103713

86. Basso K Dalla-Favera R Germinal centres and B cell lymphomagenesis Nat Rev Immunol 2015 15 3 172 184 10.1038/nri3814 25712152

87. Lenz G Nagel I Siebert R Roschke AV Sanger W Wright GW Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma J Exp Med 2007 204 3 633 643 10.1084/jem.20062041 17353367 PMC2137913

88. Matsuyama T Grossman A Mittrucker HW Siderovski DP Kiefer F Kawakami T Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE) Nucleic Acids Res 1995 23 12 2127 2136 10.1093/nar/23.12.2127 7541907 PMC306999

89. Mittrucker HW Matsuyama T Grossman A Kundig TM Potter J Shahinian A Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function Science 1997 275 5299 540 543 10.1126/science.275.5299.540 8999800

90. Yang Y Shaffer AL 3rd Emre NC Ceribelli M Zhang M Wright G Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma Cancer Cell 2012 21 6 723 737 10.1016/j.ccr.2012.05.024 22698399 PMC4059833

91. Zhang LH Kosek J Wang M Heise C Schafer PH Chopra R Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression Br J Haematol 2013 160 4 487 502 10.1111/bjh.12172 23252516

92. Shaffer AL Shapiro-Shelef M Iwakoshi NN Lee AH Qian SB Zhao H XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation Immunity 2004 21 1 81 93 10.1016/j.immuni.2004.06.010 15345222

93. Mandelbaum J Bhagat G Tang H Mo T Brahmachary M Shen Q BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma Cancer Cell 2010 18 6 568 579 10.1016/j.ccr.2010.10.030 21156281 PMC3030476

94. Pasqualucci L Compagno M Houldsworth J Monti S Grunn A Nandula SV Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma J Exp Med 2006 203 2 311 317 10.1084/jem.20052204 16492805 PMC2118216

95. Tagawa H Suguro M Tsuzuki S Matsuo K Karnan S Ohshima K Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma Blood 2005 106 5 1770 1777 10.1182/blood-2005-02-0542 15886317

96. Davis RE Ngo VN Lenz G Tolar P Young RM Romesser PB Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 2010 463 7277 88 92 10.1038/nature08638 20054396 PMC2845535

97. Chen L Monti S Juszczynski P Daley J Chen W Witzig TE SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma Blood 2008 111 4 2230 2237 10.1182/blood-2007-07-100115 18006696 PMC2234057

98. Chen L Monti S Juszczynski P Ouyang J Chapuy B Neuberg D SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas Cancer Cell 2013 23 6 826 838 10.1016/j.ccr.2013.05.002 23764004 PMC3700321

99. Gupta N DeFranco AL Lipid rafts and B cell signaling Semin Cell Dev Biol 2007 18 5 616 626 10.1016/j.semcdb.2007.07.009 17719248 PMC2169358

100. Davis RE Brown KD Siebenlist U Staudt LM Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells J Exp Med 2001 194 12 1861 1874 10.1084/jem.194.12.1861 11748286 PMC2193582

101. Jost PJ Ruland J Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications Blood 2007 109 7 2700 2707 17119127 10.1182/blood-2006-07-025809

102. Staudt LM Oncogenic activation of NF-kappaB Cold Spring Harb Perspect Biol 2010 2 6 a000109 10.1101/cshperspect.a000109 20516126 PMC2869521

103. Ngo VN Davis RE Lamy L Yu X Zhao H Lenz G A loss- of-function RNA interference screen for molecular targets in cancer Nature 2006 441 7089 106 110 10.1038/nature04687 16572121

104. Lenz G Davis RE Ngo VN Lam L George TC Wright GW Oncogenic CARD11 mutations in human diffuse large B cell lymphoma Science 2008 319 5870 1676 1679 10.1126/science.1153629 18323416

105. Shinohara H Maeda S Watarai H Kurosaki T IkappaB kinase beta-induced phosphorylation of CARMA1 contributes to CARMA1 Bcl10 MALT1 complex formation in B cells J Exp Med 2007 204 13 3285 3293 10.1084/jem.20070379 18086859 PMC2150971

106. Shinohara H Yasuda T Aiba Y Sanjo H Hamadate M Watarai H PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1 J Exp Med 2005 202 10 1423 1431 10.1084/jem.20051591 16301747 PMC2212994

107. Hu S Xu-Monette ZY Tzankov A Green T Wu L Balasubramanyam A MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Blood 2013 121 20 4021 4031 10.1182/blood-2012-10-460063 23449635 PMC3709650

108. Higashi M, Tokuhira M, Fujino S, Yamashita T, Abe K, Arai E, et al. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;1–24. 10.3109/10428194.2015.1038708 25860238

109. Roschewski M Staudt LM Wilson WH Diffuse large B-cell lymphoma-treatment approaches in the molecular era Nat Rev Clin Oncol 2014 11 1 12 23 10.1038/nrclinonc.2013.197 24217204 PMC7709161

110. Young RM Shaffer AL 3rd Phelan JD Staudt LM B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma Semin Hematol 2015 52 2 77 85 10.1053/j.seminhematol.2015.01.008 25805587 PMC4374122

111. Achten R Verhoef G Vanuytsel L De Wolf-Peeters C Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features Histopathology 2002 40 1 31 45 10.1046/j.1365-2559.2002.01291.x 11903596

112. Achten R Verhoef G Vanuytsel L De Wolf-Peeters C T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity J Clin Oncol 2002 20 5 1269 1277 10.1200/JCO.20.5.1269 11870169

113. Braeuninger A Kuppers R Strickler JG Wacker HH Rajewsky K Hansmann ML Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells Proc Natl Acad Sci USA 1997 94 17 9337 9342 10.1073/pnas.94.17.9337 9256483 PMC23186

114. Franke S Wlodarska I Maes B Vandenberghe P Delabie J Hagemeijer A Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances Blood 2001 97 6 1845 1853 10.1182/blood.V97.6.1845 11238128

115. Brauninger A Kuppers R Spieker T Siebert R Strickler JG Schlegelberger B Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells Blood 1999 93 8 2679 2687 10194448

116. Monti S Savage KJ Kutok JL Feuerhake F Kurtin P Mihm M Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response Blood 2005 105 5 1851 1861 10.1182/blood-2004-07-2947 15550490

117. Dave SS Wright G Tan B Rosenwald A Gascoyne RD Chan WC Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells N Engl J Med 2004 351 21 2159 2169 10.1056/NEJMoa041869 15548776

118. Chetaille B Bertucci F Finetti P Esterni B Stamatoullas A Picquenot JM Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome Blood 2009 113 12 2765 3775 10.1182/blood-2008-07-168096 19096012

119. Kluk MJ Chapuy B Sinha P Roy A Dal Cin P Neuberg DS Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas PLoS One 2012 7 4 e33813 10.1371/journal.pone.0033813 22511926 PMC3325231

120. Jardin F Jais JP Molina TJ Parmentier F Picquenot JM Ruminy P Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study Blood 2010 116 7 1092 1104 10.1182/blood-2009-10-247122 20435884

121. Chan FC Telenius A Healy S Ben-Neriah S Mottok A Lim R An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup Blood 2015 125 6 959 966 10.1182/blood-2013-06-507152 25395426

122. Caro P Kishan AU Norberg E Stanley IA Chapuy B Ficarro SB Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma Cancer Cell 2012 22 4 547 560 10.1016/j.ccr.2012.08.014 23079663 PMC3479446

123. Cerchietti LC Yang SN Shaknovich R Hatzi K Polo JM Chadburn A A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo Blood 2009 113 15 3397 3405 10.1182/blood-2008-07-168773 18927431 PMC2668844

124. Srinivasan L Sasaki Y Calado DP Zhang B Paik JH DePinho RA PI3 kinase signals BCR-dependent mature B cell survival Cell 2009 139 3 573 586 10.1016/j.cell.2009.08.041 19879843 PMC2787092

125. Fuentes-Panana EM Bannish G Karnell FG Treml JF Monroe JG Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation J Immunol 2006 177 11 7913 7922 10.4049/jimmunol.177.11.7913 17114463

126. Kraus M Alimzhanov MB Rajewsky N Rajewsky K Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer Cell 2004 117 6 787 800 10.1016/j.cell.2004.05.014 15186779

127. Monroe JG ITAM-mediated tonic signalling through pre-BCR and BCR complexes Nat Rev Immunol 2006 6 4 283 294 10.1038/nri1808 16557260

128. Torres RM Flaswinkel H Reth M Rajewsky K Aberrant B cell development and immune response in mice with a compromised BCR complex Science 1996 272 5269 1804 1808 10.1126/science.272.5269.1804 8650582

129. Saijo K Mecklenbrauker I Schmedt C Tarakhovsky A B cell immunity regulated by the protein kinase C family Ann N YAcad Sci 2003 987 125 134 10.1111/j.1749-6632.2003.tb06040.x 12727631

130. Saijo K Schmedt C Su IH Karasuyama H Lowell CA Reth M Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development Nat Immunol 2003 4 3 274 279 10.1038/ni893 12563261

131. Rickert RC New insights into pre-BCR and BCR signalling with relevance to B cell malignancies Nat Rev Immunol 2013 13 8 578 591 10.1038/nri3487 23883968

132. Hong JJ Yankee TM Harrison ML Geahlen RL Regulation of signaling in B cells through the phosphorylation of Syk on linker region tyrosines. A mechanism for negative signaling by the Lyn tyrosine kinase J Biol Chem 2002 277 35 31703 31714 10.1074/jbc.M201362200 12077122

133. Kloo B Nagel D Pfeifer M Grau M Duwel M Vincendeau M Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells Proc Natl Acad Sci U S A 2011 108 1 272 277 10.1073/pnas.1008969108 21173233 PMC3017191

134. Abramson JS Shipp MA Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach Blood 2005 106 4 1164 1174 10.1182/blood-2005-02-0687 15855278

135. Cardesa-Salzmann TM Colomo L Gutierrez G Chan WC Weisenburger D Climent F High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy Haematologica 2011 96 7 996 1001 10.3324/haematol.2010.037408 21546504 PMC3128218

136. Smith SM Anastasi J Cohen KS Godley LA The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma Blood Cells Mol Dis 2010 45 4 317 323 10.1016/j.bcmd.2010.08.002 20817505

137. Karube K Campo E MYC Alterations in Diffuse Large B-Cell Lymphomas Semin Hematol 2015 52 2 97 106 10.1053/j.seminhematol.2015.01.009 25805589

138. Savage KJ Johnson NA Ben-Neriah S Connors JM Sehn LH Farinha P MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy Blood 2009 114 17 3533 3537 10.1182/blood-2009-05-220095 19704118

139. Klapper W Stoecklein H Zeynalova S Ott G Kosari F Rosenwald A Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Leukemia 2008 22 12 2226 2229 10.1038/leu.2008.230 18754028

140. Slack GW Gascoyne RD MYC and aggressive B-cell lymphomas Adv Anat Pathol 2011 18 3 219 228 10.1097/PAP.0b013e3182169948 21490439

141. Yoon SO Jeon YK Paik JH Kim WY Kim YA Kim JE MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type Histopathology 2008 53 2 205 217 10.1111/j.1365-2559.2008.03076.x 18752503

142. Barrans S Crouch S Smith A Turner K Owen R Patmore R Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab J Clin Oncol 2010 28 20 3360 3365 10.1200/JCO.2009.26.3947 20498406

143. Perry AM Alvarado-Bernal Y Laurini JA Smith LM Slack GW Tan KL MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab Br J Haematol 2014 165 3 382 391 10.1111/bjh.12763 24506200

144. Johnson NA Slack GW Savage KJ Connors JM Ben-Neriah S Rogic S Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone J Clin Oncol 2012 30 28 3452 3459 10.1200/JCO.2011.41.0985 22851565 PMC3454768

145. Johnson NA Savage KJ Ludkovski O Ben-Neriah S Woods R Steidl C Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival Blood 2009 114 11 2273 2279 10.1182/blood-2009-03-212191 19597184 PMC2745846

146. Li S Lin P Fayad LE Lennon PA Miranda RN Yin CC B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome Mod Pathol 2012 25 1 145 156 10.1038/modpathol.2011.147 22002575

147. Snuderl M Kolman OK Chen YB Hsu JJ Ackerman AM Dal Cin P B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma Am J Surg Pathol 2010 34 3 327 340 10.1097/PAS.0b013e3181cd3aeb 20118770 PMC3152212

148. Pillai RK Sathanoori M Van Oss SB Swerdlow SH Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas Am J Surg Pathol 2013 37 3 323 332 10.1097/PAS.0b013e31826cebad 23348205

149. Aukema SM Siebert R Schuuring E van Imhoff GW Kluin-Nelemans HC Boerma EJ Double-hit B-cell lymphomas Blood 2011 117 8 2319 2331 10.1182/blood-2010-09-297879 21119107

150. Green TM Young KH Visco C Xu-Monette ZY Orazi A Go RS Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone J Clin Oncol 2012 30 28 3460 3467 10.1200/JCO.2011.41.4342 22665537

151. Niitsu N Okamoto M Miura I Hirano M Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations Leukemia 2009 23 4 777 783 10.1038/leu.2008.344 19151788

152. Gebauer N Bernard V Gebauer W Thorns C Feller AC Merz H TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations Leuk Lymphoma 2015 56 1 179 185 10.3109/10428194.2014.907896 24679006

153. Chang CC Liu YC Cleveland RP Perkins SL Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas Am J Clin Pathol 2000 113 4 512 518 10.1309/YHFE-R65B-D3LK-3GGV 10761452

154. Monti S Chapuy B Takeyama K Rodig SJ Hao Y Yeda KT Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma Cancer Cell 2012 22 3 359 372 10.1016/j.ccr.2012.07.014 22975378 PMC3778921

155. Young KH Leroy K Moller MB Colleoni GW Sanchez-Beato M Kerbauy FR Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study Blood 2008 112 8 3088 3098 10.1182/blood-2008-01-129783 18559976 PMC2569165

156. Xu-Monette ZY Medeiros LJ Li Y Orlowski RZ Andreeff M Bueso-Ramos CE Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies Blood 2012 119 16 3668 3683 10.1182/blood-2011-11-366062 22275381 PMC3335376

157. Xu-Monette ZY Wu L Visco C Tai YC Tzankov A Liu WM Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study Blood 2012 120 19 3986 3996 10.1182/blood-2012-05-433334 22955915 PMC3496956

158. Dybkaer K Bogsted M Falgreen S Bodker JS Kjeldsen MK Schmitz A Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis J Clin Oncol 2015 33 12 1379 1388 10.1200/JCO.2014.57.7080 25800755 PMC4397280

159. Barrios AP Gomez AV Saez JE Ciossani G Toffolo E Battaglioli E Differential properties of transcriptional complexes formed by the CoREST family Mol Cell Biol 2014 34 14 2760 2770 10.1128/MCB.00083-14 24820421 PMC4097654

160. Pham LV Fu L Tamayo AT Bueso-Ramos C Drakos E Vega F Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways Blood 2011 117 1 200 210 10.1182/blood-2010-06-290437 20889926 PMC3037744

161. Gasparini C Celeghini C Monasta L Zauli G NF-kappaB pathways in hematological malignancies Cell Mol Life Sci 2014 71 11 2083 2102 10.1007/s00018-013-1545-4 24419302 PMC11113378

162. Coiffier B Rituximab in the treatment of diffuse large B-cell lymphomas Semin Oncol 2002 29 1 Suppl 2 30 35 10.1053/sonc.2002.30153 11842386

163. Lenz G Staudt LM Aggressive lymphomas N Engl J Med 2010 362 15 1417 1429 10.1056/NEJMra0807082 20393178 PMC7316377

164. Alas S Bonavida B Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs Cancer Res 2001 61 13 5137 5144 11431352

165. Jazirehi AR Bonavida B Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention Oncogene 2005 24 13 2121 2143 10.1038/sj.onc.1208349 15789036

166. Jazirehi AR Huerta-Yepez S Cheng G Bonavida B Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug- induced apoptosis Cancer Res 2005 65 1 264 276 15665303

167. Vega MI Jazirehi AR Huerta-Yepez S Bonavida B Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively J Immunol 2005 175 4 2174 2183 10.4049/jimmunol.175.4.2174 16081784

168. Koivula S Valo E Raunio A Hautaniemi S Leppa S Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma Oncol Rep 2011 25 4 1183 1190 21318224 10.3892/or.2011.1179

169. Jazirehi AR Vega MI Bonavida B Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy Cancer Res 2007 67 3 1270 1281 10.1158/0008-5472.CAN-06-2184 17283164

170. Jazirehi AR Vega MI Chatterjee D Goodglick L Bonavida B Inhibition of the Raf-MEK1/2- ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non- Hodgkin's lymphoma B cells by Rituximab Cancer Res 2004 64 19 7117 7126 10.1158/0008-5472.CAN-03-3500 15466208

171. Alas S Bonavida B Inhibition of constitutive STAT3 activity sensitizes resistant non- Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis Clin Cancer Res 2003 9 1 316 326 12538484

172. Suzuki E Umezawa K Bonavida B Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis Oncogene 2007 26 42 6184 6193 10.1038/sj.onc.1210448 17420722

173. Stel AJ Ten Cate B Jacobs S Kok JW Spierings DC Dondorff M Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis J Immunol 2007 178 4 2287 2295 10.4049/jimmunol.178.4.2287 17277134

174. Thieblemont C Briere J Mounier N Voelker HU Cuccuini W Hirchaud E The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study J Clin Oncol 2011 29 31 4079 4087 10.1200/JCO.2011.35.4423 21947824

175. Coiffier B Thieblemont C Van Den Neste E Lepeu G Plantier I Castaigne S Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte Blood 2010 116 12 2040 2045 10.1182/blood-2010-03-276246 20548096 PMC2951853

176. Pfreundschuh M Trumper L Osterborg A Pettengell R Trneny M Imrie K CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group The Lancet Oncology 2006 7 5 379 391 10.1016/S1470-2045(06)70664-7 16648042

177. Feugier P Van Hoof A Sebban C Solal-Celigny P Bouabdallah R Ferme C Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 2005 23 18 4117 4126 10.1200/JCO.2005.09.131 15867204

178. Pfreundschuh M Schubert J Ziepert M Schmits R Mohren M Lengfelder E Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) The Lancet Oncology 2008 9 2 105 116 10.1016/S1470-2045(08)70002-0 18226581

179. Cunningham D Hawkes EA Jack A Qian W Smith P Mouncey P Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles Lancet 2013 381 9880 1817 1826 10.1016/S0140-6736(13)60313-X 23615461

180. Wilson WH Dunleavy K Pittaluga S Hegde U Grant N Steinberg SM Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers J Clin Oncol 2008 26 16 2717 2724 10.1200/JCO.2007.13.1391 18378569 PMC2409217

181. Wilson WH Jung SH Porcu P Hurd D Johnson J Martin SE A Cancer and Leukemia Group B multi-center study of DA-EPOCH- rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype Haematologica 2012 97 5 758 765 10.3324/haematol.2011.056531 22133772 PMC3342980

182. Garcia-Suarez J Banas H Arribas I De Miguel D Pascual T Burgaleta C Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study Br J Haematol 2007 136 2 276 285 10.1111/j.1365-2141.2006.06438.x 17233819

183. Garcia-Suarez J Flores E Callejas M Arribas I Gil-Fernandez JJ Olmedilla G Two-weekly dose-adjusted (DA)-EPOCH-like chemotherapy with high-dose dexamethasone plus rituximab (DA-EDOCH14-R) in poor-prognostic untreated diffuse large B-cell lymphoma Br J Haematol 2013 160 4 510 514 10.1111/bjh.12144 23228045

184. Oliansky DM Czuczman M Fisher RI Irwin FD Lazarus HM Omel J The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review Biol Blood Marrow Transplant 2011 17 1 20 47 10.1016/j.bbmt.2010.07.008 20656046

185. Bachy E Salles G Treatment Approach to Newly Diagnosed Diffuse Large B-Cell Lymphoma Semin Hematol 2015 52 2 107 118 10.1053/j.seminhematol.2015.01.001 25805590

186. Kubuschok B Held G Pfreundschuh M Management of diffuse large B-cell lymphoma (DLBCL) Cancer Treat Res 2015 165 271 288 10.1007/978-3-319-13150-4_11 25655614

187. Hernandez-Ilizaliturri FJ Czuczman MS Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches Oncology (Williston Park) 2009 23 6 546 553 19544696

188. Friedberg JW Relapsed/refractory diffuse large B-cell lymphoma Hematology Am Soc Hematol Educ Program 2011 2011 498 505 10.1182/asheducation-2011.1.498 22160081

189. Wilson WH Drug resistance in diffuse large B-cell lymphoma Semin Hematol 2006 43 4 230 239 10.1053/j.seminhematol.2006.07.005 17027657

190. Philip T Guglielmi C Hagenbeek A Somers R Van der Lelie H Bron D Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma N Engl J Med 1995 333 23 1540 1545 10.1056/NEJM199512073332305 7477169

191. Vellenga E van Putten WL van 't Veer MB Zijlstra JM Fibbe WE van Oers MH Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial Blood 2008 111 2 537 543 10.1182/blood-2007-08-108415 17971487

192. Lukenbill J Hill B Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients Leuk Lymphoma 2015 56 2 293 300 10.3109/10428194.2014.910660 24813764

193. Gisselbrecht C Glass B Mounier N Singh Gill D Linch DC Trneny M Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era J Clin Oncol 2010 28 27 4184 4190 10.1200/JCO.2010.28.1618 20660832 PMC3664033

194. Vose JM Carter S Burns LJ Ayala E Press OW Moskowitz CH Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial J Clin Oncol 2013 31 13 1662 1668 10.1200/JCO.2012.45.9453 23478060 PMC3635682

195. Crump M Kuruvilla J Couban S MacDonald DA Kukreti V Kouroukis CT Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12 J Clin Oncol 2014 32 31 3490 3496 10.1200/JCO.2013.53.9593 25267740

196. Corazzelli G Russo F Capobianco G Marcacci G Della Cioppa P Pinto A Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study Ann Oncol 2006 17 Suppl 4 iv18 24 10.1093/annonc/mdj994 16702180

197. Harting R Venugopal P Gregory SA O'Brien T Bogdanova E Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B- cell non-Hodgkin lymphoma Clin Lymphoma Myeloma 2007 7 6 406 412 10.3816/CLM.2007.n.019 17621406

198. Kewalramani T Zelenetz AD Nimer SD Portlock C Straus D Noy A Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma Blood 2004 103 10 3684 3688 10.1182/blood-2003-11-3911 14739217

199. Lignon J Sibon D Madelaine I Brice P Franchi P Briere J Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma Clin Lymphoma Myeloma Leuk 2010 10 4 262 269 10.3816/CLML.2010.n.055 20709662

200. Zelenetz AD Hamlin P Kewalramani T Yahalom J Nimer S Moskowitz CH Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma Ann Oncol 2003 14 Suppl 1 i5 10 10.1093/annonc/mdg702 12736224

201. Gutierrez M Chabner BA Pearson D Steinberg SM Jaffe ES Cheson BD Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH J Clin Oncol 2000 18 21 3633 3642 11054436 10.1200/JCO.2000.18.21.3633

202. Martin A Conde E Arnan M Canales MA Deben G Sancho JM R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Haematologica 2008 93 12 1829 1836 10.3324/haematol.13440 18945747

203. Dincol D Buyukcelik A Dogan M Akbulut H Samur M Demirkazik A Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP Med Oncol 2010 27 3 942 945 10.1007/s12032-009-9313-x 19787462

204. Emmanouilides C Lill M Telatar M Rosenfelt F Grody W Territo M Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma Clin Lymphoma 2002 3 2 111 116 10.3816/CLM.2002.n.017 12435284

205. Gopal AK Press OW Shustov AR Petersdorf SH Gooley TA Daniels JT Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium Leuk Lymphoma 2010 51 8 1523 1529 10.3109/10428194.2010.491137 20578815 PMC3018339

206. Lopez A Gutierrez A Palacios A Blancas I Navarrete M Morey M GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study Eur J Haematol 2008 80 2 127 132 10.1111/j.1600-0609.2007.00996.x 18005385

207. Mounier N Gisselbrecht C Relapses, treatments and new drugs Best Pract Res Clin Haematol 2012 25 1 49 60 10.1016/j.beha.2012.01.002 22409823

208. Gisselbrecht C Is there any role for transplantation in the rituximab era for diffuse large B- cell lymphoma? Hematology Am Soc Hematol Educ Program 2012 2012 410 416 23233612 10.1182/asheducation-2012.1.410

209. Cuccuini W Briere J Mounier N Voelker HU Rosenwald A Sundstrom C MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation Blood 2012 119 20 4619 4624 10.1182/blood-2012-01-406033 22408263 PMC3815438

210. Laursen MB Falgreen S Bodker JS Schmitz A Kjeldsen MK Sorensen S Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma Exp Hematol 2014 42 11 927 938 10.1016/j.exphem.2014.07.263 25072621

211. Stolz C Schuler M Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention Leuk Lymphoma 2009 50 6 873 885 10.1080/10428190902878471 19373595

212. Bonavida B Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance Semin Oncol 2014 41 5 667 677 10.1053/j.seminoncol.2014.08.006 25440611 PMC4254685

213. Goldie JH Coldman AJ A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat Rep 1979 63 11–12 1727 1733 526911

214. Harris CC Hollstein M Clinical implications of the p53 tumor-suppressor gene N Engl J Med 1993 329 18 1318 1327 10.1056/NEJM199310283291807 8413413

215. Tan DE Foo JN Bei JX Chang J Peng R Zheng X Genome- wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population Nat Genet 2013 45 7 804 807 10.1038/ng.2666 23749188

216. Meads MB Hazlehurst LA Dalton WS The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance Clin Cancer Res 2008 14 9 2519 2526 10.1158/1078-0432.CCR-07-2223 18451212

217. Shain KH, Dalton WS, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 2015;34(36):4673–82. 10.1038/onc.2014.403 PMC4688902 25639873

218. Shain KH Tao J The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies Oncogene 2014 33 32 4107 4113 10.1038/onc.2013.379 24037527 PMC4669099

219. Bjorklund CC Baladandayuthapani V Lin HY Jones RJ Kuiatse I Wang H Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications Leukemia 2014 28 2 373 383 10.1038/leu.2013.174 23760401 PMC3874423

220. Andreadis C Gimotty PA Wahl P Hammond R Houldsworth J Schuster SJ Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma Blood 2007 109 8 3409 3416 10.1182/blood-2006-09-047621 17179223 PMC1852238

221. Wilson WH Bates SE Fojo A Bryant G Zhan Z Regis J Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy J Clin Oncol 1995 13 8 1995 2004 7636540 10.1200/JCO.1995.13.8.1995

222. Gaynor ER Unger JM Miller TP Grogan TM White LA Jr Mills GM Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study J Clin Oncol 2001 19 3 750 755 11157027 10.1200/JCO.2001.19.3.750

223. Johnson NA Leach S Woolcock B deLeeuw RJ Bashashati A Sehn LH CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure Haematologica 2009 94 3 423 427 10.3324/haematol.2008.001024 19211644 PMC2649361

224. Hiraga J Tomita A Sugimoto T Shimada K Ito M Nakamura S Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance Blood 2009 113 20 4885 4893 10.1182/blood-2008-08-175208 19246561

225. Sar A Perizzolo M Stewart D Mansoor A Difrancesco LM Demetrick DJ Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients Leuk Res 2009 33 6 792 797 10.1016/j.leukres.2008.10.013 19054557

226. Terui Y Mishima Y Sugimura N Kojima K Sakurai T Kuniyoshi R Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma Clin Cancer Res 2009 15 7 2523 2530 10.1158/1078-0432.CCR-08-1403 19276251

227. Small GW McLeod HL Richards KL Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells PeerJ 2013 1 e31 10.7717/peerj.31 23638367 PMC3628892

228. Muris JJ Meijer CJ Ossenkoppele GJ Vos W Oudejans JJ Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma Hematol Oncol 2006 24 3 97 104 10.1002/hon.774 16715473

229. Olejniczak SH Hernandez-Ilizaliturri FJ Clements JL Czuczman MS Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression Clin Cancer Res 2008 14 5 1550 1560 10.1158/1078-0432.CCR-07-1255 18316580

230. Ruminy P Etancelin P Couronne L Parmentier F Rainville V Mareschal S The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma Leukemia 2011 25 4 681 688 10.1038/leu.2010.302 21233831

231. Niemann CU Wiestner A B-cell receptor signaling as a driver of lymphoma development and evolution Semin Cancer Biol 2013 23 6 410 421 10.1016/j.semcancer.2013.09.001 24060900 PMC4208312

232. Ezell SA Mayo M Bihani T Tepsuporn S Wang S Passino M Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma Oncotarget 2014 5 13 4990 5001 10.18632/oncotarget.2071 24970801 PMC4148116

233. Mathews Griner LA Guha R Shinn P Young RM Keller JM Liu D High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells Proc Natl Acad Sci U S A 2014 111 6 2349 2354 10.1073/pnas.1311846111 24469833 PMC3926026

234. Cheng S Coffey G Zhang XH Shaknovich R Song Z Lu P SYK inhibition and response prediction in diffuse large B-cell lymphoma Blood 2011 118 24 6342 6352 10.1182/blood-2011-02-333773 22025527

235. Wilson WH Young RM Schmitz R Yang Y Pittaluga S Wright G Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Nat Med 2015 21 8 922 926 10.1038/nm.3884 26193343 PMC8372245

236. Cai Q Westin J Fu K Desai M Zhang L Huang H Accelerated therapeutic progress in diffuse large B cell lymphoma Ann Hematol 2014 93 4 541 556 10.1007/s00277-013-1979-7 24375125

237. Advani RH Buggy JJ Sharman JP Smith SM Boyd TE Grant B Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J Clin Oncol 2013 31 1 88 94 10.1200/JCO.2012.42.7906 23045577 PMC5505166

238. Wilson WH Gerecitano JF Goy A Kenkre VP Barr PM Blum KA The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study Blood; ASH Annual Meeting Abstracts 2012 120 686

239. Ceribelli M Kelly PN Shaffer AL Wright GW Xiao W Yang Y Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors Proc Natl Acad Sci US A 2014 111 31 11365 11370 10.1073/pnas.1411701111 PMC4128109 25049379

240. Grisafi D Maestro A Grumi C Piazzoni L Tirone G Fiore W Ibrutinib: from bench side to clinical implications Med Oncol 2015 32 9 669 10.1007/s12032-015-0669-9 26223732

241. Honigberg LA Smith AM Sirisawad M Verner E Loury D Chang B The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci U S A 2010 107 29 13075 13080 10.1073/pnas.1004594107 20615965 PMC2919935

242. Younes A Thieblemont C Morschhauser F Flinn I Friedberg JW Amorim S Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study The Lancet Oncology 2014 15 9 1019 1026 10.1016/S1470-2045(14)70311-0 25042202

243. Brown JR Ibrutinib in chronic lymphocytic leukemia and B cell malignancies Leuk Lymphoma 2014 55 2 263 269 10.3109/10428194.2013.803226 23656200

244. Davids MS Brown JR Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase Future Oncol 2014 10 6 957 967 10.2217/fon.14.51 24941982 PMC4632638

245. Younes A, Zinzani PL, Sehn LH, Johnson PWM, Gascoyne RD, Ahmadi T, et al. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). J Clin Oncol J Clin Oncol 2014, 32(5s):(suppl; abstr TPS8615)

246. Friedberg JW Sharman J Sweetenham J Johnston PB Vose JM Lacasce A Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 2010 115 13 2578 2585 10.1182/blood-2009-08-236471 19965662 PMC2852362

247. Chaiwatanatorn K Stamaratis G Opeskin K Firkin F Nandurkar H Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline- based chemotherapy with and without rituximab Leuk Lymphoma 2009 50 10 1666 1675 10.1080/10428190903165233 19757311

248. Espinosa I Briones J Bordes R Brunet S Martino R Sureda A Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma Ann Hematol 2006 85 9 597 603 10.1007/s00277-006-0144-y 16830142

249. Fridberg M Servin A Anagnostaki L Linderoth J Berglund M Soderberg O Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN Leuk Lymphoma 2007 48 11 2221 2232 10.1080/10428190701636443 17926183

250. Riihijarvi S Koivula S Nyman H Rydstrom K Jerkeman M Leppa S Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients Mod Pathol 2010 23 5 686 693 10.1038/modpathol.2010.43 20190733

251. Hans CP Weisenburger DD Greiner TC Chan WC Aoun P Cochran GT Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma Mod Pathol 2005 18 10 1377 1384 10.1038/modpathol.3800434 15920548

252. Bodo J Sedlak J Maciejewski JP Almasan A Hsi ED HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells Apoptosis 2011 16 9 914 923 10.1007/s10495-011-0617-x 21667043

253. Naylor TL Tang H Ratsch BA Enns A Loo A Chen L Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas Cancer Res 2011 71 7 2643 2653 10.1158/0008-5472.CAN-10-2525 21324920

254. Robertson MJ Kahl BS Vose JM de Vos S Laughlin M Flynn PJ Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma J Clin Oncol 2007 25 13 1741 1746 10.1200/JCO.2006.09.3146 17389337

255. Ysebaert L Morschhauser F Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies Expert Opin Investig Drugs 2011 20 8 1167 1174 10.1517/13543784.2011.590130 21639821

256. Carducci MA Musib L Kies MS Pili R Truong M Brahmer JR Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer J Clin Oncol 2006 24 25 4092 4099 10.1200/JCO.2005.05.3447 16943527

257. Hainsworth JD Arrowsmith E McCleod M Fayad L Hamid O Davis L Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis J Clin Oncol J Clin Oncol 2011 29 suppl abstr 8016

258. Crump MLS Leppa S Fayad LE Lee J Di Rocco A Ogura M A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial Blood 2013 122 21 a623

259. Ngo VN Young RM Schmitz R Jhavar S Xiao W Lim KH Oncogenically active MYD88 mutations in human lymphoma Nature 2010 470 7332 115 119 10.1038/nature09671 21179087 PMC5024568

260. Schenkein D Proteasome inhibitors in the treatment of B-cell malignancies Clin Lymphoma 2002 3 1 49 55 10.3816/CLM.2002.n.011 12141956

261. Strauss SJ Higginbottom K Juliger S Maharaj L Allen P Schenkein D The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines Cancer Res 2007 67 6 2783 2790 10.1158/0008-5472.CAN-06-3254 17363600

262. Fuchs O Targeting of NF-kappaB signaling pathway, other signaling pathways and epigenetics in therapy of multiple myeloma Cardiovasc Hematol Disord Drug Targets 2013 13 1 16 34 10.2174/1871529X11313010003 23534949

263. Dunleavy K Pittaluga S Czuczman MS Dave SS Wright G Grant N Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Blood 2009 113 24 6069 6076 10.1182/blood-2009-01-199679 19380866 PMC2699229

264. Goy A Younes A McLaughlin P Pro B Romaguera JE Hagemeister F Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma J Clin Oncol 2005 23 4 667 675 10.1200/JCO.2005.03.108 15613697

265. Zinzani PL Pellegrini C Merla E Ballerini F Fabbri A Guarini A Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study Hematol Oncol 2013 31 4 179 182 10.1002/hon.2036 23108928

266. Ruan J Martin P Furman RR Lee SM Cheung K Vose JM Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma J Clin Oncol 2011 29 6 690 697 10.1200/JCO.2010.31.1142 21189393

267. Pei XY Dai Y Felthousen J Chen S Takabatake Y Zhou L Circumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cells PLoS One 2014 9 3 e89064 10.1371/journal.pone.0089064 24594907 PMC3942309

268. Shringarpure R Catley L Bhole D Burger R Podar K Tai YT Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib Br J Haematol 2006 134 2 145 156 10.1111/j.1365-2141.2006.06132.x 16846475

269. Roue G Perez-Galan P Mozos A Lopez-Guerra M Xargay-Torrent S Rosich L The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78 Blood 2011 117 4 1270 1279 10.1182/blood-2010-04-278853 21106982

270. Fontan L Melnick A Molecular pathways: targeting MALT1 paracaspase activity in lymphoma Clin Cancer Res 2013 19 24 6662 6668 10.1158/1078-0432.CCR-12-3869 24004675

271. Hailfinger S Lenz G Ngo V Posvitz-Fejfar A Rebeaud F Guzzardi M Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma Proc Natl Acad Sci U S A 2009 106 47 19946 19951 10.1073/pnas.0907511106 19897720 PMC2785272

272. Hailfinger S Nogai H Pelzer C Jaworski M Cabalzar K Charton JE Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines Proc Natl Acad Sci USA 2011 108 35 14596 14601 10.1073/pnas.1105020108 21873235 PMC3167514

273. Fontan L Yang C Kabaleeswaran V Volpon L Osborne MJ Beltran E MALT1 small molecule inhibitors specifically suppress ABC- DLBCL in vitro and in vivo Cancer Cell 2012 22 6 812 824 10.1016/j.ccr.2012.11.003 23238016 PMC3984478

274. Ferch U Kloo B Gewies A Pfander V Duwel M Peschel C Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells J Exp Med 2009 206 11 2313 2320 10.1084/jem.20091167 19841089 PMC2768866

275. Wang JQ Jeelall YS Ferguson LL Horikawa K Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation Front Immunol 2014 5 367 25132836 10.3389/fimmu.2014.00367 PMC4116802

276. Suarez-Farinas M Arbeit R Jiang W Ortenzio FS Sullivan T Krueger JG Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation PLoS One 2013 8 12 e84634 10.1371/journal.pone.0084634 24386404 PMC3874038

277. Fabre C Mimura N Bobb K Kong SY Gorgun G Cirstea D Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma Clin Cancer Res 2012 18 17 4669 4681 10.1158/1078-0432.CCR-12-0779 22806876 PMC4456190

278. Demchenko YN Brents LA Li Z Bergsagel LP McGee LR Kuehl MW Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB Oncotarget 2014 5 12 4554 4566 10.18632/oncotarget.2128 24980832 PMC4147345

279. Nicholson B Kumar S Agarwal S Eddins MJ Marblestone JG Wu J Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives JBiomolScreen 2014 19 7 989 999 10.1177/1087057114527312 24632661

280. Orlowski RZ Novel agents for multiple myeloma to overcome resistance in phase III clinical trials Semin Oncol 2013 40 5 634 651 10.1053/j.seminoncol.2013.07.007 24135408 PMC3819933

281. Witzig TE Nowakowski GS Habermann TM Goy A Hernandez-Ilizaliturri FJ Chiappella A A comprehensive review of lenalidomide therapy for B- cell non-Hodgkin lymphoma Ann Oncol 2015 26 8 1667 1677 10.1093/annonc/mdv102 25712458

282. Chamberlain PP Lopez-Girona A Miller K Carmel G Pagarigan B Chie-Leon B Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs Nature structural & molecular biology 2014 21 9 803 809 10.1038/nsmb.2874 25108355

283. Fischer ES Bohm K Lydeard JR Yang H Stadler MB Cavadini S Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide Nature 2014 512 7512 49 53 25043012 10.1038/nature13527 PMC4423819

284. Lu G Middleton RE Sun H Naniong M Ott CJ Mitsiades CS The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins Science 2014 343 6168 305 309 10.1126/science.1244917 24292623 PMC4070318

285. Du Z Fan M Kim JG Eckerle D Lothstein L Wei L Interferon-resistant Daudi cell line with a Stat2 defect is resistant to apoptosis induced by chemotherapeutic agents J Biol Chem 2009 284 41 27808 27815 10.1074/jbc.M109.028324 19687011 PMC2788831

286. Romero-Weaver AL Wang HW Steen HC Scarzello AJ Hall VL Sheikh F Resistance to IFN-alpha-induced apoptosis is linked to a loss of STAT2 Mol Cancer Res 2010 8 1 80 92 10.1158/1541-7786.MCR-08-0344 20068068 PMC2808460

287. Yue C Xu J Tan Estioko MD Kotredes KP Lopez-Otalora Y Hilliard BA Host STAT2/type I interferon axis controls tumor growth Int J Cancer 2015 136 1 117 126 10.1002/ijc.29004 24895110 PMC4199898

288. Hernandez-Ilizaliturri FJ Deeb G Zinzani PL Pileri SA Malik F Macon WR Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype Cancer 2011 117 22 5058 5066 10.1002/cncr.26135 21495023

289. Feldman T Mato AR Chow KF Protomastro EA Yannotti KM Bhattacharyya P Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma Br J Haematol 2014 166 1 77 83 10.1111/bjh.12846 24661044 PMC4283736

290. Wang M Fowler N Wagner-Bartak N Feng L Romaguera J Neelapu SS Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial Leukemia 2013 27 9 1902 1909 10.1038/leu.2013.95 23545991

291. Nowakowski GS LaPlant B Habermann TM Rivera CE Macon WR Inwards DJ Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study Leukemia 2011 25 12 1877 1881 10.1038/leu.2011.165 21720383

292. Witzig TE Vose JM Zinzani PL Reeder CB Buckstein R Polikoff JA An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma Ann Oncol 2011 22 7 1622 1627 10.1093/annonc/mdq626 21228334

293. Vose JM Habermann TM Czuczman MS Zinzani PL Reeder CB Tuscano JM Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation Br J Haematol 2013 162 5 639 647 10.1111/bjh.12449 23834234

294. Czuczman M, Davies A, Linton KM, Wagner-Johnston N, Gascoyne RD, Eberhard DA, et al. Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. Presented at the ASH 56th Annual Meeting; San Francisco, CA USA Dec 5–9, 2014; Blood: 124 (21), December 6, 2014; 2014

295. Chiappella A Tucci A Castellino A Pavone V Baldi I Carella AM Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi Haematologica 2013 98 11 1732 1738 10.3324/haematol.2013.085134 23812930 PMC3815174

296. Nowakowski GS LaPlant B Macon WR Reeder CB Foran JM Nelson GD Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study J Clin Oncol 2015 33 3 251 257 10.1200/JCO.2014.55.5714 25135992

297. Tilly H Morschhauser F Salles G Casasnovas RO Feugier P Molina TJ Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma Leukemia 2013 27 1 252 255 10.1038/leu.2012.172 22733106

298. Chiappella A Vitolo U Lenalidomide in diffuse large B-cell lymphomas Adv Hematol 2012 2012 498342 10.1155/2012/498342 22792112 PMC3390034

299. Zinzani PL Pellegrini C Gandolfi L Stefoni V Quirini F Derenzini E Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial Clin Lymphoma Myeloma Leuk 2011 11 6 462 466 10.1016/j.clml.2011.02.001 21859554

300. Hagner PR Man HW Fontanillo C Wang M Couto S Breider M CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL Blood 2015 126 6 779 789 10.1182/blood-2015-02-628669 26002965 PMC4528065

301. Nowakowski GS Evolution: IMiDs to PPMs, revolution in DLBCL? Blood 2015 126 6 698 700 10.1182/blood-2015-06-649483 26251224

302. Rasco DW, Gandhi AK, James A, Li S, O'Mara E, Chopra R. A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma. Presented at the ASH 55th Annual Meeting; Dec 7–10, 2013; New Orleans, LA USA 2013

303. Ribrag V Damian S Gharibo M Gironella M Santoro A Rasco DW CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) by Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects With Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma 2014 San Francisco, CA USA Presented at the ASH 56th Annual Meeting

304. Mortensen DS Fultz KE Xu S Xu W Packard G Khambatta G CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization Mol Cancer Ther 2015 14 6 1295 1305 10.1158/1535-7163.MCT-14-1052 25855786

305. Evans EK Tester R Aslanian S Karp R Sheets M Labenski MT Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans J Pharmacol Exp Ther 2013 346 2 219 228 10.1124/jpet.113.203489 23709115

306. Shi CX Kortum KM Zhu YX Jedlowski P Bruins L Braggio E Proteasome inhibitors block Ikaros degradation by lenalidomide in multiplemyeloma Haematologica 2015 100 8 e315 317 25975838 10.3324/haematol.2015.124297 PMC5004433

307. Huang X Meng B Iqbal J Ding BB Perry AM Cao W Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP J Clin Oncol 2013 31 36 4520 4528 10.1200/JCO.2012.45.6004 24220563 PMC3871513

308. Stewart DA Bahlis N Mansoor A pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation Leuk Lymphoma 2009 50 8 1276 1282 10.1080/10428190903015628 19562614

309. Wu WY Li J Wu ZS Zhang CL Meng XL STAT3 activation in monocytes accelerates liver cancer progression BMC Cancer 2011 11 506 10.1186/1471-2407-11-506 22136659 PMC3241618

310. Wu ZL Song YQ Shi YF Zhu J High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma J Hematol Oncol 2011 4 1 31 10.1186/1756-8722-4-31 21806788 PMC3163635

311. Sansone P Bromberg J Targeting the interleukin-6/Jak/stat pathway in human malignancies J Clin Oncol 2012 30 9 1005 1014 10.1200/JCO.2010.31.8907 22355058 PMC3341105

312. Ding BB Yu JJ Yu RY Mendez LM Shaknovich R Zhang Y Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas Blood 2008 111 3 1515 1523 10.1182/blood-2007-04-087734 17951530 PMC2214773

313. Lam LT Wright G Davis RE Lenz G Farinha P Dang L Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma Blood 2008 111 7 3701 3713 10.1182/blood-2007-09-111948 18160665 PMC2275028

314. Scuto A Kujawski M Kowolik C Krymskaya L Wang L Weiss LM STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma Cancer Res 2011 71 9 3182 3188 10.1158/0008-5472.CAN-10-2380 21521803 PMC3085657

315. Ashizawa T Miyata H Ishii H Oshita C Matsuno K Masuda Y Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation IntJ Oncol 2011 38 5 1245 1252 21369699 10.3892/ijo.2011.957

316. Hu G Witzig TE Gupta M A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling PLoS ONE 2013 8 7 e67851 10.1371/journal.pone.0067851 23861822 PMC3701620

317. Derenzini E Younes A Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib Expert Opin Investig Drugs 2013 22 6 775 785 10.1517/13543784.2013.775244 23442043

318. Rosenthal A Mesa RA Janus kinase inhibitors for the treatment of myeloproliferative neoplasms Expert Opin Pharmacother 2014 15 9 1265 1276 10.1517/14656566.2014.913024 24766055

319. Hart S Goh KC Novotny-Diermayr V Hu CY Hentze H Tan YC SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies Leukemia 2011 25 11 1751 1759 10.1038/leu.2011.148 21691275

320. William AD Lee AC Blanchard S Poulsen A Teo EL Nagaraj H Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26- triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23- decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma J Med Chem 2011 54 13 4638 4658 10.1021/jm200326p 21604762

321. Younes A Romaguera J Fanale M McLaughlin P Hagemeister F Copeland A Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes J Clin Oncol 2012 30 33 4161 4167 10.1200/JCO.2012.42.5223 22965964 PMC5950499

322. Beguelin W Sawh S Chambwe N Chan FC Jiang Y Choo JW IL10 receptor is a novel therapeutic target in DLBCLs Leukemia 2015 29 8 1684 1694 25733167 10.1038/leu.2015.57

323. Gupta M Han JJ Stenson M Maurer M Wellik L Hu G Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation Blood 2012 119 12 2844 2853 10.1182/blood-2011-10-388538 22323454 PMC3327462

324. Pfeifer M Grau M Lenze D Wenzel SS Wolf A Wollert-Wulf B PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma Proc Natl Acad Sci USA 2013 110 30 12420 12425 10.1073/pnas.1305656110 23840064 PMC3725065

325. Uddin S Hussain AR Siraj AK Manogaran PS Al-Jomah NA Moorji A Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival Blood 2006 108 13 4178 4186 10.1182/blood-2006-04-016907 16946303

326. Johnston PB Inwards DJ Colgan JP Laplant BR Kabat BF Habermann TM A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma Am J Hematol 2010 85 5 320 324 20229590 10.1002/ajh.21664 PMC4420736

327. Witzig TE Reeder CB LaPlant BR Gupta M Johnston PB Micallef IN A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma Leukemia 2011 25 2 341 347 10.1038/leu.2010.226 21135857 PMC3049870

328. Barnes JA Jacobsen E Feng Y Freedman A Hochberg EP LaCasce AS Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma Haematologica 2013 98 4 615 619 10.3324/haematol.2012.075184 23144193 PMC3659994

329. Zang C Eucker J Liu H Coordes A Lenarz M Possinger K Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma Leuk Lymphoma 2014 55 2 425 434 10.3109/10428194.2013.806800 23721513

330. Gwinn DM Shackelford DB Egan DF Mihaylova MM Mery A Vasquez DS AMPK phosphorylation of raptor mediates a metabolic checkpoint Mol Cell 2008 30 2 214 226 10.1016/j.molcel.2008.03.003 18439900 PMC2674027

331. Chen N Karantza V Autophagy as a therapeutic target in cancer Cancer Biol Ther 2011 11 2 157 168 10.4161/cbt.11.2.14622 21228626 PMC3230307

332. Gupta M Ansell SM Novak AJ Kumar S Kaufmann SH Witzig TE Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 Blood 2009 114 14 2926 2935 10.1182/blood-2009-05-220889 19641186 PMC2756203

333. O'Reilly KE Rojo F She QB Solit D Mills GB Smith D mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt Cancer Res 2006 66 3 1500 1508 10.1158/0008-5472.CAN-05-2925 16452206 PMC3193604

334. Sarbassov DD Ali SM Sabatini DM Growing roles for the mTOR pathway Curr Opin Cell Biol 2005 17 6 596 603 10.1016/j.ceb.2005.09.009 16226444

335. Harada K Miyake H Kumano M Fujisawa M Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2 British journal of cancer 2013 109 9 2389 2395 10.1038/bjc.2013.602 24091619 PMC3817337

336. Gupta M Hendrickson AE Yun SS Han JJ Schneider PA Koh BD Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies Blood 2012 119 2 476 487 10.1182/blood-2011-04-346601 22080480 PMC3257013

337. Zang C Eucker J Liu H Muller A Possinger K Scholz CW Concurrent inhibition of PI3- kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1 Cancer Lett 2013 339 2 288 297 10.1016/j.canlet.2012.11.013 23200668

338. Zhao MY Auerbach A D'Costa AM Rapoport AP Burger AM Sausville EA Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy Clin Cancer Res 2009 15 5 1708 1720 10.1158/1078-0432.CCR-08-1543 19223503

339. Keir ME Butte MJ Freeman GJ Sharpe AH PD-1 and its ligands in tolerance and immunity Annual review of immunology 2008 26 677 704 10.1146/annurev.immunol.26.021607.090331 18173375 PMC10637733

340. Blank C Gajewski TF Mackensen A Interaction of PD-L1 on tumor cells with PD-1 on tumor- specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy Cancer Immunol Immunother 2005 54 4 307 314 10.1007/s00262-004-0593-x 15599732 PMC11032914

341. Green MR Rodig S Juszczynski P Ouyang J Sinha P O'Donnell E Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy Clin Cancer Res 2012 18 6 1611 1618 10.1158/1078-0432.CCR-11-1942 22271878 PMC3321508

342. Loke P Allison JP PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells Proc Natl Acad Sci U S A 2003 100 9 5336 5341 10.1073/pnas.0931259100 12697896 PMC154346

343. Marzec M Zhang Q Goradia A Raghunath PN Liu X Paessler M Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) Proc Natl Acad Sci US A 2008 105 52 20852 20857 10.1073/pnas.0810958105 PMC2634900 19088198

344. Bryan LJ, Gordon LI. Pidilizumab in the treatment of diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2014:1–8. 10.1517/14712598.2014.942637 25056108

345. Andorsky DJ Yamada RE Said J Pinkus GS Betting DJ Timmerman JM Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor- associated T cells Clin Cancer Res 2011 17 13 4232 4244 10.1158/1078-0432.CCR-10-2660 21540239

346. Chen BJ Chapuy B Ouyang J Sun HH Roemer MG Xu ML PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies Clin Cancer Res 2013 19 13 3462 3473 10.1158/1078-0432.CCR-13-0855 23674495 PMC4102335

347. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, et al. : Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015. [Epub ahead of print]. 10.1182/blood-2015-02-629600 PMC4635115 26239088

348. Rossille D Gressier M Damotte D Maucort-Boulch D Pangault C Semana G High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial Leukemia 2014 28 12 2367 2375 10.1038/leu.2014.137 24732592

349. Armand P Nagler A Weller EA Devine SM Avigan DE Chen YB Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial J Clin Oncol 2013 31 33 4199 4206 10.1200/JCO.2012.48.3685 24127452 PMC4878008

350. Simon JA Lange CA Roles of the EZH2 histone methyltransferase in cancer epigenetics MutatRes 2008 647 1–2 21 29 10.1016/j.mrfmmm.2008.07.010 18723033

351. Wigle TJ Knutson SK Jin L Kuntz KW Pollock RM Richon VM The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states FEBS Lett 2011 585 19 3011 3014 10.1016/j.febslet.2011.08.018 21856302

352. Yap DB Chu J Berg T Schapira M Cheng SW Moradian A Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation Blood 2011 117 8 2451 2459 10.1182/blood-2010-11-321208 21190999 PMC3062411

353. Berg T Thoene S Yap D Wee T Schoeler N Rosten P A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis Blood 2014 123 25 3914 3924 10.1182/blood-2012-12-473439 24802772

354. Knutson SK Kawano S Minoshima Y Warholic NM Huang KC Xiao Y Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma Mol Cancer Ther 2014 13 4 842 854 10.1158/1535-7163.MCT-13-0773 24563539

355. McCabe MT Ott HM Ganji G Korenchuk S Thompson C Van Aller GS EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 2012 492 7427 108 112 10.1038/nature11606 23051747

356. Bradley WD Arora S Busby J Balasubramanian S Gehling VS Nasveschuk CG EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation Chem Biol 2014 21 11 1463 1475 10.1016/j.chembiol.2014.09.017 25457180

357. Knutson SK Warholic NM Johnston LD Klaus CR Wigle TJ Iwanowicz D Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas PLoS One 2014 9 12 e111840 10.1371/journal.pone.0111840 25493630 PMC4262195

358. Gascoyne RD Adomat SA Krajewski S Krajewska M Horsman DE Tolcher AW Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma Blood 1997 90 1 244 251 9207459

359. Hermine O Haioun C Lepage E d'Agay MF Briere J Lavignac C Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA) Blood 1996 87 1 265 272 8547651

360. Iqbal J Meyer PN Smith LM Johnson NA Vose JM Greiner TC BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab Clin Cancer Res 2011 17 24 7785 7795 10.1158/1078-0432.CCR-11-0267 21933893 PMC7394278

361. Mounier N Briere J Gisselbrecht C Emile JF Lederlin P Sebban C Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 2003 101 11 4279 4284 10.1182/blood-2002-11-3442 12576316

362. Iqbal J Neppalli VT Wright G Dave BJ Horsman DE Rosenwald A BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma J Clin Oncol 2006 24 6 961 968 10.1200/JCO.2005.03.4264 16418494

363. Wenzel SS Grau M Mavis C Hailfinger S Wolf A Madle H MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma Leukemia 2013 27 6 1381 1390 10.1038/leu.2012.367 23257783

364. Yecies D Carlson NE Deng J Letai A Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1 Blood 2010 115 16 3304 3313 10.1182/blood-2009-07-233304 20197552 PMC2858493

365. Saito M Novak U Piovan E Basso K Sumazin P Schneider C BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma Proc Natl Acad Sci U S A 2009 106 27 11294 11299 10.1073/pnas.0903854106 19549844 PMC2708681

366. Horn H Ziepert M Becher C Barth TF Bernd HW Feller AC MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma Blood 2013 121 12 2253 2263 10.1182/blood-2012-06-435842 23335369

367. Billard C BH3 mimetics: status of the field and new developments Mol Cancer Ther 2013 12 9 1691 1700 10.1158/1535-7163.MCT-13-0058 23974697

368. Shore GC Viallet J Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer Hematology Am Soc Hematol Educ Program 2005 2005 1 226 230 10.1182/asheducation-2005.1.226 16304385

369. Oltersdorf T Elmore SW Shoemaker AR Armstrong RC Augeri DJ Belli BA An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005 435 7042 677 681 10.1038/nature03579 15902208

370. Tse C Shoemaker AR Adickes J Anderson MG Chen J Jin S ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 2008 68 9 3421 3428 10.1158/0008-5472.CAN-07-5836 18451170

371. Dasmahapatra G Lembersky D Son MP Patel H Peterson D Attkisson E Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo Mol Cancer Ther 2012 11 5 1122 1132 10.1158/1535-7163.MCT-12-0021 22411899 PMC3601737

372. Ackler S Xiao Y Mitten MJ Foster K Oleksijew A Refici M ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo Mol Cancer Ther 2008 7 10 3265 3274 10.1158/1535-7163.MCT-08-0268 18852130

373. Ackler S Mitten MJ Foster K Oleksijew A Refici M Tahir SK The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo Cancer Chemother Pharmacol 2010 66 5 869 880 10.1007/s00280-009-1232-1 20099064

374. Scarfo L Ghia P Reprogramming cell death: BCL2 family inhibition in hematological malignancies Immunol Lett 2013 155 1-2 36 39 10.1016/j.imlet.2013.09.015 24095849

375. Souers AJ Leverson JD Boghaert ER Ackler SL Catron ND Chen J ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat Med 2013 19 2 202 208 10.1038/nm.3048 23291630

376. Vogler M Dinsdale D Dyer MJ Cohen GM ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets Br J Haematol 2013 163 1 139 142 10.1111/bjh.12457 23826785

377. Vandenberg CJ Cory S ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia Blood 2013 121 12 2285 2288 10.1182/blood-2013-01-475855 23341542 PMC3606065

378. Khaw SL Merino D Anderson MA Glaser SP Bouillet P Roberts AW Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199 Leukemia 2014 28 6 1207 1215 10.1038/leu.2014.1 24402163

379. Li L Pongtornpipat P Tiutan T Kendrick SL Park S Persky DO Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1 Leukemia 2015 29 8 1702 1712 10.1038/leu.2015.99 25882699 PMC4526343

380. Davids MS Seymour JF Gerecitano JF Kahl BS Pagel JM Wierda WG The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients Blood 2013 122 21

381. Davids MS Seymour JF Gerecitano JF Kahl BS Pagel JM Wierda WG Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non- Hodgkin lymphoma (NHL) J Clin Oncol 2013 31 15 10.1200/JCO.2012.43.3730

382. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, et al . Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol J Clin Oncol. 2014, 32(55):(suppl; abstr 8522). 25768998

383. Gregory GP Hogg SJ Kats LM Vidacs E Baker AJ Gilan O CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo Leukemia 2015 29 6 1437 1441 10.1038/leu.2015.10 25578475 PMC4498453

384. Cerchietti LC Lopes EC Yang SN Hatzi K Bunting KL Tsikitas LA A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas Nat Med 2009 15 12 1369 1376 10.1038/nm.2059 19966776 PMC2805915

385. Cerchietti LC Ghetu AF Zhu X Da Silva GF Zhong S Matthews M A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo Cancer Cell 2010 17 4 400 411 10.1016/j.ccr.2009.12.050 20385364 PMC2858395

386. Cerchietti LC, Hatzi K, Caldas-Lopes E, Yang SN, Figueroa ME, Morin RD, et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest. 2010. 10.1172/JCI42869 PMC2993589 21041953

387. Cotto M Cabanillas F Tirado M Garcia MV Pacheco E Epigenetic therapy of lymphoma using histone deacetylase inhibitors Clin Transl Oncol 2010 12 6 401 409 10.1007/s12094-010-0527-3 20534395

388. Bereshchenko OR Gu W Dalla-Favera R Acetylation inactivates the transcriptional repressor BCL6 Nat Genet 2002 32 4 606 613 10.1038/ng1018 12402037

389. Amengual JE Clark-Garvey S Kalac M Scotto L Marchi E Neylon E Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma Blood 2013 122 12 2104 2113 10.1182/blood-2013-02-485441 23913470

390. Jang KY Hwang SH Kwon KS Kim KR Choi HN Lee NR SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma Am J Surg Pathol 2008 32 10 1523 1531 10.1097/PAS.0b013e31816b6478 18724249

391. West AC Johnstone RW New and emerging HDAC inhibitors for cancer treatment J Clin Invest 2014 124 1 30 39 10.1172/JCI69738 24382387 PMC3871231

392. Gupta M Han JJ Stenson M Wellik L Witzig TE Regulation of STAT3 by histone deacetylase- 3 in diffuse large B-cell lymphoma: implications for therapy Leukemia 2012 26 6 1356 1364 10.1038/leu.2011.340 22116549 PMC3625618

393. Dai C Gu W p53 post-translational modification: deregulated in tumorigenesis Trends Mol Med 2010 16 11 528 536 10.1016/j.molmed.2010.09.002 20932800 PMC2978905

394. Nie Y Erion DM Yuan Z Dietrich M Shulman GI Horvath TL STAT3 inhibition of gluconeogenesis is downregulated by SirT1 Nat Cell Biol 2009 11 4 492 500 10.1038/ncb1857 19295512 PMC2790597

395. Crump M Coiffier B Jacobsen ED Sun L Ricker JL Xie H Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma Ann Oncol 2008 19 5 964 969 10.1093/annonc/mdn031 18296419

396. O'Connor OA Heaney ML Schwartz L Richardson S Willim R MacGregor-Cortelli B Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies J Clin Oncol 2006 24 1 166 173 10.1200/JCO.2005.01.9679 16330674

397. Watanabe T Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas Expert Opin Investig Drugs 2010 19 9 1113 1127 10.1517/13543784.2010.504710 20649502

398. Emadali A Rousseaux S Bruder-Costa J Rome C Duley S Hamaidia S Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers EMBO Mol Med 2013 5 8 1180 1195 10.1002/emmm.201202034 23828858 PMC3944460

399. Chapuy B McKeown MR Lin CY Monti S Roemer MG Qi J Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma Cancer Cell 2013 24 6 777 790 10.1016/j.ccr.2013.11.003 24332044 PMC4018722

400. Mertz JA Conery AR Bryant BM Sandy P Balasubramanian S Mele DA Targeting MYC dependence in cancer by inhibiting BET bromodomains Proc Natl Acad Sci USA 2011 108 40 16669 16674 10.1073/pnas.1108190108 21949397 PMC3189078

401. Ott CJ Kopp N Bird L Paranal RM Qi J Bowman T BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia Blood 2012 120 14 2843 2852 10.1182/blood-2012-02-413021 22904298 PMC3466965

402. Picaud S Da Costa D Thanasopoulou A Filippakopoulos P Fish PV Philpott M PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains Cancer Res 2013 73 11 3336 3346 10.1158/0008-5472.CAN-12-3292 23576556 PMC3673830

403. Loven J Hoke HA Lin CY Lau A Orlando DA Vakoc CR Selective inhibition of tumor oncogenes by disruption of super-enhancers Cell 2013 153 2 320 334 10.1016/j.cell.2013.03.036 23582323 PMC3760967

404. Fiskus W Sharma S Qi J Valenta JA Schaub LJ Shah B Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells Mol Cancer Ther 2014 13 5 1142 1154 10.1158/1535-7163.MCT-13-0770 24435446

405. Chaidos A Caputo V Gouvedenou K Liu B Marigo I Chaudhry MS Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762 Blood 2014 123 5 697 705 10.1182/blood-2013-01-478420 24335499

406. Trabucco SE Gerstein RM Evens AM Bradner JE Shultz LD Greiner DL Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma Clin Cancer Res 2015 21 1 113 122 10.1158/1078-0432.CCR-13-3346 25009295 PMC4286476

407. Boi M Gaudio E Bonetti P Kwee I Bernasconi E Tarantelli C The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs Clin Cancer Res 2015 21 7 1628 1638 10.1158/1078-0432.CCR-14-1561 25623213

408. Lenburg ME Sinha A Faller DV Denis GV Tumor-specific and proliferation-specific gene expression typifies murine transgenic B cell lymphomagenesis J Biol Chem 2007 282 7 4803 4811 10.1074/jbc.M605870200 17166848 PMC2819333

409. Noel JK Iwata K Ooike S Sugahara K Nakamura H Daibata M Development of the BET bromodomain inhibitor OTX015 Mol Cancer Ther 2013 12 11 Suppl C244 10.1158/1535-7163.TARG-13-C244

410. Stathis A Quesnel B Amorim S Thieblemont C Zucca E Raffoux E Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies Eur J Cancer 2014 50 Abstract 5LBA 196 10.1016/S0959-8049(14)70726-9

411. Lu J Qian Y Altieri M Dong H Wang J Raina K Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4 Chem Biol 2015 22 6 755 763 10.1016/j.chembiol.2015.05.009 26051217 PMC4475452

412. Winter GE Buckley DL Paulk J Roberts JM Souza A Dhe-Paganon S DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation Science 2015 348 6241 1376 1381 10.1126/science.aab1433 25999370 PMC4937790

413. Zengerle M Chan KH Ciulli A Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 ACS chemical biology 2015 10 8 1770 1777 10.1021/acschembio.5b00216 26035625 PMC4548256

414. Cunningham JT Moreno MV Lodi A Ronen SM Ruggero D Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer Cell 2014 157 5 1088 1103 10.1016/j.cell.2014.03.052 24855946 PMC4140650

415. Rai D Kim SW McKeller MR Dahia PL Aguiar RC Targeting of SMAD5 links microRNA-155 to the TGF-beta pathway and lymphomagenesis Proc Natl Acad Sci U S A 2010 107 7 3111 3116 10.1073/pnas.0910667107 20133617 PMC2840369

416. Jiang D Aguiar RC MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-beta1/SMAD5 signaling module Blood 2014 123 1 86 93 10.1182/blood-2013-07-515254 24136167 PMC3879909

417. Clozel T Yang S Elstrom RL Tam W Martin P Kormaksson M Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma Cancer Discov 2013 3 9 1002 1019 10.1158/2159-8290.CD-13-0117 23955273 PMC3770813

418. Pan H Jiang Y Boi M Tabbo F Redmond D Nie K Epigenomic evolution in diffuse large B-cell lymphomas Nat Commun 2015 6 6921 10.1038/ncomms7921 25891015 PMC4411286

419. Lyons J Bayar E Fine G McCullar M Rolens R Rubinfeld J Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies Curr Opin Investig Drugs 2003 4 12 1442 1450 14763130

420. Pleyer L Greil R Digging deep into "dirty" drugs - modulation of the methylation machinery Drug Metab Rev 2015 47 2 252 279 10.3109/03602532.2014.995379 25566693 PMC4733942

421. Feld J Barta SK Schinke C Braunschweig I Zhou Y Verma AK Linked-in: design and efficacy of antibody drug conjugates in oncology Oncotarget 2013 4 3 397 412 10.18632/oncotarget.924 23651630 PMC3717303

422. Teicher BA Chari RV Antibody conjugate therapeutics: challenges and potential Clin Cancer Res 2011 17 20 6389 6397 10.1158/1078-0432.CCR-11-1417 22003066

423. Nadler LM Anderson KC Marti G Bates M Park E Daley JF B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes J Immunol 1983 131 1 244 250 6408173

424. Uckun FM Jaszcz W Ambrus JL Fauci AS Gajl-Peczalska K Song CW Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins Blood 1988 71 1 13 29 3257143

425. Bradbury LE Kansas GS Levy S Evans RL Tedder TF The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules J Immunol 1992 149 9 2841 2850 1383329

426. Younes A Kim S Romaguera J Copeland A Farial Sde C Kwak LW Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma J Clin Oncol 2012 30 22 2776 2782 10.1200/JCO.2011.39.4403 22753910 PMC5950497

427. Ribrag V Dupuis J Tilly H Morschhauser F Laine F Houot R A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma Clin Cancer Res 2014 20 1 213 220 10.1158/1078-0432.CCR-13-0580 24132920

428. Wagner-Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015:1-7. [Epub ahead of print]. 10.3109/10428194.2015.1017821 25707288

429. Fayad L Offner F Smith MR Verhoef G Johnson P Kaufman JL Safety and clinical activity of a combination therapy comprising two antibody- based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab J Clin Oncol 2013 31 5 573 583 10.1200/JCO.2012.42.7211 23295790 PMC4878046

430. Shor B Gerber HP Sapra P Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies Mol Immunol 2015 67 2 Pt A 107 116 10.1016/j.molimm.2014.09.014 25304309

431. Biberacher V Decker T Oelsner M Wagner M Bogner C Schmidt B The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-betaII depletion Haematologica 2012 97 5 771 779 10.3324/haematol.2011.049155 22180432 PMC3342982

432. Jacobsen ED Sharman JP Oki Y Advani RH Winter JN Bello CM Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression Blood 2015 125 9 1394 1402 10.1182/blood-2014-09-598763 25573987

433. Pfeifer M Zheng B Erdmann T Koeppen H McCord R Grau M Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes Leukemia 2015 29 7 1578 1586 10.1038/leu.2015.48 25708834

434. Forero-Torres A, Moskowitz C, Advani RH, Shah BD, Kostic A, Albertson TM, et al. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). ASCO Annual Meeting. Oral Abstract Session. J Clin Oncol. 2014, 32:((suppl; abstr 8505)).

435. Albertson TM Sandalic L Zhao B Kostic A Law C SGN-CD19A: A novel Anti-CD19 antibody drug conjugate. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR Cancer Res 2014 74 19 Suppl DDT01 04

436. Hill BT Manilich EA Smith MR Hsi ED CD30 immunohistochemical expression in diffuse large B-cell lymphoma is associated with decreased overall survival and the non-germinal center molecular subtype Blood 2013 122 4318

437. Hu S Xu-Monette ZY Balasubramanyam A Manyam GC Visco C Tzankov A CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study Blood 2013 121 14 2715 2724 10.1182/blood-2012-10-461848 23343832 PMC3700465

438. Slack GW Steidl C Sehn LH Gascoyne RD CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia Br J Haematol 2014 167 5 608 617 10.1111/bjh.13085 25135752

439. Palanca-Wessels MC Czuczman M Salles G Assouline S Sehn LH Flinn I Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study The Lancet Oncology 2015 16 6 704 715 10.1016/S1470-2045(15)70128-2 25925619

440. Kochenderfer JN Rosenberg SA Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors Nat Rev Clin Oncol 2013 10 5 267 276 10.1038/nrclinonc.2013.46 23546520 PMC6322669

441. Katz BZ Herishanu Y Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond Leuk Lymphoma 2014 55 5 999 1006 10.3109/10428194.2013.828354 23885836

442. Garfall AL Fraietta JA Maus MV Immunotherapy with chimeric antigen receptors for multiple myeloma DiscovMed 2014 17 91 37 46 24411699

443. Gill S June CH Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies Immunological reviews 2015 263 1 68 89 10.1111/imr.12243 25510272

444. Le Jeune C Thomas X Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia Eur J Haematol 2015 94 2 99 108 10.1111/ejh.12408 24981395

445. Lee DW Kochenderfer JN Stetler-Stevenson M Cui YK Delbrook C Feldman SA T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial Lancet 2015 385 9967 517 528 10.1016/S0140-6736(14)61403-3 25319501 PMC7065359

446. Wang Y Zhang WY Han QW Liu Y Dai HR Guo YL Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells Clin Immunol 2014 155 2 160 175 10.1016/j.clim.2014.10.002 25444722

447. Eshhar Z Waks T Gross G Schindler DG Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors Proc Natl Acad Sci USA 1993 90 2 720 724 10.1073/pnas.90.2.720 8421711 PMC45737

448. Irving BA Weiss A The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways Cell 1991 64 5 891 901 10.1016/0092-8674(91)90314-O 1705867

449. Kershaw MH Teng MW Smyth MJ Darcy PK Supernatural T cells: genetic modification of T cells for cancer therapy Nat Rev Immunol 2005 5 12 928 940 10.1038/nri1729 16322746

450. Sadelain M Brentjens R Riviere I The promise and potential pitfalls of chimeric antigen receptors Curr Opin Immunol 2009 21 2 215 223 10.1016/j.coi.2009.02.009 19327974 PMC5548385

451. Brentjens RJ Latouche JB Santos E Marti F Gong MC Lyddane C Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat Med 2003 9 3 279 286 10.1038/nm827 12579196

452. Kochenderfer JN Feldman SA Zhao Y Xu H Black MA Morgan RA Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor J Immunother 2009 32 7 689 702 10.1097/CJI.0b013e3181ac6138 19561539 PMC2747302

453. Kochenderfer JN Yu Z Frasheri D Restifo NP Rosenberg SA Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells Blood 2010 116 19 3875 3886 10.1182/blood-2010-01-265041 20631379 PMC2981541

454. Restifo NP Dudley ME Rosenberg SA Adoptive immunotherapy for cancer: harnessing the T cell response Nat Rev Immunol 2012 12 4 269 281 10.1038/nri3191 22437939 PMC6292222

455. Jensen MC Popplewell L Cooper LJ DiGiusto D Kalos M Ostberg JR Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans Biol Blood Marrow Transplant 2010 16 9 1245 1256 10.1016/j.bbmt.2010.03.014 20304086 PMC3383803

456. Kochenderfer JN Dudley ME Carpenter RO Kassim SH Rose JJ Telford WG Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation Blood 2013 122 25 4129 4139 10.1182/blood-2013-08-519413 24055823 PMC3862276

457. Kochenderfer JN Dudley ME Feldman SA Wilson WH Spaner DE Maric I B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen- receptor-transduced T cells Blood 2012 119 12 2709 2720 10.1182/blood-2011-10-384388 22160384 PMC3327450

458. Kochenderfer JN Wilson WH Janik JE Dudley ME Stetler-Stevenson M Feldman SA Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 20 4099 4102 10.1182/blood-2010-04-281931 20668228 PMC2993617

459. Kochenderfer JN Dudley ME Kassim SH Carpenter RO Yang JC Phan GQ Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor Blood 2013 122 21 10.1182/blood-2013-08-519413

460. Kochenderfer JN Dudley ME Kassim SH Somerville RP Carpenter RO Stetler-Stevenson M Chemotherapy-Refractory Diffuse Large B- Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor J Clin Oncol 2015 33 6 540 549 10.1200/JCO.2014.56.2025 25154820 PMC4322257

461. Schuster SJ, Svoboda J, Nasta S, Porter DL, Mato A, Shah GD, et al . Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas, American Society of Clinical Oncology Annual Meeting 1 June 2015. J Clin Oncol 33, 2015 (suppl; abstr 8516)2015. Abstract 8516..

462. Byrd JC Furman RR Coutre SE Flinn IW Burger JA Blum KA Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 2013 369 1 32 42 10.1056/NEJMoa1215637 23782158 PMC3772525

463. Wang ML Rule S Martin P Goy A Auer R Kahl BS Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 2013 369 6 507 516 10.1056/NEJMoa1306220 23782157 PMC4513941

464. Zhu YX Braggio E Shi CX Bruins LA Schmidt JE Van Wier S Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide Blood 2011 118 18 4771 4779 10.1182/blood-2011-05-356063 21860026 PMC3208291

465. Woyach JA Furman RR Liu TM Ozer HG Zapatka M Ruppert AS Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib N Engl J Med 2014 370 24 2286 2294 10.1056/NEJMoa1400029 24869598 PMC4144824

466. Scott DW Gascoyne RD The tumour microenvironment in B cell lymphomas Nat Rev Cancer 2014 14 8 517 534 10.1038/nrc3774 25008267

467. Giachelia M Voso MT Tisi MC Martini M Bozzoli V Massini G Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma Leuk Lymphoma 2012 53 3 411 416 10.3109/10428194.2011.621566 21902578

468. Sanda T Tyner JW Gutierrez A Ngo VN Glover J Chang BH TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia Cancer Discov 2013 3 5 564 577 10.1158/2159-8290.CD-12-0504 23471820 PMC3651770

469. Juszczynski P Kutok JL Li C Mitra J Aguiar RC Shipp MA BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate Mol Cell Biol 2006 26 14 5348 5359 10.1128/MCB.02351-05 16809771 PMC1592708

470. Camicia R Bachmann SB Winkler HC Beer M Tinguely M Haralambieva E BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFNgamma-STAT1-IRF1- p53 axis in diffuse large B-cell lymphoma J Cell Sci 2013 126 Pt 9 1969 1980 10.1242/jcs.118174 23487038

471. Bachmann SB Frommel SC Camicia R Winkler HC Santoro R Hassa PO DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells Mol Cancer 2014 13 125 10.1186/1476-4598-13-125 24886089 PMC4070648

472. Aguiar RC Yakushijin Y Kharbanda S Salgia R Fletcher JA Shipp MA BAL is a novel risk- related gene in diffuse large B-cell lymphomas that enhances cellular migration Blood 2000 96 13 4328 4334 11110709

473. Juszczynski P Nowak J Warzocha K Host immune response in B-cell lymphomas: friend or foe? Arch Immunol Ther Exp (Warsz) 2008 56 4 245 255 10.1007/s00005-008-0028-z 18726146

474. Cho SH Ahn AK Bhargava P Lee CH Eischen CM McGuinness O Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family Proc Natl Acad Sci U S A 2011 108 38 15972 15977 10.1073/pnas.1017082108 21911376 PMC3179111

475. Hottiger MO Boothby M Koch-Nolte F Luscher B Martin NM Plummer R Progress in the function and regulation of ADP-Ribosylation Sci Signal 2011 4 174 mr5 21610250 10.1126/scisignal.2001645

476. Hottiger MO Hassa PO Luscher B Schuler H Koch-Nolte F Toward a unified nomenclature for mammalian ADP-ribosyltransferases Trends Biochem Sci 2010 35 4 208 219 10.1016/j.tibs.2009.12.003 20106667

477. Sung VM Mechanistic overview of ADP-ribosylation reactions Biochimie 2015 113 35 46 10.1016/j.biochi.2015.03.016 25828806

478. Aguiar RC Takeyama K He C Kreinbrink K Shipp MA B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity J Biol Chem 2005 280 40 33756 33765 10.1074/jbc.M505408200 16061477

479. Goenka S Boothby M Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor Proc Natl Acad Sci USA 2006 103 11 4210 4215 10.1073/pnas.0506981103 16537510 PMC1449672

480. Goenka S Cho SH Boothby M Collaborator of Stat6 (CoaSt6)-associated poly(ADP-ribose) polymerase activity modulates Stat6-dependent gene transcription J Biol Chem 2007 282 26 18732 18739 10.1074/jbc.M611283200 17478423

481. Karlberg T Langelier MF Pascal JM Schuler H Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling Mol Aspects Med 2013 34 6 1088 1108 10.1016/j.mam.2013.02.002 23458732 PMC3726583

482. Forst AH Karlberg T Herzog N Thorsell AG Gross A Feijs KL Recognition of mono-ADP-ribosylated ARTD10 substrates by ARTD8 macrodomains Structure 2013 21 3 462 475 10.1016/j.str.2012.12.019 23473667

483. Timinszky G Till S Hassa PO Hothorn M Kustatscher G Nijmeijer B A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation Nat Struct Mol Biol 2009 16 9 923 929 10.1038/nsmb.1664 19680243

484. Curtin N PARP inhibitors for anticancer therapy Biochem Soc Trans 2014 42 1 82 88 10.1042/BST20130187 24450632

485. Rouleau M Patel A Hendzel MJ Kaufmann SH Poirier GG PARP inhibition: PARP1 and beyond Nat Rev Cancer 2010 10 4 293 301 10.1038/nrc2812 20200537 PMC2910902

486. Hassa PO The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival FrontBiosci (Landmark Ed) 2009 14 72 111 10.2741/3232 19273055

487. Hassa PO Hottiger MO The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases Front Biosci 2008 13 3046 3082 10.2741/2909 17981777

488. Lupo B, Trusolino L. Inhibition of polyADP-ribosylation in cancer: Old and new paradigms revisited. Biochim Biophys Acta . 2014 10.1016/j.bbcan.2014.07.004 25026313

489. Weston VJ Oldreive CE Skowronska A Oscier DG Pratt G Dyer MJ The PARP inhibitor olaparib induces significant killing of ATM- deficient lymphoid tumor cells in vitro and in vivo Blood 2010 116 22 4578 4587 10.1182/blood-2010-01-265769 20739657

490. Weaver AN Yang ES Beyond DNA Repair: Additional Functions of PARP-1 in Cancer Front Oncol 2013 3 290 10.3389/fonc.2013.00290 24350055 PMC3841914

491. Helleday T The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings Mol Oncol 2011 5 4 387 393 10.1016/j.molonc.2011.07.001 21821475 PMC5528309

492. Stark GR Darnell JE Jr The JAK-STAT pathway at twenty Immunity 2012 36 4 503 514 10.1016/j.immuni.2012.03.013 22520844 PMC3909993

493. Regis G Pensa S Boselli D Novelli F Poli V Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling Semin Cell Dev Biol 2008 19 4 351 359 10.1016/j.semcdb.2008.06.004 18620071

494. Sikorski K Czerwoniec A Bujnicki JM Wesoly J Bluyssen HA STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNgamma, TLR4 and IL-6 in vascular disease Cytokine Growth Factor Rev 2011 22 4 211 219 10.1016/j.cytogfr.2011.06.003 21752694

495. Qing Y Stark GR Alternative activation of STAT1 and STAT3 in response to interferon- gamma J Biol Chem 2004 279 40 41679 41685 10.1074/jbc.M406413200 15284232

496. Schiavone D Avalle L Dewilde S Poli V The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3 FEBS Lett 2011 585 15 2455 2460 10.1016/j.febslet.2011.06.020 21723864

497. Dunn GP Koebel CM Schreiber RD Interferons, immunity and cancer immunoediting Nat Rev Immunol 2006 6 11 836 848 10.1038/nri1961 17063185

498. Mowen K David M Regulation of STAT1 nuclear export by Jak1 Mol Cell Biol 2000 20 19 7273 7281 10.1128/MCB.20.19.7273-7281.2000 10982844 PMC86281

499. Meyer T Hendry L Begitt A John S Vinkemeier U A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors J Biol Chem 2004 279 18 18998 19007 10.1074/jbc.M400766200 15010467

500. Meyer T Vinkemeier U Nucleocytoplasmic shuttling of STAT transcription factors Eur J Biochem 2004 271 23-24 4606 4612 10.1111/j.1432-1033.2004.04423.x 15606747

501. Lodige I Marg A Wiesner B Malecova B Oelgeschlager T Vinkemeier U Nuclear export determines the cytokine sensitivity of STAT transcription factors J Biol Chem 2005 280 52 43087 43099 10.1074/jbc.M509180200 16195225

502. Meyer T Marg A Lemke P Wiesner B Vinkemeier U DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1 Genes Dev 2003 17 16 1992 2005 10.1101/gad.268003 12923054 PMC196254

503. Pilz A Ramsauer K Heidari H Leitges M Kovarik P Decker T Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons EMBO Rep 2003 4 4 368 373 10.1038/sj.embor.embor802 12671680 PMC1319158

504. Zakharova N Lymar ES Yang E Malik S Zhang JJ Roeder RG Distinct transcriptional activation functions of STAT1alpha and STAT1beta on DNA and chromatin templates J Biol Chem 2003 278 44 43067 43073 10.1074/jbc.M308166200 12939262

505. Baran-Marszak F Feuillard J Najjar I Le Clorennec C Bechet JM Dusanter-Fourt I Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells Blood 2004 104 8 2475 2483 10.1182/blood-2003-10-3508 15217838

506. Alvarez GR Zwilling BS Lafuse WP Mycobacterium avium inhibition of IFN-gamma signaling in mouse macrophages: Toll-like receptor 2 stimulation increases expression of dominant-negative STAT1 beta by mRNA stabilization J Immunol 2003 171 12 6766 6773 10.4049/jimmunol.171.12.6766 14662881

507. Najjar I Schischmanoff PO Baran-Marszak F Deglesne PA Youlyouz-Marfak I Pampin M Novel function of STAT1beta in B cells: induction of cell death by a mechanism different from that of STAT1alpha J Leukoc Biol 2008 84 6 1604 1612 10.1189/jlb.0508287 18753311

508. Semper C Leitner NR Lassnig C Parrini M Mahlakoiv T Rammerstorfer M STAT1beta Is Not Dominant Negative and Is Capable of Contributing to Gamma Interferon-Dependent Innate Immunity Mol Cell Biol 2014 34 12 2235 2248 10.1128/MCB.00295-14 24710278 PMC4054301

509. Decker T Kovarik P Serine phosphorylation of STATs Oncogene 2000 19 21 2628 2637 10.1038/sj.onc.1203481 10851062

510. Xu W Nair JS Malhotra A Zhang JJ B cell antigen receptor signaling enhances IFN-gamma- induced Stat1 target gene expression through calcium mobilization and activation of multiple serine kinase pathways J Interferon Cytokine Res 2005 25 2 113 124 10.1089/jir.2005.25.113 15695932

511. Stephanou A Latchman DS STAT-1: a novel regulator of apoptosis Int J Exp Pathol 2003 84 6 239 244 10.1111/j.0959-9673.2003.00363.x 14748743 PMC2517573

512. Townsend PA Scarabelli TM Davidson SM Knight RA Latchman DS Stephanou A STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis J Biol Chem 2004 279 7 5811 5820 10.1074/jbc.M302637200 14602726

513. Taniguchi T Ogasawara K Takaoka A Tanaka N IRF family of transcription factors as regulators of host defense Annu Rev Immunol 2001 19 623 655 10.1146/annurev.immunol.19.1.623 11244049

514. Romeo G Fiorucci G Chiantore MV Percario ZA Vannucchi S Affabris E IRF-1 as a negative regulator of cell proliferation J Interferon Cytokine Res 2002 22 1 39 47 10.1089/107999002753452647 11846974

515. Khodarev NN Beckett M Labay E Darga T Roizman B Weichselbaum RR STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells Proc Natl Acad Sci U S A 2004 101 6 1714 1719 10.1073/pnas.0308102100 14755057 PMC341831

516. Khodarev NN Minn AJ Efimova EV Darga TE Labay E Beckett M Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells Cancer Res 2007 67 19 9214 9220 10.1158/0008-5472.CAN-07-1019 17909027

517. Khodarev NN Roach P Pitroda SP Golden DW Bhayani M Shao MY STAT1 pathway mediates amplification of metastatic potential and resistance to therapy PLoS ONE 2009 4 6 e5821 10.1371/journal.pone.0005821 19503789 PMC2688034

518. Khodarev NN Roizman B Weichselbaum RR Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth Clin Cancer Res 2012 18 11 3015 3021 10.1158/1078-0432.CCR-11-3225 22615451

519. Pitroda SP Wakim BT Sood RF Beveridge MG Beckett MA MacDermed DM STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect BMC Med 2009 7 68 10.1186/1741-7015-7-68 19891767 PMC2780454

520. Patterson SG Wei S Chen X Sallman DA Gilvary DL Zhong B Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells Oncogene 2006 25 45 6113 6122 10.1038/sj.onc.1209632 16652143

521. Magkou C Giannopoulou I Theohari I Fytou A Rafailidis P Nomikos A Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer Histopathology 2012 60 7 1125 1132 10.1111/j.1365-2559.2011.04143.x 22320867

522. Stronach EA Alfraidi A Rama N Datler C Studd JB Agarwal R HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer Cancer Res 2011 71 13 4412 4422 10.1158/0008-5472.CAN-10-4111 21571862 PMC3130134

523. Weichselbaum RR Ishwaran H Yoon T Nuyten DS Baker SW Khodarev N An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer Proc Natl Acad Sci US A 2008 105 47 18490 18495 10.1073/pnas.0809242105 PMC2587578 19001271

524. Fryknas M Dhar S Oberg F Rickardson L Rydaker M Goransson H STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines Int J Cancer 2007 120 1 189 195 10.1002/ijc.22291 17072862

525. Kovacic B Stoiber D Moriggl R Weisz E Ott RG Kreibich R STAT1 acts as a tumor promoter for leukemia development Cancer Cell 2006 10 1 77 87 10.1016/j.ccr.2006.05.025 16843267

526. Lukacher AE IFN-gamma suspends the killing license of anti-tumor CTLs J Clin Invest 2002 110 10 1407 1409 12438437 10.1172/JCI17209 PMC151825

527. Choo A Palladinetti P Passioura T Shen S Lock R Symonds G The role of IRF1 and IRF2 transcription factors in leukaemogenesis Curr Gene Ther 2006 6 5 543 550 10.2174/156652306778520683 17073600

528. Erb HH Langlechner RV Moser PL Handle F Casneuf T Verstraeten K IL6 sensitizes prostate cancer to the antiproliferative effect of IFNalpha2 through IRF9 Endocr Relat Cancer 2013 20 5 677 689 10.1530/ERC-13-0222 23913484 PMC3753051

529. Andersson CD Karlberg T Ekblad T Lindgren AE Thorsell AG Spjut S Discovery of Ligands for ADP- Ribosyltransferases via Docking-Based Virtual Screening J Med Chem 2012 55 17 7706 7718 10.1021/jm300746d 22823910

530. Ekblad T Lindgren AE Andersson CD Caraballo R Thorsell AG Karlberg T Towards small molecule inhibitors of mono-ADP-ribosyltransferases Eur J Med Chem 2015 95 546 551 10.1016/j.ejmech.2015.03.067 25847771

531. Klein Wolterink RG Garcia-Ojeda ME Vosshenrich CA Hendriks RW Di Santo JP The intrathymic crossroads of T and NK cell differentiation Immunol Rev 2010 238 1 126 137 10.1111/j.1600-065X.2010.00960.x 20969589

532. Ruffell B DeNardo DG Affara NI Coussens LM Lymphocytes in cancer development: polarization towards pro-tumor immunity Cytokine Growth Factor Rev 2010 21 1 3 10 10.1016/j.cytogfr.2009.11.002 20005150 PMC2834837

533. Erener S Petrilli V Kassner I Minotti R Castillo R Santoro R Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-kappaB target genes Molecular cell 2012 46 2 200 211 10.1016/j.molcel.2012.02.016 22464733

534. Hassa PO Haenni SS Buerki C Meier NI Lane WS Owen H Acetylation of poly(ADP-ribose) polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-kappaB-dependent transcription J Biol Chem 2005 280 49 40450 40464 10.1074/jbc.M507553200 16204234

535. Mehrotra P Riley JP Patel R Li F Voss L Goenka S PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation J Biol Chem 2011 286 3 1767 1776 10.1074/jbc.M110.157768 21081493 PMC3023471

536. Minotti R Andersson A Hottiger MO ARTD1 Suppresses Interleukin 6 Expression by Repressing MLL1-Dependent Histone H3 Trimethylation Mol Cell Biol 2015 35 18 3189 3199 10.1128/MCB.00196-15 26149390 PMC4539373

537. Ni Z Abou El Hassan M Xu Z Yu T Bremner R The chromatin-remodeling enzyme BRG1 coordinates CIITA induction through many interdependent distal enhancers Nat Immunol 2008 9 7 785 793 10.1038/ni.1619 18500344

538. Paulson M Pisharody S Pan L Guadagno S Mui AL Levy DE Stat protein transactivation domains recruit p300/CBP through widely divergent sequences J Biol Chem 1999 274 36 25343 25349 10.1074/jbc.274.36.25343 10464260

539. Zhang Y Takami K Lo MS Huang G Yu Q Roswit WT Modification of the Stat1 SH2 domain broadly improves interferon efficacy in proportion to p300/CREB-binding protein coactivator recruitment J Biol Chem 2005 280 40 34306 34315 10.1074/jbc.M503263200 16107341

540. Korzus E Torchia J Rose DW Xu L Kurokawa R McInerney EM Transcription factor-specific requirements for coactivators and their acetyltransferase functions Science 1998 279 5351 703 707 10.1126/science.279.5351.703 9445475

541. Liu B Gross M ten Hoeve J Shuai K A transcriptional corepressor of Stat1 with an essential LXXLL signature motif Proc Natl Acad Sci USA 2001 98 6 3203 3207 10.1073/pnas.051489598 11248056 PMC30631

542. Takeyama K Aguiar RC Gu L He C Freeman GJ Kutok JL The BAL- binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity J Biol Chem 2003 278 24 21930 21937 10.1074/jbc.M301157200 12670957

543. Obiero J Walker JR Dhe-Paganon S Fold of the conserved DTC domain in Deltex proteins Proteins 2012 80 5 1495 1499 10.1002/prot.24054 22411408

544. Matsuno K Eastman D Mitsiades T Quinn AM Carcanciu ML Ordentlich P Human deltex is a conserved regulator of Notch signalling Nat Genet 1998 19 1 74 78 10.1038/ng0598-74 9590294

545. Cui J Li Y Zhu L Liu D Songyang Z Wang HY NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4 Nat Immunol 2012 13 4 387 395 10.1038/ni.2239 22388039 PMC3760161

546. Liu WM Laux H Henry JY Bolton TB Dalgleish AG Galustian C A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro Mol Biol Rep 2010 37 4 1801 1814 10.1007/s11033-009-9614-3 19597962

547. Yan Q Dutt S Xu R Graves K Juszczynski P Manis JP BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response Mol Cell 2009 36 1 110 120 10.1016/j.molcel.2009.08.019 19818714 PMC2913878

548. Yan Q Xu R Zhu L Cheng X Wang Z Manis J BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8 Mol Cell Biol 2013 33 4 845 857 10.1128/MCB.00990-12 23230272 PMC3571337

549. Thang ND Yajima I Kumasaka MY Iida M Suzuki T Kato M Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway Oncotarget 2015 6 16 14290 14299 10.18632/oncotarget.3742 26033450 PMC4546467

550. Izon DJ Aster JC He Y Weng A Karnell FG Patriub V Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1 Immunity 2002 16 2 231 243 10.1016/S1074-7613(02)00271-6 11869684

551. Huber RM Rajski M Sivasankaran B Moncayo G Hemmings BA Merlo A Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival PLoS One 2013 8 2 10.1371/journal.pone.0057793 23451269 PMC3581491

552. South AP Cho RJ Aster JC The double-edged sword of Notch signaling in cancer Semin Cell Dev Biol 2012 23 4 458 464 10.1016/j.semcdb.2012.01.017 22309843 PMC3360804

553. Masuda S Kumano K Suzuki T Tomita T Iwatsubo T Natsugari H Dual antitumor mechanisms of Notch signaling inhibitor in a T-cell acute lymphoblastic leukemia xenograft model Cancer Sci 2009 100 12 2444 2450 10.1111/j.1349-7006.2009.01328.x 19775286 PMC11159026

554. Lee SY Kumano K Nakazaki K Sanada M Matsumoto A Yamamoto G Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma Cancer Sci 2009 100 5 920 926 10.1111/j.1349-7006.2009.01130.x 19445024 PMC11158873

555. Wang Z Michaud GA Cheng Z Zhang Y Hinds TR Fan E Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination Genes Dev 2012 26 3 235 240 10.1101/gad.182618.111 22267412 PMC3278890

556. Cho SH Goenka S Henttinen T Gudapati P Reinikainen A Eischen CM PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells Blood 2009 113 11 2416 2425 10.1182/blood-2008-03-144121 19147789 PMC2656269

557. Lu X Nechushtan H Ding F Rosado MF Singal R Alizadeh AA Distinct IL-4- induced gene expression, proliferation, and intracellular signaling in germinal center B-cell- like and activated B-cell-like diffuse large-cell lymphomas Blood 2005 105 7 2924 2932 10.1182/blood-2004-10-3820 15591113

558. Lu X Malumbres R Shields B Jiang X Sarosiek KA Natkunam Y PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling Blood 2008 112 10 4098 4108 10.1182/blood-2008-03-148726 18716132 PMC2582009

559. Barbarulo A Iansante V Chaidos A Naresh K Rahemtulla A Franzoso G Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma Oncogene 2013 32 36 4231 4242 10.1038/onc.2012.448 23045269

560. Dasmahapatra G Lembersky D Kramer L Fisher RI Friedberg J Dent P The pan- HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo Blood 2010 115 22 4478 4487 10.1182/blood-2009-12-257261 20233973 PMC2881506

561. Dasmahapatra G Patel H Dent P Fisher RI Friedberg J Grant S The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib Br J Haematol 2013 161 1 43 56 10.1111/bjh.12206 23360303 PMC3739300

562. Dasmahapatra G Patel H Friedberg J Quayle SN Jones SS Grant S In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells Mol Cancer Ther 2014 13 12 2886 2897 10.1158/1535-7163.MCT-14-0220 25239935 PMC4304772

563. Nicolae CM Aho ER Choe KN Constantin D Hu HJ Lee D A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress Nucleic Acids Res 2015 43 6 3143 3153 10.1093/nar/gkv147 25753673 PMC4381061

564. Dutta C Day T Kopp N van Bodegom D Davids MS Ryan J BCL2 suppresses PARP1 function and nonapoptotic cell death Cancer Res 2012 72 16 4193 4203 10.1158/0008-5472.CAN-11-4204 22689920 PMC4075432

565. Ambrose HE Papadopoulou V Beswick RW Wagner SD Poly-(ADP-ribose) polymerase-1 (Parp-1) binds in a sequence-specific manner at the Bcl-6 locus and contributes to the regulation of Bcl-6 transcription Oncogene 2007 26 42 6244 6252 10.1038/sj.onc.1210434 17404575

566. Kannan S Fang W Song G Mullighan CG Hammitt R McMurray J Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression Blood 2011 117 10 2891 2900 10.1182/blood-2009-12-253419 21224467 PMC3062299

567. Novikov L, Park JW, Chen H, Klerman H, Jalloh AS, Gamble MJ: QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation. Mol Cell Biol 31(20):4244-4255. 10.1128/MCB.05244-11 PMC3187283 21844227

568. Ouararhni K Hadj-Slimane R Ait-Si-Ali S Robin P Mietton F Harel-Bellan A The histone variant mH2A1.1 interferes with transcription by down-regulating PARP-1 enzymatic activity Genes Dev 2006 20 23 3324 3336 10.1101/gad.396106 17158748 PMC1686608

569. Kummar S Chen A Ji J Zhang Y Reid JM Ames M Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas Cancer Res 2011 71 17 5626 5634 10.1158/0008-5472.CAN-11-1227 21795476 PMC3166628

570. Kummar S Ji J Morgan R Lenz HJ Puhalla SL Belani CP A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas Clin Cancer Res 2012 18 6 1726 1734 10.1158/1078-0432.CCR-11-2821 22307137 PMC3306481

571. Szelag M Sikorski K Czerwoniec A Szatkowska K Wesoly J Bluyssen HA In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity Eur J Pharmacol 2013 720 1-3 38 48 10.1016/j.ejphar.2013.10.055 24211327

572. Fagard R Metelev V Souissi I Baran-Marszak F STAT3 inhibitors for cancer therapy: Have all roads been explored? Jakstat 2013 2 1 e22882 24058788 10.4161/jkst.22882 PMC3670264

573. Costantino L Barlocco D STAT 3 as a target for cancer drug discovery Curr Med Chem 2008 15 9 834 843 10.2174/092986708783955464 18473793

574. Dave B Landis MD Tweardy DJ Chang JC Dobrolecki LE Wu MF Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model PLoS One 2012 7 8 e30207 10.1371/journal.pone.0030207 22879872 PMC3412855

575. Vultur A Cao J Arulanandam R Turkson J Jove R Greer P Cell-to- cell adhesion modulates Stat3 activity in normal and breast carcinoma cells Oncogene 2004 23 15 2600 2616 10.1038/sj.onc.1207378 15007380

576. Page BD Croucher DC Li ZH Haftchenary S Jimenez-Zepeda VH Atkinson J Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma J Med Chem 2013 56 18 7190 7200 10.1021/jm3017255 23968501

577. Zhang X Sun Y Pireddu R Yang H Urlam MK Lawrence HR A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation Cancer Res 2013 73 6 1922 1933 10.1158/0008-5472.CAN-12-3175 23322008 PMC4030628

578. Bozeman R Abel EL Macias E Cheng T Beltran L DiGiovanni J A novel mechanism of skin tumor promotion involving interferon-gamma (IFNgamma)/signal transducer and activator of transcription-1 (Stat1) signaling Mol Carcinog 2015 54 8 642 653 10.1002/mc.22132 24464587 PMC4139479

579. Zimmerman MA Rahman NT Yang D Lahat G Lazar AJ Pollock RE Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance Cancer Res 2012 72 18 4724 4732 10.1158/0008-5472.CAN-12-1347 22805310 PMC3564959

580. Datta S Parajuli N Tymoszuk P Ottina E Parson W Sgonc R Replenishment of the B cell compartment after doxorubicin-induced hematopoietic toxicity is facilitated by STAT1 JLeukoc Biol 2014 95 6 853 866 10.1189/jlb.0113053 24295829

581. Pinto AF Schuler H Comparative structural analysis of the putative mono-ADP- ribosyltransferases of the ARTD/PARP family Curr Top Microbiol Immunol 2015 384 153 166 25015788 10.1007/82_2014_417

582. Wahlberg E Karlberg T Kouznetsova E Markova N Macchiarulo A Thorsell AG Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors NatBiotechnol 2012 30 3 283 288 10.1038/nbt.2121 22343925

583. Antolin AA Jalencas X Yelamos J Mestres J Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology ACS chemical biology 2012 7 12 1962 1967 10.1021/cb300317y 23025350

584. Antolin AA Mestres J Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors Oncotarget 2014 5 10 3023 3028 10.18632/oncotarget.1814 24632590 PMC4102788

585. Chuang HC Kapuriya N Kulp SK Chen CS Shapiro CL Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells Breast Cancer Res Treat 2012 134 2 649 659 10.1007/s10549-012-2106-5 22678161 PMC4297209

586. Alvarado Y Giles FJ Swords RT The PIM kinases in hematological cancers Expert Rev Hematol 2012 5 1 81 96 10.1586/ehm.11.69 22272708

587. Wang S Fischer PM Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology Trends Pharmacol Sci 2008 29 6 302 313 10.1016/j.tips.2008.03.003 18423896

588. Warrener P Kim S Williams SM Biery M Gordon M Toniatti C Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-gamma Apoptosis 2012 17 7 691 701 10.1007/s10495-012-0707-4 22392482

589. Kishi N Tang Z Maeda Y Hirai A Mo R Ito M Murine homologs of deltex define a novel gene family involved in vertebrate Notch signaling and neurogenesis Int J Dev Neurosci 2001 19 1 21 35 10.1016/S0736-5748(00)00071-X 11226752

590. Landre V Rotblat B Melino S Bernassola F Melino G Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities Oncotarget 2014 5 18 7988 8013 10.18632/oncotarget.2431 25237759 PMC4226663

591. Luo J Solimini NL Elledge SJ Principles of cancer therapy: oncogene and non-oncogene addiction Cell 2009 136 5 823 837 10.1016/j.cell.2009.02.024 19269363 PMC2894612

592. Kaelin WG Jr The concept of synthetic lethality in the context of anticancer therapy Nat Rev Cancer 2005 5 9 689 698 10.1038/nrc1691 16110319

593. Pfeifer M Lenz G PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma Cell Cycle 2013 12 21 3347 3348 10.4161/cc.26575 24091535 PMC3895419

594. Devlin JR Hannan KM Ng PY Bywater MJ Shortt J Cullinane C AKT signalling is required for ribosomal RNA synthesis and progression of Emu-Myc B-cell lymphoma in vivo Febs J 2013 280 21 5307 5316 10.1111/febs.12135 23331925

595. Han SS Yun H Son DJ Tompkins VS Peng L Chung ST NF- kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma Mol Cancer 2010 9 97 10.1186/1476-4598-9-97 20433747 PMC2876994

596. Civallero M Cosenza M Bari A Sacchi S Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma Expert Opin Investig Drugs 2011 20 8 1029 1031 10.1517/13543784.2011.594793 21702717

597. Rahmani M Aust MM Benson EC Wallace L Friedberg J Grant S PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1- dependent mechanisms in vitro and in vivo Clin Cancer Res 2014 20 18 4849 4860 10.1158/1078-0432.CCR-14-0034 25070836 PMC4166554

598. Schult C Dahlhaus M Glass A Fischer K Lange S Freund M The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells Anticancer Res 2012 32 2 463 474 22287733

599. Shortt J Martin BP Newbold A Hannan KM Devlin JR Baker AJ Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas Blood 2013 121 15 2964 2974 10.1182/blood-2012-08-446096 23403624 PMC3624942

600. Micallef IN Maurer MJ Wiseman GA Nikcevich DA Kurtin PJ Cannon MW Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma Blood 2011 118 15 4053 4061 10.1182/blood-2011-02-336990 21673350 PMC3204728

601. Intlekofer AM Younes A Precision therapy for lymphoma-current state and future directions Nat Rev Clin Oncol 2014 11 10 585 596 10.1038/nrclinonc.2014.137 25135367

602. Mehta-Shah N Younes A Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma Semin Hematol 2015 52 2 126 137 10.1053/j.seminhematol.2015.01.007 25805592

603. Rui L Emre NC Kruhlak MJ Chung HJ Steidl C Slack G Cooperative epigenetic modulation by cancer amplicon genes Cancer Cell 2010 18 6 590 605 10.1016/j.ccr.2010.11.013 21156283 PMC3049192

604. Green MR Monti S Rodig SJ Juszczynski P Currie T O'Donnell E Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma Blood 2010 116 17 3268 3277 10.1182/blood-2010-05-282780 20628145 PMC2995356

605. Ritz O Guiter C Dorsch K Dusanter-Fourt I Wegener S Jouault H STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-cell lymphoma Leukemia 2008 22 11 2106 2110 10.1038/leu.2008.85 18401415

606. Ritz O Guiter C Castellano F Dorsch K Melzner J Jais JP Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B- cell lymphoma Blood 2009 114 6 1236 1242 10.1182/blood-2009-03-209759 19423726 PMC2824656

607. Shi M Roemer MG Chapuy B Liao X Sun H Pinkus GS Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain Am J Surg Pathol 2014 38 12 1715 1723 10.1097/PAS.0000000000000297 25025450 PMC4994970

608. Twa DD Chan FC Ben-Neriah S Woolcock BW Mottok A Tan KL Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma Blood 2014 123 13 2062 2065 10.1182/blood-2013-10-535443 24497532

609. Hirsch B Grunbaum M Wagner F Bi Y Lucka L Du MQ A novel A20 (TNFAIP3) antibody (Ber-A20) can be used to detect unmutated A20 by immunohistology Histopathology 2012 60 6B E19 27 10.1111/j.1365-2559.2012.04181.x 22393903

610. Steidl C Shah SP Woolcock BW Rui L Kawahara M Farinha P MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers Nature 2011 471 7338 377 381 10.1038/nature09754 21368758 PMC3902849

611. Tsang P Cesarman E Chadburn A Liu YF Knowles DM Molecular characterization of primary mediastinal B cell lymphoma Am J Pathol 1996 148 6 2017 2025 8669486 PMC1861633

612. Iqbal J Greiner TC Patel K Dave BJ Smith L Ji J Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma Leukemia 2007 21 11 2332 2343 10.1038/sj.leu.2404856 17625604 PMC2366166

613. Rao PH Houldsworth J Dyomina K Parsa NZ Cigudosa JC Louie DC Chromosomal and gene amplification in diffuse large B-cell lymphoma Blood 1998 92 1 234 240 9639522

614. Stoffel A Filippa D Rao PH The p73 locus is commonly deleted in non-Hodgkin's lymphomas Leuk Res 2004 28 12 1341 1345 10.1016/j.leukres.2004.04.010 15475076

615. Gene inactivation promotes immune escape in DLBCL. Cancer Discov 2012, 2(2):OF8. 10.1158/2159-8290.CD-RW2011-64 22585868

616. Challa-Malladi M Lieu YK Califano O Holmes AB Bhagat G Murty VV Combined genetic inactivation of beta2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma Cancer Cell 2011 20 6 728 740 10.1016/j.ccr.2011.11.006 22137796 PMC3660995

617. Costello RT Mallet F Barbarat B Schiano De Colella JM Sainty D Sweet RW Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity Leukemia 2003 17 12 2500 2507 10.1038/sj.leu.2403175 14562115

618. Takahashi H Feuerhake F Kutok JL Monti S Dal Cin P Neuberg D FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes Clin Cancer Res 2006 12 11 Pt 1 3265 3271 10.1158/1078-0432.CCR-06-0076 16740746

619. Houldsworth J Olshen AB Cattoretti G Donnelly GB Teruya-Feldstein J Qin J Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas Blood 2004 103 5 1862 1868 10.1182/blood-2003-04-1359 14615382

620. Saito M Gao J Basso K Kitagawa Y Smith PM Bhagat G A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma Cancer Cell 2007 12 3 280 292 10.1016/j.ccr.2007.08.011 17785208

621. Walker MP Stopford CM Cederlund M Fang F Jahn C Rabinowitz AD FOXP1 potentiates Wnt/beta-catenin signaling in diffuse large B cell lymphoma Science signaling 2015 8 362 ra12 10.1126/scisignal.2005654 25650440 PMC4356208

622. van Keimpema M Gruneberg LJ Mokry M van Boxtel R Koster J Coffer PJ FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-kappaB to promote survival of human B cells Blood 2014 124 23 3431 3440 10.1182/blood-2014-01-553412 25267198 PMC4246697

623. Guney S Jardin F Bertrand P Mareschal S Parmentier F Picquenot JM Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes Genes Chromosomes Cancer 2012 51 9 858 867 10.1002/gcc.21970 22619049

624. Gisselbrecht C Schmitz N Mounier N Singh Gill D Linch DC Trneny M Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma J Clin Oncol 2012 30 36 4462 4469 10.1200/JCO.2012.41.9416 23091101 PMC3646314

625. Dunleavy K Double-hit lymphomas: current paradigms and novel treatment approaches Hematology Am Soc Hematol Educ Program 2014 2014 1 107 112 10.1182/asheducation-2014.1.107 25696842

626. Walsh K McKinney MS Love C Liu Q Fan A Patel A PAK1 mediates resistance to PI3K inhibition in lymphomas Clin Cancer Res 2013 19 5 1106 1115 10.1158/1078-0432.CCR-12-1060 23300274 PMC3594365

627. Houldsworth J Petlakh M Olshen AB Chaganti RS Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response Leuk Lymphoma 2008 49 11 2170 2180 10.1080/10428190802428369 19021061

628. Foroutan B Ali Ruf A Jerwood D Anderson D In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy J Pharmacol Toxicol Methods 2007 55 1 58 64 10.1016/j.vascn.2006.02.012 16624596

629. Kerbauy FR Colleoni GW Saad ST Regis Silva MR Correa Alves A Aguiar KC Detection and possible prognostic relevance of p53 gene mutations in diffuse large B-cell lymphoma. An analysis of 51 cases and review of the literature Leuk Lymphoma 2004 45 10 2071 2078 10.1080/10428190410001713170 15370252

630. Song YH Zhong MZ Gan PP Yi PY Tang YH Liu YP ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen Tumour Biol 2014 35 12 11809 11817 10.1007/s13277-014-2335-9 25344211

631. Derenzini E Agostinelli C Imbrogno E Iacobucci I Casadei B Brighenti E Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma Oncotarget 2015 6 9 6553 6569 10.18632/oncotarget.2720 25544753 PMC4466634

632. Johnson DP Spitz GS Tharkar S Quayle SN Shearstone JR Jones S HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma Oncotarget 2015 6 7 4863 4887 10.18632/oncotarget.3120 25605023 PMC4467121

633. Singh RR Kunkalla K Qu C Schlette E Neelapu SS Samaniego F ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma Oncogene 2011 30 49 4874 4886 10.1038/onc.2011.195 21625222 PMC3165099

634. Lamason RL McCully RR Lew SM Pomerantz JL Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain Biochemistry 2010 49 38 8240 8250 10.1021/bi101052d 20799731 PMC2943563

635. Mallya S Fitch BA Lee JS So L Janes MR Fruman DA Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1 PLoS One 2014 9 2 e88865 10.1371/journal.pone.0088865 24586420 PMC3931643

636. Aravind L The WWE domain: a common interaction module in protein ubiquitination and ADP ribosylation Trends in biochemical sciences 2001 26 5 273 275 10.1016/S0968-0004(01)01787-X 11343911

637. He F Tsuda K Takahashi M Kuwasako K Terada T Shirouzu M Structural insight into the interaction of ADP-ribose with the PARP WWE domains FEBS Lett 2012 586 21 3858 3864 10.1016/j.febslet.2012.09.009 23010590

638. Feijs KL Forst AH Verheugd P Luscher B Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation Nat Rev Mol Cell Biol 2013 14 7 443 451 10.1038/nrm3601 23736681 PMC7097401

639. Daubner GM Clery A Allain FH RRM-RNA recognition: NMR or crystallography…and new findings Curr Opin Struct Biol 2013 23 1 100 108 10.1016/j.sbi.2012.11.006 23253355

640. Kita K Sugaya S Zhai L Wu YP Wano C Chigira S Involvement of LEU13 in interferon-induced refractoriness of human RSa cells to cell killing by X rays Radiat Res 2003 160 3 302 308 10.1667/RR3039 12926988

641. Luszczek W Cheriyath V Mekhail TM Borden EC Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression Mol Cancer Ther 2010 9 8 2309 2321 10.1158/1535-7163.MCT-10-0309 20682643

642. Rickardson L Fryknas M Dhar S Lovborg H Gullbo J Rydaker M Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles Br J Cancer 2005 93 4 483 492 10.1038/sj.bjc.6602699 16012520 PMC2361589

643. Rickardson L Wickstrom M Larsson R Lovborg H Image-based screening for the identification of novel proteasome inhibitors JBiomolScreen 2007 12 2 203 210 10.1177/1087057106297115 17208922

644. Efimova EV Liang H Pitroda SP Labay E Darga TE Levina V Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling IntJ Radiat Biol 2009 85 5 421 431 10.1080/09553000902838566 19437244 PMC2690884

645. Ernst M Jenkins BJ Acquiring signalling specificity from the cytokine receptor gp130 Trends Genet 2004 20 1 23 32 10.1016/j.tig.2003.11.003 14698616

646. Zweifel ME Leahy DJ Barrick D Structure and Notch receptor binding of the tandem WWE domain of Deltex Structure 2005 13 11 1599 1611 10.1016/j.str.2005.07.015 16271883

647. Steinhardt JJ Peroutka RJ Mazan-Mamczarz K Chen Q Houng S Robles C Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase Blood 2014 124 25 3758 3767 10.1182/blood-2014-07-589689 25320244 PMC4263984

648. Cerchietti L Leonard JP Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP Hematology Am Soc Hematol Educ Program 2013 2013 591 595 10.1182/asheducation-2013.1.591 24319236

649. Witzig TE Gupta M Signal transduction inhibitor therapy for lymphoma Hematology Am Soc Hematol Educ Program 2010 2010 265 270 10.1182/asheducation-2010.1.265 21239804 PMC3626402

650. Witzens-Harig M Memmer ML Dreyling M Hess G A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial BMC Cancer 2013 13 308 10.1186/1471-2407-13-308 23799873 PMC3701613

651. Burke RT Meadows S Loriaux MM Currie KS Mitchell SA Maciejewski P A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor Oncotarget 2014 5 4 908 915 10.18632/oncotarget.1484 24659719 PMC4011593

652. Vitolo U Chiappella A Franceschetti S Carella AM Baldi I Inghirami G Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial Lancet Oncol 2014 15 7 730 737 10.1016/S1470-2045(14)70191-3 24831981